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Three plasmid-mediated quinolone resistance (PMQR) mechanisms have recently 
been described; the first mechanism is related to Qnr proteins of the pentapeptide 
repeat family that protect type II topoisomerases from inhibition by quinolones, the 
second  mechanism involves the AAC(6')-Ib-cr protein representing a new variant of 
the common aminoglycoside acetyltransferase which is capable of acetylating and 
thus reducing the activity of norfloxacin and ciprofloxacin, and the third and most 
lately described mechanism involves the quinolone efflux pump protein QepA.  
 
The aim of this study was to examine the presence of plasmid-mediated qnr and 
aac(6')-Ib-cr resistance genes among Escherichia coli and Klebsiella spp. clinical 
isolates obtained between 2003 and 2005 from Norway and Sweden. The isolates 
were selected based on resistance to nalidixic acid and/or reduced susceptibility or 
resistance to ciprofloxacin.  
 
The prevalence of qnr genes was low (1.6 %) with qnr genes being more common 
among Klebsiella spp. (7.7 %) than E. coli (0.7). qnrS1 was detected in six isolates 
and was the most prevalent, qnrB was detected in two isolates (one was qnrB1 and the 
other was qnrB7), while no qnrA was detected. The aac(6’)-Ib gene was detected in 
15.4 % of the isolates, 69 (92%) of these were of the aac(6‘)-Ib-cr variant. Transfer of 
the qnr genes was successfully achieved in five isolates, three by transconjugation and 
two by transformation. The qnrS1 genes were located on plasmids ranging in size 
from 140 to ≥200 kb. However, one qnrS1 gene could be chromosome-located.  
ISEcl2 (orfB-∆orfA) was detected downstream and ∆res, orf259, and orf213 were 
detected upstream to the qnrS1 gene in all the 6 qnrS1-positive isolates. In addition, 
the pbp3 and blaLAP1 genes were detected further downstream to the qnrS1 gene in 
three isolates. The presence of ISEcl2 close to qnrS1 could play a role in the 
dissemination of this gene while the repeated association between qnrS1 and blaLAP-1 
could be a factor in the growing spread of ciprofloxacin- and β-lactam-resistant 


























Antimicrobial agents  
 
Antimicrobial agents represent a main therapeutic tool to control and treat a variety of 
bacterial infectious diseases. The first antimicrobial compounds used in modern 
medicine were produced and isolated from living organisms such as the penicillins 
from fungi of the genus Penicillium, or streptomycin produced by bacteria of the 
genus Streptomyces. With the advent of organic chemistry many antimicrobial agents 
are now obtained by chemical synthesis, such as the sulfa drugs and the quinolones. 
At the highest level, antibmicrobial agents can be classified as either bactericidal or 
bacteriostatic (Hancock. 2005). Bactericidals kill bacteria directly while 
bacteriostatics prevent them from dividing. However, in practice, both of these are 
capable of ending a bacterial infection.  
 
Classification of antimicrobials can also be done according to their mechanism of 
action (Tenover. 2006). Mechanisms include interference with cell wall synthesis 
(e.g., β-lactams), inhibition of protein synthesis (macrolides), interference with 
nucleic acid synthesis (quinolones), inhibition of a metabolic pathway (trimethoprim-
sulfamethoxazole), and disruption of bacterial membrane structure (polymyxins) 












Table 1. Mechanisms of action of antimicrobial agents (Tenover. 2006). 
Mechanism Antimicrobial(s)  
1- Interference with cell wall synthesis β-lactams: penicillins, cephalosporins, 
carbapenems, monobactams. 
Glycopeptides: vancomycin, teicoplanin 
2- Protein synthesis inhibition 
• Bind to 50S ribosomal subunit 
• Bind to 30S ribosomal subunit 
 
Macrolides, chloramphenicol, clindamycin. 
Aminoglycosides, tetracyclines. 
3- Interference with nucleic acid synthesis 
• Inhibit DNA synthesis 




4- Inhibition of metabolic pathway Sulfonamides, folic acid analogues 





Bacterial antimicrobial resistance 
 
During the last five decades, the use and sometimes misuse of antimicrobials in both 
human and veterinary medicine has resulted in the emergence of strains of bacteria 
that no longer respond to antimicrobial therapy (McDermott et al. 2003). Anti 
microbial resistance develops through a number of different mechanisms: (1) changes 
in the permeability of the bacterial cell wall/membrane, restricting the access of anti 
microbials to target sites; (2) active efflux of the anti microbials out the cell; (3) 
mutation in the target site; (4) enzymatic degradation or modification of the anti 
microbial agent; and (5) acquisition of alternative metabolic pathways to those 







Table 2. Mechanisms of antimicrobial resistance (McDermott et al. 2003). 
Mechanisms of resistance Antimicrobial(s) affected  
1. Modification of the antimicrobial agent Aminoglycosides, chloramphenicol, 
and ß-lactams. 
2. Alteration or protection of the target site Aminoglycosides, ß-lactams, 
macrolides, quinolones, rifampicin, 
trimethoprim, and tetracycline. 
3. Decreased antibiotic accumulation 
•  Decreased uptake 
•  Increased efflux 
 
Many antibiotics (quinolones). 
Tetracycline, macrolides, quinolones, 
and chloramphenicol. 
4. Alteration of the metabolic pathway Sulfonamides, trimethoprim. 
 
 
Bacteria may be intrinsically resistant to one class or more of antimicrobial agents, or 
resistance can be acquired by de novo mutation or by the acquisition of resistance 
genes from other organisms (Tenover. 2006). Intrinsic resistance can be described as a 
natural phenomenon when it is displayed by all members of a species and is a 
function of the physiological or biochemical structure of that species (Harbottle et al. 
2006). For example, Enterococci are intrinsically resistant to cephalosporins due to a 
decreased binding affinity to the penicillin-binding proteins. On the other hand, 
acquired resistance can result from the acquisition of a mutation in the regulatory or 
structural genes and/or the acquisition of a foreign resistance gene (Harbottle et al. 
2006). Acquired resistance is not present in the entire species but within only a certain 
lineage of bacteria derived from a susceptible parent. 
 
 
Horizontal transfer of antimicrobial resistance 
    
Most bacterial genomes that have been sequenced contain DNA segments that have 
been acquired from other sources (Normark & Normark. 2002). It was found that this 
horizontally acquired DNA usually encodes functions that are of selective advantage 
to the organism such as antibiotic resistance, virulence and biodegradation pathways. 
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The three common mechanisms for horizontal gene transfer are: (1) Transformation, a 
process by which bacteria take up free DNA directly from their environment, (2) 
Transduction, through which bacterial DNA is moved from one bacterium to another 
by a bacteriophage, and (3) Conjugation, a process by which a living bacterial cell 
transfers genetic material through cell-to-cell contact. A number of different DNA 
elements have played a main role in the development of resistance in bacteria 
(Normark & Normark. 2002). Such genetic elements include plasmids, transposons, 





Plasmids are extra-chromosomal DNA molecules that replicate independently of the 
chromosome (Baron et al. 1996). They are typically supercoiled, circular, and double-
stranded DNA molecules. However, linear plasmids have also been discovered in 
Borrelia and Streptomyces (Baron et al. 1996). There may be one copy, generally for 
large plasmids, to hundreds of copies of the plasmid in a single cell, and cells can 
harbor more than one type of plasmids. Plasmids vary in size from about five to more 
than several hundred kilobase pairs and they generally do not encode functions 
essential to bacterial growth, such as RNA polymerase, ribosomal subunits, or 
enzymes of the tricarboxylic acid cycle (Baron et al. 1996). Instead, plasmids often 
carry genes that confer a selective advantage to the bacterium harboring them, such as 
genes conferring antibiotic resistance. Other functions carried by plasmids include: 
synthesis of antibiotics, synthesis of toxins and proteins for bacterial pathogenesis, 
synthesis of enzymes for the utilization of unusual carbon sources, and resistance to 
heavy metals.   
  
Some plasmids are transferable (figure 1); they contain genes (the tra genes) that 
encode all the functions they need to transfer themselves and other DNA elements 
among cells (Snyder & Champness. 2007). Transconjugation is most commonly 
mediated by such plasmids. Whereas, other plasmids are only mobilizable (figure 2); 
they encode some but not all of the proteins required for transfer and consequently 
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need the help of the transferable plasmids to move from one bacteriuom to another 
(Snyder & Champness. 2007). 
 
Figure 1. An F-plasmid, an example of a transferable plasmid 
(www.science.siu.edu/microbiology/micr302) 
 
Plasmids that carry resistance genes are called R plasmids (Harbottle et al. 2000) 
(figure 2). These plasmids, originally called R factors, were first discovered from 
Shigella flexneri strains in the 1950s (Watanabe & Fukasawa. 1961). Since then, they 
have been increasingly associated with both Gram-positive and Gram-negative 
bacterial pathogens and commensal organisms. Plasmid-associated resistance genes 
have been detected for almost all the clinically available antimicrobials, including 
most recently the quinolones, and it is not uncommon for a single plasmid to 
simultaneously mediate resistance to multiple antimicrobials and to be shared among 
different bacterial genera (Harbottle et al. 2000). In addition to carrying resistance 
genes, plasmids can serve as vehicles for other genetic elements important in 
antimicrobial resistance, such as transposons and integrons. 
 
 
Figure 2. Plasmid pGNB2, an example of a mobilizable R-plasmid containing the qnrS2 gene  




Transposons are mobile genetic DNA elements that encode a site-specific transposase 
allowing site-specific insertions and excisions (Normark & Normark. 2002). There are 
three types of transposable elements: Insertion sequence elements, composite 
transposons, and non-composite transposons (figure 3).  
5`-CS 3`-CS
sulIintI
General structure of an integron
Pant
IS element
















Insertion sequence (IS) elements are usually 750 to 2000 bp long and consist of a 
gene encoding the transposase enzyme that promotes their transposition and two 
inverted repeats at the ends (Snyder & Champness. 2007). Thus far, thousends of 
different IS elements have been identified in bacteria. Plasmids also often contain IS 
elements. Composite transposons are made of two IS elements of the same type (two 
copies of the same IS element) bracketing other genes (Snyder & Champness. 2007). 
Different resistance determinants have been detected inside composite transposons in 
many bacterial species. Noncomposite transposons do not have complete copies of IS 
elements at their ends, still they contain short inverted repeats at their ends (Snyder & 
Champness. 2007). They contain tnpA (the transposase gene), tnpR (the resolvase 
gene), and res (the site at which resolvase acts). Noncomposite transposons may also 
contain resistance genes as an integrated part of the transposon.Transposons may 
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move into various genera of bacteria during transfer of promiscuous plasmids or via 
transducing phage. Furthermore, some transposons are themselves conjugative or can 
be induced to form phage (Harbottle et al. 2006). Conjugative transposons are able to 
excise from the genome of the donor cell, promote their conjugation to a neighboring 




Gene cassettes and integrons 
 
Gene cassettes are discrete genetic elements that exist as free, circular, non-replicating 
DNA molecules when moving from one genetic site to another (Bennett. 1999). Gene 
cassettes are part of the integron only when they are integrated. They normally contain 
only a single gene and a short sequence, called a 59 base element, which functions as 
a specific recombination site, called attC standing for attachment Cassette. The 
cassettes are small, normally of the order of 500–1000 bp and the genes carried on 
gene cassettes usually lack promoters and are expressed from a promoter on the 
integron. Integrons are genetic elements capable of capturing and mobilizing gene 
cassettes, but they themselves are not mobile (Bennett. 1999) (Fluit & Schmitz. 2003). 
An integron is defined as a genetic element that (1) encodes an enzyme called 
integrase and mediates site-specific recombination events; the integrase excises and 
integrates the gene cassettes from and into the integron, and (2) possesses a site called 
attI standing for attachment Integron and at which additional DNA, in the form of 
gene cassettes, can be integrated by these site-specific recombination. The promoters 
for genes carried on the cassettes are mostly found within the intI gene. 
 
Integrons can be divided into two main groups: the resistance integrons which carry 
mostly gene cassettes that encode resistance to antibiotics and can be located either on 
the chromosome or on plasmids, and the super-integrons which are chromosomally-
located and contain gene cassettes with a varity of functions (Fluit & Schmitz. 2003). 
At least three distinct classes of resistance integrons have been discovered based on 
the integrase gene sequence. Class 1 are the most prevalent integrons among clinical 
isolates to date. The structure of class1 integrons consist of two conserved regions, 
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called 5'-CS region and 3'-CS region, flanking a variable region of gene cassettes 
(Bennett. 1999). The 5'-CS region contains the integrase gene, intI, the site for 
insertion of gene cassettes, attI, and a promoter region, which is located within intI. 
While the 3'-CS region encodes resistance to sulphonamides, mediated by the 
sul1gene, and has a truncated version of the detergent resistance gene qacE∆1, and 
two open reading frames, orf5 and orf6, encoding proteins of unknown functions 
(figure 4).  
3‘-CS1




Figure 4. Class 1 integron structure (adapted from Bennett, 1999).
 
 
Both class 2 and class 3 integrons show the distinctive features of an integron (the 
integrase gene intI and its associated attI site). Nevertheless, it is important to know 
that the intI2 integrase is not functional due to an internal stop codon while the 
properties of the IntI3 integrase are comparable to those of the IntI1 integrase. The 
first super-integrons was detected in V. cholerae and was considered as a class 4 
integron (Fluit & Schmitz. 2003). Although super-integrons can be very large and 
may contain hundreds of ORFs, the super-integron of Shewanella oneidensis contains 
only three gene cassettes. Many scientists consider these super-integrons as the 









While some of the first antibiotics discovered during the past century were isolated 
from living organisms, the quinolone class of antimicrobial agents was synthesized by 
chemists (Andriole. 2005). Nalidixic acid was accidentally discovered in 1962 as a 
by-product of the synthesis of the antimalarial compound chloroquine. This discovery 
led to the development of a set of quinolone compounds widely described in clinical 




Figure 5. Chemical structures of fluoroquinolones (Andriole. 2005). 
 
 
The antimicrobial activity of the early quinolones (the first-generation quinolones), 
such as nalidixic acid and cinoxacin, were excellent against aerobic Gram-negative 
bacteria but not very active against aerobic Gram-positive bacteria or anaerobic 
bacteria (Andriole. 2005). The second-generation quinolones, including norfloxacin, 
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ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, and pefloxacin, have 
antimicrobial activity against both aerobic Gram-positive and Gram-negative bacteria, 
but they still lacked activity against anaerobic bacteria. The addition of fluorine at the 
C-6 position resulted in the innovation of the “fluoroquinolones” with norfloxacin 
being the first fluoroquinolone to be discovered. Newer fluoroquinolones (the third-
generation fluoroquinolones), including grepafloxacin, gatifloxacin, sparfloxacin, and 
temafloxacin, had greater potency against Gram-positive bacteria, particularly 
pneumococci; they also had good activity against anaerobic bacteria. The last group 
of quinolone compounds (trovafloxacin, clinafloxacin, sitafloxacin, moxifloxacin, and 
gemifloxacin) was termed “fourth-generation fluoroquinolones,” and had effective 
activity against anaerobes and improved activity against pneumococci (table 3). 
 
Table 3. Classification of quinolone antimicrobials (adopted from Andriole. 2005). 
Generation Selected examples 
First generation Nalidixic acid 
Second generation Norfloxacin, Ciprofloxacin*, Ofloxacin, Levofloxacin 
Third generation^ Sparfloxacin, Gatifloxacin, Grepafloxacin 
Fourth generation˝ Trovafloxacin, Moxifloxacin, Gemifloxacin 
* Most potent agent against Pseudomonas aeruginosa. 
^ More potent against Streptococcus pneumoniae and anaerobes. 
˝ Most potent against Streptococcus pneumoniae and anaerobes. 
 
 
Molecular mechanisms of action of quinolones 
 
Each bacterium contains a chromosome which is 1300 mm long, but the average 
bacterium is only 2 mm long and 1 mm wide so bacteria have to deal with this 
topological problem (Nordmann & Poirel. 2005). Therefore, the chromosome is 
subdivided into ~65 regions, which are called “domains,” each of which is ~20 mm 
long, and the size of each domain is reduced by negative supertwisting (i.e., 
supertwisting that occurs against the normal direction of the helical state of DNA in 
its linear form). Several DNA topoisomerases have been identified in bacteria, all of 
them are able to nick one or both of the strands of a double-stranded circular DNA, 
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introduce or remove negative supercoils, and then seal the nicked DNA (Nordmann & 
Poirel. 2005). Introducing and removing such supercoils are vital in DNA replication, 
transcription, recombination, and repair.  
 
Quinolones act by inhibiting the action of topoisomerases II (DNA gyrase) and 
topoisomerase IV. For Gram-negative bacteria the prime target of quinolones is the 
DNA gyrase, whereas in the Gram-positives it is the topoisomerase IV (Andriole. 
2005). Quinolones act by binding to gyrase/topoisomerase IV–DNA complex. 
Formation of quinolone-gyrase/topoisomerase IV-DNA complex is responsible for the 
inhibition of DNA replication and the bacteriostatic action of the quinolones while 
their lethal action is thought to be a separate event from complex formation, and to 
arise from the relapse of free DNA ends from quinolone–gyrase–DNA complexes 
(Nordmann & Poirel. 2005).  
 
 
Resistance to quinolones 
 
Successful treatment outcomes of bacterial infections with quinolones have led to 
increasing use and the extensive use of fluoroquinolones, in turn, has led to mounting 
resistance to these antimicrobials (Hooper. 1999). High rates of resistance to 
quinolones have been reported from different parts of the world. In China, for 
example, more than 50% of the clinical strains of E. coli isolated during 1997-1999 
were resistant to ciprofloxacin (Wang et al. 2001). In Norway, rates of resistance to 
quinolones are somewhat lower (NORM/NORM-VET report, 2006); the prevalence 
of resistance to nalidixic acid for urinary tract and bloodstream E. coli clinical isolates 
was 5.4% and 9.3 %, respectively, while it was 13.1 % for bloodstream Klebsiella 
spp. clinical isolates.  
 
Quinolone resistance generally results from stepwise chromosomal mutations (Ruiz. 
2003). Three mechanisms of chromosomal-mediated quinolone resistance have been 
established to date: alterations in the targets of quinolones and decreased 
accumulation of quinolones due to impermeability of the membrane or due to an over 
expression of efflux pump systems. Target alterations are predominantly in the 
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quinolone-resistance determining region (QRDR), a portion of the DNA-binding 
surface of the topoisomerase at which amino acid substitutions can diminish 
quinolone binding and subsequently cause resistance to quinolones (Ruiz. 2003). 
Recently, plasmid-mediated quinolone resistance (PMQR) has been discovered. This 
resistance comprises the production of Qnr proteins protecting the targets against the 
effects of quinolones (Robicsek et al. 2006), the enzymatic inactivation of certain 
quinolones (Robicsek et al. 2006), and most recently an efflux pump encoded by the 
qepA gene (Yamane et al. 2007). 
 
 
The Qnr proteins 
 
Three Qnr determinants have been discovered so far, namely QnrA, QnrS, and QnrB. 
The first plasmid-mediated quinolone resistance gene, named qnrA1, was detected in 
a K. pneumoniae clinical isolate from the USA in 1998 (Martinez-Martinez et al. 
1998). Later on, the qnrS1 and the qnrB1 genes were first discovered from a clinical 
Shigella flexeneri 2b isolate in Japan (Hata et al. 2005) and from a K. pneumoniae 
strain isolated in South India (Jacoby et al. 2006), respectively.  
 
Although QnrB and QnrS share only about 40% and 60% amino acid identity with 
QnrA, respectively, the three determinants belong to the pentapeptide repeat family 
and they all protect the DNA gyrase and topoisomerase IV from the action of 
quinolone agents, including the fluoroquinolones (Robicsek et al. 2006). By making a 
search in the GenBank® sequence database (http://www.ncbi.nlm.nih.gov/Genbank/) 
provided by the National Center for Biotechnology Information (NCBI), 6 variants of 
QnrA, 2 variants of QnrS and 17 variants of QnrB have been identified so far 








Distribution and origin of Qnr determinants 
 
Qnr determinants have then been identified worldwide in remotely related areas from 
America, Europe, Asia, and Africa (Nordmann & Poirel. 2005 and Touati et al. 2008).  
They have been detected in a series of enterobacterial species, including E. coli, 
Citrobacter freudii, Enterobacter spp, Klebsiella spp, Providencia stuartii, 
Salmonella spp, Proteus mirabilis, and Serratia marcescens (Jeong et al. 2005, 
Mammeri et al. 2005, Nazic et al. 2005, Poirel et al. 2006, Rodriguez-Martinez et al. 
2006, Wang et al. 2003, Cambau et al. 2006, and Park et al. 2007). In addition, QnrA 
has recently been discovered in Acinetobacter baumannii, a non-Enterobacterial 
Gram-negative (Touati et al. 2008). So far, none of these determinants have been 
identified in Pseudomonas aeruginosa, a clinically important non-enterobacterial 
Gram-negative bacterium, though this could be due to modest screening (Robicsek et 
al. 2006). The wide geographical distribution of qnr genes in different enterobacterial 
species means that these genes have been in flow, though hidden, for some time.  
 
While the qnrA gene is thought to have originated in Shewanella algae, an 
environmental species from marine and fresh water (Poirel et al. 2005), Qnr-like 
proteins have been detected from water-borne Vibrionaceae bacterial isolates and also 
proposed to be a possible origin of the clinically more important QnrA, QnrS, and 
QnrB determinants (Poirel et al. 2005). These Qnr-like proteins shared 40-67% 
identity with the clinically important Qnr-proteins and once cloned in E. coli they 
conferred reduced susceptibility to quinolones. Moreover, two new genes named 
qnrVS1 and qnrVS2 were identified from Vibro splendidus and another Vibro spp. 
environmental isolates, respectively, and considered as a natural reservoir of qnrS 
genes (Cattoir et al. 2007). All these findings underlines that Gram-negative bacterial 
species of the aquatic environment such as Shewanellaceae and Vibrionaceae maybe 







Resistance levels mediated by Qnr determinants 
 
The qnrA determinant increased MICs of nalidixic acid and fluoroquinolones when 
was cloned in E. coli J53 from 4 µg/ml to 32 µg/ml and from 0.008 µg/ml to 0.25 
µg/ml, respectively (Tran & Jacoby. 2002). By comparing the results from several 
reports, it can be found that the increase in quinolone resistance due to qnrA, qnrS, or 
qnrB gene is quite comparable. Also, it was noticed that qnr proteins reduce the 
activity of nalidixic acid less than that of ciprofloxacin. The qnrA-mediated resistance 
to nalidixic acid was increased 2 folds (from 4 µg/ml to 8 µg/ml) in some studies to 12 
folds (from 4 µg/ml to 48 µg/ml) in other studies while qnrA-mediated ciprofloxacin 
resistance was increased between 12.5 folds (from 0.008 µg/ml to 0.1 µg/ml) and 250 
folds (from 0.008 µg/ml to 2 µg/ml) (Wang et al. 2004, Corkill et al. 2005, Nordmann 
& Poirel. 2005, and Robicsek et al. 2006). The qnrS gene increased the MIC of 
nalidixic acid 3 - 8 folds and of ciprofloxacin between 16 - 62.5 folds (Chen et al. 
2006, Gay et al. 2006, Kehrenberg et al. 2006, Poirel et al. 2006, and Hu et al. 2008). 
Transfer of qnrB resulted in 4 - 8 folds increase in the MIC of nalidixic acid and 8 - 
62.5 folds in the MIC of ciprofloxacin (Jakoby et al. 2006, Gay et al. 2006, Pai et al. 
2007, Kehrenberg et al. 2007).  
 
The donor bacteria, which are generally clinical isolates, most often exhibited higher 
levels of quinolone resistance than the transconjugants. This can be explained by the 
co-presence of additional chromosome-encoded mechanism of quinolone resistance, 
particularly mutations in the QRDR of gyrA and parC genes (Nordmann & Poirel. 
2005). In some cases, the differences in resistance levels among transconjugants can 
be due to the transfer of other PMQR mechanisms, such as the AAC(6`)-Ib-cr enzyme 
(Robicsek et al. 2005). 
 
 
Genetic environment of qnrA 
 
The qnrA variants are typically located on plasmids (Nordmann & Poirel. 2005). 
These plasmids frequently carry other antibiotic resistance genes and although they 
were generally transferable, in some cases they were not (Nordmann & Poirel. 2005). 
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However, qnrA was recently detected in an E. coli clinical isolate from Denmark 
where, interestingly, hybridization with the qnrA probe was observed to the 
chromosomal DNA (Cavaco et al. 2007).  
 
qnrA genes were often embedded in complex sul1-type integrons (Nordmann & 
Poirel. 2005). These genetic structures possess one 5`-conserved segment (5`-CS) 
which contains intI1 gene encoding for the integrase enzyme and duplicated 3`-
conserved segments (3`-CS) each of them contains qacE∆1 and sul1 genes. The two 
3`-CS surround a common region (CR) which contains the ISCR1 (orf513) and a 
unique region (Nordmann & Poirel. 2005). The Orf513 protein may act as a 
recombinase for mobilization of downstream-located antibiotic resistance genes. The 
qnrA gene was not associated with a 59-be element as a form of a gene cassette 
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Figure 6. Genetic environment of qnrA located in complex 






Genetic environment of qnrS 
 
The qnrS genes are also typically located on plasmids but, in contrast to qnrA, they 
are not part of a sul1-type class 1 integron structure (Hata et al. 2005). Association 
between qnrS1 and a Tn3-like blaTEM-1-containing transposon has frequently been 
detected; on a conjugative 47 kb plasmid, pAH0376, from a Sh. Flexneri isolate from 
Jaban (Hata et al. 2005) (figure 7), on a conjugative 58 kb plasmid, pINF53, from a 
Salmonella enterica serovar Infantis isolate from Germany (Kehrenberg et al. 2006) 
(figure 7), and in three Salmonella enterica serovar Virchow isolated from Turkish 
foods of avian origin (Avsaroglu et al. 2007).  
 
A novel Ambler classA ß-lactamase gene, now named blaLAP-1, instead of the Tn3 
element, has also been repeatedly detected upstream to qnrS; on a non-conjugative 98-
kb plasmid, pK245, from a clinical K. pneumoniae strain isolated in Taiwan (Chen et 
al. 2006), in five E. cloacae isolates from France as well as in one E. cloacae isolate 
from Vietnam (Poirel et al. 2007), and on a conjugative plasmid isolated from a 
clinical K. pneumoniae strain from Spain (Lavilla et al. 2007). The region containing 
qnrS and bla in pK245 appears to be a composite transposon bounded by two flanking 
IS26 elements in a head-to-tail arrangement which may be responsible for the 




Figure 7. Schematic diagram comparing the qnrS-containing region of pK245, pAH0376 
from S. flexneri, and pINF5 from S. enterica serovar Infantis (Chen et al. 2006) 
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In addition, the two resistance genes were always separated by 1,597 bp that included 
the insertion sequence ISEcl2 (Poirel et al. 2007). In silico analysis showed that this 
ISEcl2 element was also present in the qnrS1-positive pINF5 plasmid of S. enterica 
serotype Infantis and in the qnrS1-positive pAH0376 plasmid of Sh. flexeneri 2b 
(Poirel et al. 2007) (figure 8). A truncated resolvase protein and a segment showing 
significant homology with the E. coli CS12 fimbrial gene cluster have been identified 
downstream to the qnrS1 gene (Kehrenberg et al. 2006 and Poirel et al. 2007) (figure 
8). However, this segment was not detected in two E. cloacae isolates from France 
(Poirel et al. 2007) (figure 8). Furthermore, it was in the opposite orientation in three 
other E. cloacae isolates from France (Poirel et al. 2007) (figure 8) and in one 











orfA qnrS1 ∆res 213259 res 196
∆orfAbla LAP-1pbp-3
∆ISEcl2
orfB qnrS1 ∆res 213259 res 196
∆orfAbla LAP-1pbp-3
∆ISEcl2




E. Cloacae isolate S3
E. Cloacae isolates 
S1, S5, and S6
E. Cloacae isolates 
S4 and 287  
 
 
Figure 8. Schematic diagram comparing the qnrS-containing region of pAH0376 from S. 
flexneri and pINF5 from S. enterica serovar Infantis with that detected in E. cloacae isolates 
(adapted from Poirel et al. 2007). 
 
 
Another variant, QnrS2, having 92% amino acid identity to QnrS1 was later on 
detected in a highly mobile broad-host-range 8.5 kb plasmid, pGNB2, isolated from 
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an activated sludge bacterial community of a wastewater treatment plant in Germany 
(Bonemann et al. 2006). This qnrS2 gene was not part of an integron but was linked to 
orf1, a remnant of a Tn1721-like transposon. Interestingly, the G+C content of the 
orfI-qnrS2 gene region differs considerably from the rest of the plasmid, suggesting 
that pGNB2 acquired qnrS2 together with Tn1721 orfI (Bonemann et al. 2006).  
 
 
Genetic environment of qnrB 
 
Although qnrB variants are generally plasmid-carried, a chromosomal location of 
qnrB12 gene appeared most likely since repeated plasmid transformation-conjugation 
experiments yielded negative results, and Southern blot hybridization studies with 
plasmid profiles and with I-CeuI-digested genomic DNA gave a signal only with the 
largest fragment, approximately 800 kb, in each strain (Kehrenberg et al. 2008). 
 
The qnrB1 gene was reported to be associated with the orf1005 gene, encoding a 
putative transposase (Jacoby et al. 2006). Between orf1005 and qnrB1, there was an 
open reading frame, orf1, which resembles a truncated pspF gene coding for the 
transcriptional activator of the stress-inducible psp operon (figure 9). orf1 was again 
found upstream qnrB2 while downstream it there were other two open reading frames; 
orf2, which resembles genes encoding hypothetical proteins of several Gram-negative 
species, and orf3, which has 83% identity to the sapA gene encoding a peptide 
transport periplasmic protein (Jacoby et al. 2006). orf1005 was not present in any of 







Figure 9. Genetic environment of qnrB1 and qnrB2 genes. orf1 resembles pspF, orf2 is 
related to genes of unknown function in various Gram-negative bacteria, and orf3 resembles 
sapA (adapted from Jacoby et al. 2006).  
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The qnrB2 determinant was also reported to be located in a complex sul1-type 
integron (Garnier et al. 2006). The genetic structure contained two class 1 integrons 
surrounding two common regions (CRs) separated by a partial 3'-conserved segment. 
The qnrB2 gene was adjacent to the first CR and in the opposite orientation (figure 
10). Once more, the qnrB2 determinant and the qnrB6 determinant in Citrobacter spp. 
clinical isolates from Spain were all carried in complex sul1-type integrons (Sanchez-





Figure 10. Genetic environment of the qnrB2 gene (adapted from Garnier et al. 2006). 
 
 
The genetic environment of the qnrB4 gene was found to be bracketed at its 5' 
extremity by a psp operon coding for putative phage shock proteins and at its 3' 
extremity by a sap operon coding for a putative peptide transport system permease 
(Cattoir et al. 2007). However, the qnrB4 gene carried on plasmid pHS7 from a 
clinical isolate of K. pnemoniae from China was located in a sul1-type integron with 
orf1, blaDHA-1, ampR, psp operon, and partial qacE∆1 upstream and aphA1, IS26, and 
sapA and partial sapB genes downstream the qnrB4 gene (Hu et al. 2008) (figure 11). 
The structure adjacent to qnrB4 was similar to that in plasmids, pRBDHA and 
pMPDHA with GenBank accession numbers AJ971343 and AJ971344, respectively 
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Figure 11. Genetic environment of the qnrB4 gene (Hu et al. 2008). 
 
 
qnrB10 was located in the unique region of three different complex class 1 integrons 
downstream of ISCR1 (orf513), one of them also containing aac(6')-Ib-cr within its 
the variable region (Quiroga et al. 2007) (figure 12). While, the qnrB12 gene was 
located downstream of four open reading frames, pspF, pspA, pspB, and pspC, 


































Figure 12. Genetic environment of the qnrB10 gene (adapted from Quiroga et al. 2007). 
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The AAC(6`)-Ib-cr enzyme 
 
Bacterial enzymes that modify antimicrobial agents have principally coevolved with 
the antimicrobial agent on which they act (Robiscek et al. 2006). Therefore, selective 
enzymatic modification of fluoroquinolone by bacteria has been thought not to exist 
in nature since quinolones are fully synthetic and consequently the time for 
coevolving such quinolone-modifying enzymes is limited. However, a plasmid-
mediated enzyme able to attack some quinolone agents has recently been discovered 
(Robiscek et al. 2006). This enzyme, AAC(6`)-Ib-cr, represents a new variant of a 
common aminoglycoside acetyltransferase, AAC(6`)-Ib, that reduces the activity of 
both the aminoglycosides kanamycin, tobramycin, and amikacin and the 
fluoroquinolones ciprofloxacin and norfloxacin and hence stands for an unpredictable 
new mechanism of quinolone resistance.  
 
The -cr variant of AAC(6`)-Ib has two amino acid changes, Trp102Arg and 
Asp179Tyr, which together are necessary and sufficient for the enzyme’s ability to 
acetylate ciprofloxacin (Robiscek et al. 2006). This enzyme reduces the activity of 
ciprofloxacin by N-acetylation at the amino nitrogen on its piperazinyl substitute. 
Ciprofloxacin and norfloxacin are the only fluoroquinolones with diminished activity 
in the presence of aac(6`)-Ib-cr since they are the only compounds harboring an 
unsubstituted piperazinyl group.  
 
AAC(6`)-Ib-cr plays an important role in fluoroquinolone-resistance. First of all, the 
prevalence of aac(6`)-Ib-cr has been reported to be common in clinical isolates of 
Gram-negative bacteria (Nordman & Poirel. 2005). For example, 51% of the 
ciprofloxacin-resistant clinical E. coli isolates collected from China had aac(6`)-Ib-
cr(Robiscek et al. 2006). The prevalence of aac(6`)-Ib-cr in this collection exceeded 
that of qnr by over six folds. Secondly, although the degree of resistance conferred by 
aac(6`)-Ib-cr is low, when both qnr and aac(6`)-Ib-cr are present in the same cell, the 
level of resistance is increased to a value near the clinical breakpoint for 
susceptibility. Thirdly and maybe most importantly, the presence of aac(6`)-Ib-cr 
increased substantially the frequency of selection of chromosomal mutants upon 
























































• Evaluate the prevalence of aac(6’)-Ib, qnrA, qnrB, and qnrS genes among E. 
coli and K. pnumoniae clinical isolates from Norway and Sweden.  
• Analyse the susceptibility profile of the qnr-positive isolates. 
• Sequencing the quinolone resistance-determining region (QRDR) of gyrA and 
parC for the qnr-positive isolates to detect chromosomal mutations that could 
be linked to quinolone resistance. 
• Evaluate the mobility of the qnr-genes by transconjugation and transformation 
experiments. 
• Characterize the qnr-carrying plasmids with respect to number, size, and 
incompatibility group. 














































A total of 487 clinical isolates of E. coli (426) and Klebsiella spp. (61) was chosen for 
this study. Resistance to nalidixic acid (MIC > 16 µg/ml) and resistance or reduced 
susceptibility to ciprofloxacin (MIC ≥ 0.125 µg/ml) were the criteria used for 
selecting these isolates. The clinical MIC breakpoints for nalidixic acid and 
ciprofloxacin were used as defined by NWGA (Norwegian Working Group on 
Antibiotics) or EUCAST (European Committee on Antimicrobial Susceptibility 
Testing) (appendix A, table 2). 
 
Overall, the study included 472 nalidixic acid-resistant, 12 nalidixic acid-susceptible 
but with reduced susceptibility to ciprofloxacin, and 3 nalidixic acid-susceptible but 
ciprofloxacin-resistant isolates. The isolates taken in this study were drawn from five 
different collections (Table 4). Two collections, Kronoberg collection and NORM 
collection, contained clinical isolates from Sweden and Norway representing the 
common bacterial population; they together comprised 370 isolates. The rest, 117 
isolates, was picked from three different K-res (the Reference Centre for Detection of 
Antimicrobial Resistance) studies; the AmpC study, Ullevål ESBL study, and 
Norwegian ESBL study representing a collection of clinical isolates with other 
resistance mechanisms. The five collections are:  
   
1- Kronoberg collection (n= 152) 
 
This collection included 152 consecutive E. coli clinical isolates from urine specimens 
collected between June 2004 and January 2005 in Kronoberg County, Sweden 
(Bengtsson et al. 2007). 151 isolates were nalidixic acid-resistant and only 1 isolate 
was nalidixic acid susceptible but showed reduced susceptibility to ciprofloxacin 
(appendix A, table 3). 
 
 38
2- NORM collection 2005 (n= 218) 
 
This collection included 165 E. coli and 53 Klebsiella spp. consecutive clinical 
isolates from blood or urine specimens collected during 2005 from several clinical 
microbiology laboratories in Norway (NORM/NORM-VET 2006 report). 207 isolates 
were resistant to nalidixic acid (161 E. coli and 46 Klebsiella spp.) and 11 isolates (4   
E. coli and 7 Klebsiella spp.) were nalidixic acid-susceptible, 2 of them were resistant 
to ciprofloxacin and 9 showed reduced susceptibility to ciprofloxacin (appendix A,     
table 4).  
 
3- E. coli AmpC study (n= 13) 
 
13 nalidixic acid-resistant E. coli clinical isolates from the E. coli AmpC study were 
selected and screened (appendix A, table 5). All the isolates of the E. coli AmpC 
study had an AmpC phenotypic susceptibility profile and were firstly collected to 
analysis their genetic AmpC profile (Haldorsen et al. 2007).  
   
4- Ullevål ESBL study (n= 60) 
 
60 nalidixic acid-resistant clinical isolates (59 E. coli and 1 K. pnumoniae) from the 
Ullevål ESBL study were included in this study (appendix A, table 6).  
  
5- Norwegian ESBL study (n= 44) 
 
44 clinical isolates (33 E. coli and 11 K. pnumoniae) from the Norwegian ESBL study 
were included in this study (Tofteland et al. 2007). Of these isolates, 41 isolates were 
nalidixic acid-resistant (33 E. coli and 8 K. pnumoniae) and 3 nalidixic acid-
susceptible Klebsiella spp. (two isolates were ciprofloxacin-resistant and 1 isolate 




Strains with known qnr genes (E. coli A2-67 containing qnrA gene, E. coli A3-22 
with qnrB gene, E. coli A3-20 with qnrS gene, and E. coli A3-21 with aac(6’)-Ib-cr 
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gene) were used as positive controls while reaction mixes without DNA template 
served as negative controls for the polymerase chain reactions (PCR). In addition, the 
rifampicin-resistant E. coli J53-2 and the chemically competent E. coli TOP’10 
(Invitrogen, USA) were used as the recipient strains in transconjugation and 
transformation experiments, respectively.  
 














Kronoberg collection  152 152 0 151 1 0 
NORM collection  218 165 53 207 9 2 
E. coli AmpC study  13 13 0 13 0 0 
Ullevål ESBL study  60 59 1 60 0 0 
Norwegian ESBL study  44 33 11 41 2 1 
Total  487 422 65 472 12 3 
* All isolates were identified at participating sites by routine procedures performed at each laboratory. 
 
 
Preparation of stock cultures 
 
Stock cultures were prepared of all the clinical isolates examined in this study using 
glycerol as the osmotic protector.  
 
Procedure:  
1. 8 to 10 colonies from an overnight incubated green agar plates (appendix C) 
were inoculated in 1 ml freeze broth (appendix C). 
2. The broth was homogenized on a vortex mixer and stored at -70°C. 
3. Control green agar plates were inoculated and incubated at 37°C overnight to 
check for contamination. 
4. If the control plate showed contamination, the strain was purified by re-





Isolation of DNA from bacterial cells 
  
Procedure for isolating the DNA using the robot GenoM™-48 (Geno Vision, USA): 
1. An inoculum of 0.5 McFarland was prepared in 200 µl of 0.9 % NaCl.  
2. The sample tubes were placed in the robot which performed all steps of 
isolation, including sample lysis, binding to the GenoPrep™ beads, washing 
steps, and the elution. 
3. When the robot was finished, the screw caps were replaced and samples were 
stored at 2 to 8º C. 
 
Procedure for rapid isolating of DNA: 
1. 8 to 10 colonies of bacteria were dissolved in 1 ml TE-buffer (appendix C) in 
an Eppendrof tube. 
2. The tubes were spun at 5000 rpm for 5 min. 
3. The pellets were re-suspended in 100 µl TE-buffer. 
4. The tubes were boiled for 10 min at 100º C. 
5. Then they were spun at 5000 rpm for 5 min (Eppendrof tubes were placed on 
ice).    
6. The supernatants were transferred to new clean Eppendrof tubes. 
7. Samples were stored at 2 to 8º C. 
 
 
Polymerase Chain Reaction (PCR) 
 
In 1983, Kary Mullis invented a process of amplifying the number of specific nucleic 
acid fragments present in a sample (Mullis. 1990). This process was termed 
Polymerase Chain Reaction (PCR) and has become the most common technique used 
in medical and biological research laboratories for isolating and exponentially 
amplifying a specific region of DNA (Wolcott. 1992). To carry out a PCR 





These components include: 
1. DNA template containing the region of the DNA fragment to be amplified. 
2. DNA polymerase used to synthesize a DNA copy of the region to be 
amplified. 
3. A pair of oligonucleotide primers complementary to the DNA regions at the 5` 
and 3` ends of the DNA region that is to be amplified. 
4. A supply of Deoxynucleotide triphosphates (dNTPs) from which the DNA 
polymerase builds the new DNA. 
 
The PCR reaction most commonly follows three steps (Brown. 2002). In the 
denaturation step, the PCR reaction is heated to a temperature of around 95 °C where 
the hydrogen bonds of the double helix are broken resulting in single-stranded 
molecules to be used as templates. In the annealing step, the reaction temperature is 
lowered to around 50-60°C so that the primers can anneal to the single-stranded DNA 
template forming short segments of double-stranded DNA where the polymerase 
attaches and begins DNA synthesis. During the extension/elongation step, the DNA 
polymerase synthesizes new DNA strands complementary to the DNA template 
strands. A temperature of 72°C, the optimum for Taq polymerase, is generally used at 
this step.  
 
In this first cycle of the PCR, a pair of long PCR products is synthesized from each 
strand of the target DNA (Brown. 2002). These polynucleotides have identical 5′ ends 
but random 3′ ends representing positions where DNA synthesis terminates by 
chance. By repeating the cycle of denaturation-annealing- synthesis, the long products 
act as templates for new DNA synthesis, giving rise to short amplicons whose 5′ and 




                         
 
Figure 13. The first cycle of denaturation-annealing-synthesis results in two long products. 
Then, the next cycle leads to four products two of which are identical to the first cycle 
products and two of which are made entirely of new DNA. During the third cycle, the latter 




When the PCR reaction components are mixed at room temperature (below the 
optimal primer annealing temperature), non-specific primer annealing may take place 
and extension products possibly will be formed. These products can later be amplified 
in the PCR, resulting in non-specific PCR products (Birch et al. 1996). In hot-start 
PCR technique, one essential reagent is withheld from the PCR mixture until the PCR 
machine has reached a temperature that favours specific primer annealing (Birch et al. 
1996). This can be achieved either by mechanically separating one reagent or by 
blocking the polymerase enzyme with antibodies. Hot start PCRs have greatly 
improved specificity, sensitivity, and yield (Birch et al. 1996).  
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In this study, hot-start PCRs were performed by using the JumpStart™ REDTaq® 
ReadyMix™ PCR Reaction Mix (Sigma-Aldrich LP, USA). The antibody-inactivated 
polymerase enzyme employed in this study helped in minimizing non-specific 
amplifications without compromising the desired high target yield as its activity is 
fully restored during the first denaturation cycle of the PCR reaction.  
 
 
PCR-based detection of 16SrDNA  
 
The 16SrDNA-PCR provides a quick check of the quality of the DNA extraction and 
can be used as a positive control for other PCRs (Ivanova et al. 2007). Strong 
16SrDNA-PCR products indicate that DNA templates are generally of high quality 
while unsuccessful amplification of 16SrDNA reflects poor DNA isolation, DNA 
degradation, or the presence of PCR inhibitors. Universal primers, to give PCR 
product of about 1500 bp, were used (Weisburg et al. 1991) (appendix A, table 8). 
 
Procedure: 
1. PCR Mastermix: 
Reagent Amount 
JumpStart™ REDTaq® ReadyMix™ PCR Reaction Mix* 
(Sigma-Aldrich LP, USA): 
500 µl 
16SrDNA-F primer 50 pmole/µl (Eurogentec S.A., Belgium): 8 µl 
16SrDNA-R primer 50 pmole/µl (Eurogentec S.A., Belgium): 8 µl 
ddH2O: 384 µl 
   * http://www.sigmaaldrich.com/sigma/bulletin/P0982bul.pdf 
 
2. For each reaction, 2.5 µl template was added to 22.5 µl PCR Mastermix. 
3. The PCR thermocycler was programmed (appendix A. table 9). 
 
 
Multiplex PCR-based screening for qnrA, qnrB, and qnrS  
 
In multiplex PCR more than one target sequence are amplified by including more than 
one pair of primers in the reaction (Elnifro et al. 2000). Multiplex PCR has the 
potential to produce considerable savings of time and effort within the laboratory 
without compromising test utility. In addition using several uniplex PCRs can be 
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limited by the availability of adequate volume of the test samples, PCR templates. 
Screening for the presence of qnrA, qnrB, and qnrS genes was done by modification 
of previously described PCR protocol (Robicsek et al 2006). The amplification was 
done using JumpStart REDTaq ReadyMix ReactionMix and using specific primers for 
qnrA, to give a 516-bp product, for qnrB, to give a 469-bp product, and for qnrS, to 
give a 417-bp product (Robicsek et al 2006) (appendix A, table 8). The conditions 
were altered to 95°C for 5 minutes then 30 cycles of 95°C for 15 seconds, 55°C for 15 
seconds, and 72°C for 40 seconds, then 72°C for 4 minutes (appendix A, table 9).  
 
Procedure: 
1. PCR Mastermix: 
Reagent Amount 
JumpStart™ REDTaq® ReadyMix™ PCR Reaction Mix      
(Sigma-Aldrich LP, USA): 
12.5 µl 
qnrA-F.multiplex primer 50 pmole/µl (Eurogentec S.A., Belgium) 1 µl 
qnrA-R.multiplex primer 50 pmole/µl (Eurogentec S.A., Belgium) 1 µl 
qnrB-F.multiplex primer 50 pmole/µl (Eurogentec S.A., Belgium) 1 µl 
qnrB-R.multiplex primer 50 pmole/µl (Eurogentec S.A., Belgium) 1 µl 
qnrS-F.multiplex primer 50 pmole/µl (Eurogentec S.A., Belgium) 1 µl 
qnrS-R.multiplex primer 50 pmole/µl (Eurogentec S.A., Belgium) 1 µl 
ddH2O 5.5 µl 
 
2. For each reaction, 1 µl template was added to 24 µl PCR Mastermix. 
3. The PCR thermocycler was programmed (appendix A. table 9). 
 
 
PCR-based screening for aac(6')-Ib  
 
Screening for the presence of aac(6’)-Ib gene was done by modification of previously 
described PCR protocol (Park et al. 2006). The amplification was done using 
JumpStart REDTaq ReadyMix ReactionMix and using specific primers for aac(6’)-Ib 
to give a 482-bp product (Park et al, 2006) (appendix A, table 8). The PCR conditions 
were altered to 95°C for 5 minutes then 30 cycles of 95°C for 15 seconds, 58°C for 15 






1. PCR Mastermix: 
 Reagent Amount 
JumpStart™ REDTaq® ReadyMix™ PCR Reaction Mix 
(Sigma-Aldrich LP, USA): 
12.5 µl 
aac(6’)-Ib-F primer 50 pmole/µl (Eurogentec S.A., Belgium): 1 µl 
aac(6’)-Ib-R primer 50 pmole/µl (Eurogentec S.A., Belgium): 1 µl 
ddH2O: 9.5 µl 
 
2. For each reaction, 1 µl template was added to 24 µl PCR Mastermix. 
3. The PCR thermocycler was programmed (appendix A. table 9). 
 
 
Agarose gel electrophoresis  
  
Gel electrophoresis is a simple, rapid and highly sensitive method that is widely used 
to separate DNA and RNA molecules by size (Lodish et al. 2000). Because the rates 
at which these molecules travel are inversely proportional to their molecular weight, 
gel electrophoresis can also be used to estimate the unknown size of nucleic acid 
molecules by comparison with the migration of molecules of known size, called 
molecular ladders. DNA and RNA nucleic acids are negatively charged so they 
migrate through the gel in the direction toward the positive electrode of the electric 
field (Lodish et al. 2000). The gel acts as a sieve; it normally impedes the movement 
of larger molecules. Therefore, smaller molecules move faster along the gel matrix 
than larger molecules and so molecules of different length are separated by size.  
 
Procedure:  
1. 1.5 % agarose (Bio-Rad, USA) in 0.75x TBE buffer (appendix C) was made 
(the agarose was dissolved by boiling the solution in microwave oven).  
2. 0.5 µg/ml EtBr (Sigma-Aldrich LP, USA) was added for staining the DNA 
molecules. 
3. The agarose-EtBr solution was poured into the gel tray of the electrophoresis 
apparatus containing the combs and allowed to set for about 20 minutes. 
4. 5 µl of each PCR product was loaded into the gel wells. 
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5. 5 µl of 1 KB plus DNA molecular size marker (Invitrogen, USA) (appendix C, 
figure 1) was loaded into the flanking wells.  
6. The electrophoresis was run at 120V for approximately 1 hour and 15 minutes. 
7. The gel was visualized on GelDoc system (BioRad, USA) and stored on disks 





A test may be said to be repeatable when it is repeated by the same person or 
instrument on the same item and under the same conditions and it re-yields the same 
results or the variation in the results is smaller than some agreed limit (Taylor et al, 
1994). According to NIST (National Institute of Standards and Technology), 
repeatability conditions include: 
1. The same measurement procedure 
2. The same observer 
3. The same measuring instrument, used under the same conditions 
4. The same location 
5. Repetition over a short period of time. 
 
For this study, all the qnr- and aac(6’)-Ib-positive as well as a randomly chosen qnr- 
and aac(6’)-Ib-negative clinical isolates were re-tested for presence/absence of qnr 
and aac(6’)-Ib genes, respectively. 
 
 
Identification of the aac(6’)-Ib-cr variant by restriction digestion  
 
Restriction endonucleases are enzymes that recognize specific DNA sequences and 
cleave the DNA in or close to the recognition site (Snyder & Champness. 2007). The 
restriction endonucleases are made only by bacteria where they are mostly associated 
with a methylating activity. The methylating activity modifies the bacterial own DNA 
and turns it immune to cutting while the restriction activity plays a role in protecting 
these bacteria from invading foreign unmodified phage DNA. These enzymes are 
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classified into three groups. The enzymes of the three groups differ in the relationship 
between their cutting and methylating activities. The type II enzymes serve as leading 
tools in molecular biology since the sequences recognized by many of them are 
palindromic, resulting in complementary sticky ends that are practical for DNA 
cloning (Snyder & Champness. 2007). More than 3500 type II restriction 
endonucleases with over 200 different specificities have been isolated (Roberts et al. 
2005).  
 
Restriction enzyme identification of the aac(6’)-Ib-cr variant was done as previously 
described (Park et al. 2006). However, BtsCI restriction enzyme (New England 
Biolabs, USA) which has the same recognition site as BstF5I used by Park et al. 2006 
was used in this study (figure 14). This recognition site is only present in the aac(6’)-
Ib wild-type gene while the aac(6’)-Ib-cr gene variant lacks it (Park et al. 2006). 
Subsequently, when the positive aac(6`)-Ib-PCR products were purified and treated 
with BtsCI, only those of  wild-type gene were digested into two fragment products 
while those of the -cr variant were not been cut. 
 
5` GGATG   NN ˇ  3` 
3` CCTAC ˇ NN    5` 
Figure 14. The recognition sequence of restriction enzymes BtsCI and BstF5I  




1. All the positive aac(6’)-Ib-PCR products detected in this study were purified 
according to the E.Z.N.A™ Cycle-Pure Kit Spin Protocol (Omega Bio-tek, 
USA) (appendix D, kit 1) and used as template for the restriction digestion 
reaction.  
2. Restriction digestion Mastermix: 
Reagent Amount 
NEB Buffer4 (10×)* (New England Biolabs, USA): 2 µl 
BtsCI ** (New England Biolabs, USA): 1 µl 





3. For each reaction, 5 µl template was added to 15 µl restriction digestion 
Mastermix. 
4. Digestion was carried out for 2 hours at 50°C. 
5. Gel electrophoresis was performed as mentioned above. However, 4 µl 
Loading Buffer 6X (Promega, USA) was added to each digestion product and 
then 15 µl of each digestion product was loaded for gel electrophoresis. 
 
       
DNA Sequencing  
 
Determining the precise sequence of nucleotides of a DNA fragment is the ultimate 
characterization of its genetic structure (Griffiths et al. 1999). The sequencing method 
most commonly used nowadays was developed by Fred Sanger (Sanger et al. 1977). 
It is based on DNA synthesis in the presence of dideoxynucleotides, which differ from 
normal deoxynucleotides in that they lack a 3′-hydroxyl group.  
 
In the traditional dideoxy sequencing methods, four parallel base-specific reactions 
should be conducted using a mix of all four dNTPs and a small proportion of one of 
the four ddNTPs (Griffiths et al. 1999). DNA synthesis proceeds normally until, by 
chance, DNA polymerase inserts a dideoxynucleotide instead of the normal 
deoxynucleotide. When a dideoxynucleotide is added to the growing DNA strand, it 
terminates the chain elongation because there is no 3′-OH for the next nucleotide to be 
attached. Therefore, in any given tube, various truncated chain lengths will be 
produced. These fragments are next separated by electrophoresis of the four samples 
in four lanes on an acrylamide gel. By scanning up the gel and analyzing the bands, 





Figure 15. Dideoxy DNA sequencing relies on synthesizing new DNA strands from a single-
stranded DNA template and random incorporation of a base-specific dideoxynucleotide to 
terminate chain synthesis. (A) Principle of dideoxy sequencing. (B) Conventional DNA 
sequencing (Griffiths et al. 1999). 
 
 
The recent procedures have employed a different fluorescent color emitter for each of 
the four reactions and have used automated fluorescence detection machines 
(Strachan & Read. 1999). As a result, all four reactions can be loaded into a single 
lane and a monitor will detect and record the fluorescence signal as the DNA passes 





Figure 16. Automated DNA sequencing using fluorescent primers. (A) Principles of 
automated DNA sequencing. (B) Example of DNA sequence output (Strachan & Read. 1999). 
 
 
Sequencing of the qnr- and aac(6`)-Ib-cr positives 
 
Sequencing was performed in this study by using the BigDye v3.1 sequencing 
chemistry (Applied Biosystems, USA). To confirm the identification of qnrB, qnrS 
genes detected by multiplex PCR screening and to determine to which variant those 
qnrB and qnrS genes belong, same primers used in the qnr-multiplex PCR screening 
were used for sequencing both strands of the detected qnrS and qnrB genes (Robicsek 
et al, 2006). To confirm the identification of aac(6’)-Ib-cr genes (detected by PCR 
screening and identified by restriction digestion), sequencing of one strand of the 
aac(6’)Ib gene was performed using primer aac(6’)Ib-SEQ (Park et al. 2006) 
(appendix A, table 8).  
 
Procedure:  
1. The positive qnr-multiplex PCR products, all positive aac(6’)-Ib PCR 
products identified by restriction as aac(6’)-Ib-cr, and 10 positive aac(6’)-Ib 
PCR products identified by restriction as aac(6’)-Ib wild-type were purified 
(appendix D, kit1) and used as template for sequencing. 
 51
 
2. Sequencing master mix: 
Reagent Amount 
Big-Dye v3.1 (Applied Biosystems, USA):            2 µl 
Sequencing buffer (Applied Biosystems, USA): 3 µl 
Primer 3.2 pmol/µl:   1 µl 
ddH2O:                   12 µl 
 
3. For each reaction, 2 µl template was added to 18 µl master mix: 
4. The PCR thermocycler was programmed (appendix A. table 9).  
5. Nucleotide sequencing was performed at the Sequencing core facility. 
6. Searching for nucleotide sequence homology was performed using BLAST 
available at the National Center for Biotechnology Information website 
(http://www.ncbi.nlm.nih.gov/BLAST). 
7. Nucleotide and deduced amino acid sequences were aligned, compared with 
published sequences of qnrS1, qnrS2, qnrB1 to qnrB17, aac(6’)-Ib, and 
aac(6’)-Ib-cr using the lasergene software package (DNASTAR) and the 
online software ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2). 
 
 
Etest susceptibility testing   
             
Etest is an extensively used method for antibiotic susceptibility testing of a wide 
variety of microorganisms (Pfaller et al. 1999). The Etest strips contain known 
gradients of antimicrobial agents and calibrated in a special teqnique to give a stable-
gradient agar diffusion, allowing quantitative measurement of the minimal inhibitory 
concentrations (MICs) of the agents (Pfaller et al. 1999). The MIC is the lowest 
concentration of the antibiotic that results in inhibition of visible growth (i.e. colonies 
on a plate or turbidity in broth culture) under standard conditions (Mayer. 2007). 
 
Antibiotic susceptibility for the qnrS- and qnrB-positive clinical isolates detected in 
this study as well as E. coli J53-2 and E. coli TOP’10 which was used as a recipients 
in the transfer experiments was determined using Etest (AB BIODISK, Solna, 
Sweden) on Mueller-Hinton (MH) agar plates (appendix C) with 16 to 20 hour of 
incubation at 37°C. The isolates were tested against: nalidixic acid, norfloxacin, 
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ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gatifloxacin, ampicillin, 
amoxicillin–clavulanic acid, cefoxitin, cefuroxime, cefotaxime, ceftazidime, 
ceftazidime–clavulanic acid, piperacillin, piperacillin–tazobactam, cefepime, 
cefepime/clavulanic acid, amikacin, gentamicin, tobramycin, imipenem, meropenem, 
trimethoprim, and trimethoprim–sulfamethoxazol.  
 
Procedure: 
1. Etest strips kept in - 20°C were taken out the freezer and allowed to achieve 
room temperature. 
2. Colonies from an overnight green agar plate were suspended in 3 ml 0.9 % 
NaCl and the turbidity was measured by a densitometer and adjusted to 0.45 – 
0.55 McFarland.  
3. A sterile cotton swab was dipped into the bacterial suspension; excess fluid 
was removed by pressing the swab against the tube wall. 
4. The surface of an MH agar plate (appendix C) was swabbed using of a rotator. 
5. A control spread to check for contaminants was performed. 
6. The surface was let to dry for 10-15 min. 
7. Etest strips were applied, ensuring that no air bubbles were trapped underneath 
them. 
8. The MH agar plates were incubated overnight at 37°C, in stables of 5 plates. 
9. The minimum inhibitory concentration (MIC) values were read at the points 
where the bacterial population is completely inhibited, according to the Etest 
reading guide (http://www.abbiodisk.com/pdf/etm_html/03_etm.htm).    
 
 
VITEK 2, identification and susceptibility testing  
 
Automated systems for bacterial identification and susceptibility testing have been 
used for more than two decades (Ling et al. 2001). The VITEK 2 system (bioMérieux, 
USA) is widely used system that exploits the fluorescence-based technology. VITEK 
2 system has several advantages such as being a closed system that minimizes 
unwanted cross-contamination or environmental contamination. It also has a recheck 
system that can detect and cease operation if a specimen card is misplaced on the 
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specimen cartridge (the Smart Carrier). Furthermore, the VITEK 2 system improves 
efficiencies of routine clinical laboratories since it is able to handle dozens of 
specimens automatically in relatively short time (Ling et al. 2001).  
 
The qnrS- and qnrB-positive clinical isolates detected in this study as well as E. coli 
J53-2 which was used as a recipient in the conjugation test were all tested. The 
VITEK®2 Gram-negative susceptibility cards (AST-NO29) evaluate the following 
antibiotics: nalidixic acid, ciprofloxacin, ampicillin, amoxicillin-clavulanic acid, 
piperacillin-tazobactam, ceftazidime, cefoxitin, cefotaxime, cefpirome, cefpodoxime, 
cephalothin, cefuroxime, cefuroxime axetil, aztreonam, meropenem, mecillinam; 
nitrofurantoin, gentamicin, tobramycin, and trimethoprim-sulfamethoxazole. 
 
Procedure: 
1. The VITEK 2 Gram-negative identification (ID-GNB) and the VITEK 2 
Gram-negative susceptibility (AST-NO29) cards were taken out the 
refrigerator and allowed to achieve room temperature. 
2. A Smart Carrier containing room for 14 tubes and 14 cards were placed. 
3. The identity numbers of the bacterial strains were manually entered in the 
“Accession number” field. 
4. Colonies from an overnight green agar plate was suspended in 3 ml 0.45 % 
NaCl (bioMérieux, USA) and the turbidity was measured by a densitometer 
and adjusted to 0.52 – 0.63 McFarland.  
5. A control spread to check for contaminants was performed. 
6. The inoculum tubes were placed at the first positions while empty tubes were 
placed at the following positions. 
7. The ID-GNB card barcode labels were scanned and the cards were placed in 
the card positions next to the inoculum tubes. 
8. The AST-NO29 card barcode labels were scanned and the cards were placed 
in the card positions next to the empty tubes. 
9. The Smart Carrier containing the inoculum tubes, empty tubes, ID-GNB cards, 
and AST-NO29 cards were placed in VITEK 2 where each test card was 
automatically filled with a bacterial suspension and automatic identification 
and susceptibility testing was performed by kinetic fluorescence measurement 
every 15 min. The software then analyzed the data and reported the results. 
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Agar disk diffusion susceptibility testing   
 
In the disk diffusion test, the bacterial isolate is inoculated uniformly onto the surface 
of an agar plate and a filter disk impregnated with a standard amount of an antibiotic 
is applied to the surface of the plate, resulting in a gradient of the antibiotic 
surrounding the disk (Mayer. 2007). Following incubation, a bacterial lawn appears 
on the plate and zones of inhibition of bacterial growth would be present around the 
antibiotic disk. The test is performed under standardized conditions hence the size of 
the inhibition zone is dependent on the degree of sensitivity of the microorganism to 
the antibiotic (Mayer. 2007).  
 
In this study, susceptibility of the qnr-positive isolates to nalidixic acid and 
ciprofloxacin was measured using 30µg nalidixic acid and 10µg ciprofloxacin paper 
disks (Oxoid Ltd, UK). 
 
Procedure:  
1. The paper disks were taken out from the refrigerator and allowed to achieve 
room temperature. 
2. Colonies from an overnight green agar plate were suspended in 3 ml PBS 
(appendix C) and the turbidity was measured by a densitometer and adjusted 
to 0.45 – 0.55 McFarland. 
3. One drop of the solution was diluted in 5 ml PBS. 
4. A sterile cotton swab was dipped into the bacterial suspension; excess fluid 
was removed by pressing the swab against the tube wall. 
5. The surface of an Iso-Sensitest Agar plate (appendix C) was swabbed by the 
use of a rotator. 
6. A control spread to check for contaminants was performed. 
7. 30µg nalidixic acid and 10µg ciprofloxacin paper disks were applied onto the 
surface. 
8. The plates were pre-incubated in room temperature for 30 minutes, then at 
37°C overnight. 
9. The diameters of the inhibition zone were measured. 
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Analysis of the quinolone resistance determining regions (QRDRs)  
 
Alterations in the targets for quinolones due to chromosomal mutations in their genes 
are responsible for the majority of known cases of quinolone resistance (Gruger et al. 
2004). These mutations are particularly encountered within conserved regions of 
gyrA, the gene encoding the A subunit of DNA gyrase, and parC, the gene encoding 
the homologous A subunit of topoisomerase IV (Robicsek et al. 2006). These hot 
spots for quinolone resistance have been termed the quinolone resistance determining 
regions (QRDR) and furthermore specific amino acid substitutions involved in the 
development of quinolone resistance have been described at specific positions at these 
regions (Ruiz. 2003) (table 5).  
 
Table 5.  Mutations described in GyrA and GyrB subunits of quinolone-resistant 
strains of   E. coli (Ruiz. 2003). 
Codon Wild amino acid* Mutations described* 
GyrA     51b Ala Val 
              67b Ala Ser 
              81     Gly Cys, Asp 
              82b Asp Gly 
              83    Ser Leu, Trp, Ala, Val 
              84 Ala Pro, Val 
              87 Asp Asn, Gly, Val, Tyr, His 
             106b  Gln Arg, His 
ParC     78 Gly Asp 
             80 Ser Ile, Arg 
             84      Glu Lys, Val, Gly 
*Asn/N: Asparagine, Asp/D: Aspartic acid, Ser/S: Serine, Leu/L: Leucine, Gly/G: Glycine, 




Mutations in the quinolone resistance determining region (QRDR) of the genes gyrA 
and parC in qnr-positive isolates were evaluated by PCR and sequencing (Lavilla S. 
et al. 2008). The PCR amplifications were performed using DNA extracted from the 
qnr-positive isolates as template and using primer sets (gyrA6 and gyrA631R) to give 
a 620-bp product (Weigel et al. 1998) and (parCF and parCR) to give a 559-bp 
product (Qiang et al, 2002) (appendix A, table 8). Nucleotide and deduced amino acid 
sequences were aligned, compared with wild-type sequences of gyrA (GenBank 
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accession no. NP_416734) and parC (GenBank accession no. NP_417491) and 
analyzed using the online software ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2) 
and the lasergene software package (DNASTAR). 
 
Procedure: 
1. PCR Mastermixes: 
Reagent Amount 
JumpStart™ REDTaq® ReadyMix™ PCR Reaction Mix 
(Sigma-Aldrich LP, USA): 
250 µl 
Primer-F 50 pmole/µl (Eurogentec S.A., Belgium): 4 µl 
Primer-R 50 pmole/µl (Eurogentec S.A., Belgium): 4 µl 
ddH2O: 192 µl 
 
2. For each reaction, 2.5 µl template was added to 22.5 µl PCR Mastermix 
3. The PCR thermocycler was programmed (appendix A. table 9). 
4. Gel electrophoresis was done in a 1.5 % agarose gel containing 0.5 µg/ml EtBr 
at 120V for 1 hour in 0.75X TBE. 
5. The PCR products were purified according to the E.Z.N.A™ Cycle-Pure Kit 
Spin Protocol (Omega Bio-tek, USA) (appendix D, kit 1) and used as template 
for sequencing. 
6. Sequencing Mastermixes were prepared:  
Reagent Amount 
BigDye v3.1 (Applied Biosystems, USA): 2 µl 
Sequencing buffer (Applied Biosystems, USA): 3 µl 
Primer 3.2 pmol/µl:   1 µl 
ddH2O: 8 µl 
 
7. For each reaction, 6 µl template was added to 14 µl Sequencing Mastermix 
8. The PCR thermocycler was programmed (appendix A. table 9). 
9. Sequencing was performed at the Sequencing core facility. 
10. Nucleotide sequences were aligned and analyzed using the online software 







Transfer of quinolone resistance 
 
Transconjugation and transformation experiments were performed to examine the 
ability to horizontally transfer resistance to quinolones conferred by qnrS or qnrB 
genes. Conjugation experiments involving the 8 qnr-positive isolates detected in this 
study were performed by the liquid mating assay (Sambrook et al. 1989). Rifampicin-
resistant E. coli J53-2 was used as the recipient strain and Luria-Bertani (LB) agar 
plates (appendix C) containing rifampicin 100 µg/ml, sodium azide 100 µg/ml, 
sodium azide 50 µg/ml, ampicillin 100 µg/ml, ampicillin 20 µg/ml, ceftazidim 4 
µg/ml, or nalidixic acid 6 µg/ml (Sigma-Aldrich LP, USA) were used for selection as 
required. Transformation experiments were performed for qnr-positive isolates for 
which no transconjugants were obtained. Plasmid DNA was extracted from the donor 
strains and introduced into chemically competent E. coli TOP’10 (Invitrogen, USA). 
Transformants were selected on Luria-Bertani plates supplemented with ampicillin 





1. The ability of the donor isolates to grow on 100 µg/ml rifampicin-containing 
LB agar plates was examined. 
2. Green agar plates were inoculated from donors and the recipient and incubated 
over night at 37°C. 
3. 5 ml LB-broth media (appendix C) were inoculated with 4-5 colonies from the 
agar plates and incubated over night at 37°C, shaking. 
4. The overnight cultures were diluted 100 folds and incubated at 37°C, shaking 
until the cultures were in exponential growth (OD600: 0.3-0.5). This was 
obtained after approximately 2 hours of incubation. 
5. The donor and the recipient were mixed in a ratio 1:9 (0.5 ml of the donor was 
added to 4.5 ml of the recipient) and the incubation was continued at 37°C, 
very slow shaking (25-50 rpm). 
6. After 60 minutes, samples were withdrawn and diluted in 0.9 % saline solution 
to 10-1, 10-2, 10-5, and 10-6.  
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7. 100µl aliquots from dilutions 10-1 and 10-2 were spread on LB agar plates 
selecting for transconjugants and 100µl aliquots from dilutions 10-5 and 10-6 
were spread on LB plates selecting for donors and on LB plates selecting for 
recipients. Plates were incubated at 37°C over night. 
8. Plates were counted and transconjugation frequencies were calculated by 
dividing the number of transconjugants by the number of donors or by the 
number of reciepients.  
9. Transconjugants were inoculated on LB agar plates containing 0.06 µg/ml 
ciprofloxacin to screen for transconjugants that co-acquired ciprofloxacin 
resistance of ≥ 0.06 µg/ml. 
10. Plasmid isolation from transconjugants was performed according to the 
E.Z.N.A™ Plasmid Miniprep Protocol (Omega Bio-tek) (appendix D, kit 2). 
11. Detection of qnrS and qnrB genes in transconjugants was carried out by 
multiplex PCR amplification of qnrA, qnrB, and qnrS using same primers and 
following same procedure had already applied during the screening except for 
using isolated plasmid as template. 
12. Extended susceptibility test on qnr positive transconjugants was performed 
using Etests and VITEK 2 as described above. 






1. For each transformation, one 50 µl vial of One Shot® E. coli TOP’10 cells 
(Invitrogen, USA) was thawed on ice. 
2. 2 µl of isolated plasmid was pipetted directly into the vial of competent cells 
and mixed by tapping gently. 
3. The vial was incubated on ice for 30 min. 
4. The vial was incubated for 30 seconds at 42ºC in Eppendorf thermomixer 
device. 
5. 250 µl of pre-warmed S.O.C medium was added to the vial. 
6. The vial was incubated at 37ºC for 1 hour with shaking at 225 rpm. 
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7. 50 µl from the transformation vial was spread on labelled LB agar plate 
supplied with the selecting antibiotic. 
8. The plate was incubated at 37ºC overnight. 
9. The number of colonies growing on the overnight plate was counted. 
10. Transformants were inoculated on LB-plates containing 0.06 µg/ml 
ciprofloxacin to screen for transcformants that co-acquired ciprofloxacin 
resistance of ≥ 0.06 µg/ml. 
14. Plasmid isolation from transformants was performed according to the 
E.Z.N.A™ Plasmid Miniprep Protocol (Omega Bio-tek) (appendix D, kit 2). 
15. Detection of qnrS gene in transformants was carried out by multiplex PCR 
amplification of qnrA, qnrB, and qnrS using same primers and following same 
procedure had already applied during the screening except for using isolated 
plasmid as template. 
11. Extended susceptibility test on qnr positive transformants was performed 
using Etest and VITEK 2 as described above. 





To reliably estimate the number and molecular sizes of small and large plasmids, two 
techniques were applied; in the first technique, plasmid DNA was isolated and 
separated by agarose gel electrophoresis. Two bacterial strains containing plasmids of 
known size were used as standard size markers. In the second technique, total DNA 
was digested with S1 nuclease and subjected to pulsed-field gel electrophoresis (S1–
PFGE). Appropriate linear DNA markers were used as size markers. Then, plasmid 
DNA was transferred from the agarose gel onto positively charged nylon membranes 
and hybridized with specific probe for qnrS1 obtained by PCR with same primers 






Plasmid extraction-horizontal gel electrophoresis 
 
Examination of plasmid DNA can be simply performed by plasmid DNA extraction 
followed by direct agarose gel electrophoresis of extracted DNA (Woodford et al. 
1994). Most the commercial kits for plasmid DNA isolation exploit a silica membrane 
column. The procedure generally includes: (1) alkaline-sodium dodecyl sulfate (SDS) 
lysis of the bacterial cells, (2) application of the lysate onto silica that adsorbs plasmid 
DNA, (3) removal of contaminants by wash step, and (4) elution of bound plasmid 
DNA in TE buffer (http://www.omegabiotek.com/protocols/PlasmidMini.pdf).  
 
In this study, the E.Z.N.A™ Plasmid Miniprep kit (Omega Bio-tek) was used for 
extracting the plasmid DNA from the qnr-positive clinical isolates, their 
transconjugants/transformants, Escherichia coli strains NCTC 50192 (containing 
plasmids of 148, 63.5, 36, and 7 kb in size) and NCTC 50193 (containing plasmids of 
48.3, 7.8, 5.2, 4.5, 3.3, 2.6, 2.3, and 1.8 kb in size). The unknown plasmids were 




1. Plasmid DNA was isolated according to the E.Z.N.A™ Plasmid Miniprep 
Protocol I (Omega Bio-tek) (appendix D, kit 2). 
2. For gel electrophoresis, 0.8 % agarose gel with 0.5µg/ml EtBr was used. 
3. 3 µl loading buffer was added to15 µl of each plasmid DNA product. 
4. Plasmids isolated from E. coli strains NCTC 50193 and NCTC 50192 were 
used as standard size markers. 
5. The electrophoresis was run at 120V for approx. 3 hours. 
6. The gel was visualized on GelDoc system (BioRad, USA) and stored on disks 








S1-PFGE plasmid analysis  
 
S1 nuclease, isolated from the mold Aspergillus oryzae, is an endonuclease that 
attacks only single-stranded DNA (Wiegand et al. 1975). When a supercoiled plasmid 
is treated with S1 nuclease, the enzyme will introduce breaks at regions that have a 
single-stranded character, as a result of this nicking, supercoiling is lost and the 
plasmid is converted into full-length linear molecule (Barton et al. 1995). Since 
isolation and size determination of supercoiled large plasmids could be problematic, 
the facility of S1 nuclease was used and a method was described for detecting and 
estimating the sizes of large bacterial plasmids in the presence of genomic DNA 
(Barton et al. 1995). The procedure included (1) lysis of bacterial cells embedded in 
agarose plugs, (2) S1 nuclease treatment to convert the plasmids into unit-length 
linear molecules, and (3) pulsed-field gel electrophoresis (PFGE) of linearized 
plasmid samples together with an appropriate marker.  
 
Procedure: 
Preparation of PFGE plugs: 
1. Green agar plates were streaked and incubated over night at 37ºC. 
2. 5-10 colonies were inoculated into Falcon tubes with 5 ml BHI-media 
(appendix C) and incubated over night at 37ºC, shaking. 
3. 50 µl of the cultures were transferred into Falcon tubes with 5 ml BHI-media 
and incubated for 4 hours at 37ºC, shaking. 
4. The tubes were centrifuged at 3500 rpm for 10 min. 
5. The supernatant was removed with a Pasteur pipette, and the pellet was re-
suspended in 1 ml cold PIV-buffer (appendix C). 
6. 495 µl of the suspension was transferred to an Eppendorf tube and 5 µl 
lysozyme (100 mg/ml) (Sigma-Aldrich LP, USA) was added. The tubes were 
mixed well by vortexing and equilibrated in water bath at 50 ºC. 
7. 500 µl of 2% low melting point (LMP)-agarose (appendix C) was added. 
8. The agarose/bacteria solution was mixed well by vortexing, and then the 
mixture was rapidly transferred to the plug mould.  
9. The plug was let to solidify at 4 ºC for 15 min. 
10. The plug was transferred to Eppendorf tubes containing 1.8 ml lysis buffer 
(appendix C) and incubated for 2 hours at 37 ºC, slow shaking. 
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11. The lysisbuffer was removed and the plug was washed in 1 ml ddH2O for 15 
min.  
12. The water was removed and 1 ml ESP-buffer containing 50 µg/ml proteinase 
K-solution (appendix C) and incubated overnight at 50 ºC. 
13. The proteinase K-solution was removed and the plug was washed in 1 ml TE-
buffer for 30 min twice. 
 
S1 nuclease plasmid linearization: 
14. A thin slice of the plug was cut out and transferred to an Eppendorf tube. 
15. The plug was washed in 1 ml 1M Tris-HCL (pH7.5) for 30 min (so EDTA was 
removed). 
16. The plug was washed in 125 µl of S1-nuclease buffer (Sigma-Aldrich, USA) 
for 30 min.  
17. The plug was transferred into 125 µl of S1-nuclease master mix and incubated 
at 37ºC for 25 min. S1-nuclease Master Mix: 
Reagent Amount 
S1-nuclease buffer (10X) (Sigma-Aldrich, USA) 12.5 µl 
S1-nuclease (50 U/µl) (Sigma-Aldrich, USA) 0.5 µl 
dd H2O: 112 µl 
 
18. The S1-nuclease master mix was removed and the plug was washed twice in 1 
ml cold TE-buffer.  
 
Pulsed field gel electrophoresis (PFGE): 
19. The electrophoresis chamber was filled with 1900 ml of 0.5X TBE-buffer. The 
circulation was turn on and the cooler was set to 15 ºC.   
20. 1 % agarose gel was prepared; 1 g agarose (Bio-Rad, USA) was added to 100 
ml 0.5X TBE buffer and dissolved by boiling in the microwave. 
21. The gel equipment was prepared and the gel was let to solidify for 30 min at 
room temperature. 
22. The plugs were added after removing the comb. 
23. Low Range PFG Marker (New England Biolabs, USA) was used as standard 
marker (appendix C, figure 2). 
24. The gel was released from the mould and all excess agarose was removed 
from the sides and under the black support. 
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25. The gel with the support plate was placed into the frame in the electrophoresis 
chamber. 
26. The PFGE device was programmed and the electrophoresis was run. 
Program parameters  
Pulse time: initial pulse-final pulse 1-12 sec 
Total runtime 15 hours 
Volt  6 v/cm 
Angle 120º 
Buffer temperature 15 ºC 
Gel running buffer 0.5X TBE 
 
27. When the run was done, the gel was stained in EtBr-solution (500 ml ddH2O 
+ 50 µl EtBr) for 45 min. 
28. The gel was photographed then it was de-stained in ddH2O for 50 min. 
29. The TBE-buffer was removed from the chamber and replaced by water. The 
circulation was run for few minutes then the water was removed and all 





A Southern blot is a method named after its inventor Edwin Southern and used to 
transfer the size-separated DNA, generally by agarose gel electrophoresis, to a filter 
membrane (Southern E.M, 1975). DNA transfer is frequently followed by probe 
hybridization and is mostly used to check for the presence of a specific DNA 
sequence. In this study, the TurboBlotter™ system was used for transferring the 
plasmid DNA separated by S1-PFGE into Nytran® SuPerCharge Nylon Membranes 









Denaturation of DNA gels: 
1. The gel was incubated in depurination buffer (Appendix C) for 2 X 30 min. 
2. The gel was incubated in denaturing buffer (Appendix C) for 2 X 30 min.  
3. The gel was washed in neutralizing buffer (Appendix C) for 15 min. 
 
Transfer: 
4. The transfer membrane (Nytran® SuPerCharge nylon) was soaked in ddH2O 
for 15 min. 
5. The “stack tray” of transfer device was placed on bench, making sure it was 
level. 
6. 20 sheets of dry GB004 blotting paper (thick) were placed in stack tray. 
7. 4 sheets of dry 3MM Chr blotting paper (thin) were placed on top of stack. 
8. One sheet of prewet 3MM Chr blotting paper in neutralizing buffer was placed 
on stack. 
9. Transfer membrane was placed on stack. 
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10. The membrane was covered with agarose gel; the gel was cut to the size of the 
membrane, making sure there were no air bubbles between the gel and the 
membrane. 
11. The top surface of the gel was wetted with neutralizing buffer, and 3 sheets of 
3MM Chr blotting paper, presoaked in neutralizing buffer, were placed on top 
of the gel. 
12. The “buffer tray” of the transfer device was attached to the bottom tray, using 
the circular alignment buttons to align both trays. 
13. The buffer tray was filled with about 125 ml neutralizing buffer. 
14. The transfer was started by connecting the gel stack with the buffer tray using 
the precut “buffer wick” (included in each blotter stack), presoaked in 
neutralizing buffer.  
15. The wick was placed across the stack so that the short dimension of the wick 
completely 
16. The blotting stack was covered and both ends of the long dimension extend 
into the buffer tray.  
17. The “wick cover” was placed on top of the stack to prevent evaporation. The 
edges of the wick were checked out to be immersed in the transfer buffer. 
18. The transfer was continued for 2 hours. 
 
Immobilization: 
19. The membrane was placed on a fresh sheet of dry 3MM Chr blotting paper to 
remove any excess of neutralizing buffer. 
20. The blot was exposed to a source of UV light (254 nm) for a total dose of 120 
mJ/cm2 for a damp membrane (by doing so the DNA was covalently bound to 
the membrane (cross-linking the molecule to the nylon matrix in the presence 
of UV light).  
 
Storage:  






Labeling and purification of probe 
 
Procedure: 
Making a template for the probe: 
1. Extracted plasmid DNA from clinical isolates K38-15 was used as template 
for multiplex-PCR amplification of qnr genes.  
2. The PCR Master Mix, PCR reaction, PCR primers, and PCR conditions were 
same as in the qnr PCR-based screening. 
3. The gel electrophoresis was performed in a 1.5% agarose gel containing 0.05 
0.5 µg/ml EtBr at 120 V for 1 Hour in 0.75X TBE and a photo of the gel was 
taken on GelDoc system (BioRad, USA) and stored on disks as TIFF files.  
4. PCR product was purified according to the E.Z.N.A™ Cycle-Pure Kit Spin 
Protocol (Omega Bio-tek, USA) (appendix D. kit1) and used as template for 
the probe. 
 
Template labeling (DIG DNA labeling and detection kit, Roche Applied Science, 
Germany): 
5. 15 µl from each template was taken. For a control labeling reaction, 10 µl of 
double distilled water was added to 5 µl of control DNA 2 (vial 2). 
6. The DNA was denatured by heating in a boiling water bath for 10 min and 
quickly chilling in an ice/water bath. 
7. Master Mix: Hexanucleotide Mix, 10 × (vial 5): 2 µl 
dNTP Labeling Mix (vial 6): 2 µl 
Klenow enzyme labeling grade (vial 7): 1 µl 
8. For each Reaction, 15 µl sample was added to 5 µl Mastermix.                  
9. The tubes were mixed and centrifuged briefly. 
10. Tubes were incubated overnight at 37°C. 
11. The reaction was stopped by heating to 65° C for 10 min. 
 
Determination of labeling efficiency (DIG DNA labeling and detection kit, Roche 
Applied Science, Germany): 
12. The labeled probes and the DIG-labeled control DNA (vial4) were diluted 10-1 
to 10-5 times in ddH2O. A 10-1 dilution of the DIG-labeled control DNA 
corresponds to 0.5 µg/ml.  
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13. 1 µl of each dilution was spotted in a row on a nylon membrane and left to air 
dry for 20 minutes.  
14. The membrane was transferred into a plastic container with 20 ml Maleic acid 
buffer (appendix C) and incubated under shaking for 2 min at 20° C. 
15. The membrane was incubated for 30 min in 20 ml Blocking solution 
(appendix C). 
16. The membrane was incubated for 30 min in 20 ml Antibody solution 
(appendix C). 
17. The membrane was washed twice with 20 ml Washing buffer (appendix C) for 
15 min each time. 
18. The membrane was equilibrated in 20 ml Detection buffer (appendix C) for 3 
min.  
19. The membrane was incubated in 2 ml freshly prepared Color substrate 
solution (aapendix C) in an appropriate plastic box in the dark. 
20. The color was developed fast and in 5 min the desired spot intensities were 
achieved and the reaction was stopped by taking the membrane out the bag 
and washing it in plastic container with sterile double distilled water for 5 min. 
21. A photo was taken on GelDoc system (BioRad, USA) and stored on disks as 
TIFF files.  
22. The intensity of the spots of the labeled probes was compared to the control 





Two strands of DNA, RNA, or one strand DNA and one strand RNA are held together 
forming double-stranded helix, provided that their sequences are complementary. This 
process is called hybridization (Synder & Champness. 2007). The common aim of 
hybridization assays is to use a DNA or RNA sequence (probe) to identify a particular 
complementary DNA or RNA sequence (target) among thousands of other sequences. 
The basis of the standard nucleic acid hybridization assays currently in use involves 
(1) immobilizing the target DNA on a solid support, such as a membrane made of 
nitrocellulose or nylon, (2) adding labeled probe that will attach to the immobilized 
target DNA, (3) removing the solution containing unbound probe DNA, (4) extensive 
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washing and drying in preparation for detection, and finally (5) detecting the signal of 
the probe fixed to its complementary target (Synder & Champness. 2007). The 
objective of the hybridization assay in this study was to identify the location of qnrS 
and qnrB genes in the eight qnr-positive clinical isolates as well in the five qnr-
positive transconjugants and transformants. 
 
Procedure: 
1. The hybridization-incubator and 20 ml prehybridization solution (appendix C) 
were pre-warmed to 68°C. The filter was pre-hybridized for 1-2 h in a 
hybridization tube. 
2. The required amount of probe was diluted in a small volume of hybridization 
solution (appendix C) and boiled for 10min for denaturation. The probe was 
quickly cooled in ice water and 8 ml of pre-warmed hybridization solution 
were added to it. The tube was mixed thoroughly (bubbles were avoided).  
3. The pre-hybridization solution was removed and the probe/hybridization 
solution was added to the filter. Hybridization was done for 16-20h.  
4. The filter was washed in 100ml 2 x stringency-buffer (appendix C) 2 x 5 min 
at 68°C then in 100 ml 0.5 x stringency buffer (appendix C) 2 x 15 min at 
68°C.  
 
Detection of hybridization (DIG luminescence detection kit for nucleic acid, Roche 
Applied Science, Germany):   
 
1. The membrane was rinsed briefly for 5 min in Wash buffer at room 
temperature.  
2. The wash buffer was replaced with 100 ml 1% Blocking solution and the 
membrane was incubated with agitation for 30 min. 
3. The blocking solution was replaced with 30 ml of Antibody solution and the 
membrane was incubated with agitation for 30 min. 
4. Container was shifted. The membrane was washed in 100 ml Wash buffer for 
15 min twice. 
5. The filter was equilibrated in 30ml Detection buffer for 2-5 min.  
6. The membrane was incubated in 2 ml freshly prepared Color substrate 
solution in an appropriate plastic box in the dark. 
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7. The color was developed fast and in 5 min the desired spot intensities were 
achieved and the reaction was stopped by washing the membrane with sterile 
ddH2O for 5 min. 




PCR-based plasmid typing 
 
Identification and classification should always be based on traits that are universally 
present and are constant (Couturier et al. 1988). In plasmids, these criteria are best 
met by the genetic elements concerned with initiation of replication, control of 
replication, and partitioning. Plasmids have traditionally been classified according to 
their incompatibility with other plasmids, a property that is related to their replication 
and/or partitioning systems. The basis of incompatibility typing is that two plasmids 
sharing common replication and/or partitioning elements are unable to proliferate 
stably in the same cell line (Johanson et al. 2007). Although the incompatibility 
grouping method has been an important tool to identify and classify plasmids, this 
method can not be applied to a large number of strains; its application has been 
limited by the laborious and time-consuming work required. Therefore, a PCR-based 
replicon typing (inc/rep PCR-based typing) method has recently been developed for 
classification of plasmids occurring in members of the Enterobacteriaceae (Carattoli 
et al. 2005). Currently, there are 26 known Inc groups occurring among the 
Enterobacteriaceae, a number which has remained static for several years (Johanson 
et al. 2007). In this method, 5 multiplex- and 3 simplex-PCRs are performed to 
recognize 18 replicon types (FIA, FIB, FIC, HI1, HI2, I1-Iγ, L/M, N, P, W, T, A/C, 
K, B/O, X, Y, F, and FIIA) representative of the major plasmid groups circulating 
among the Enterobacteriaceae (Carattoli et al. 2005). 
 
Identification of the inc/rep type of the plasmids extracted from the eight qnr-positive 
isolates, and from four qnr-positive transconjugants/transformant was performed as 
previously described (Carattoli et al. 2005). The PCR amplifications were done using 
plasmid DNA extracted from the qnr-positive strains as template (appendix D. kit 2), 
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JumpStart REDTaq Ready Mix Reaction Mix (Sigma-Aldrich LP, USA), and specific 
primers (Carattoli et al. 2005) (appendix A, table 8). 
 
Procedure: 
1. Mastermixes for the multiplex-PCRs: 
Reagent Amount 
JumpStart™ REDTaq® Ready Mix™ PCR Reaction Mix (Sigma-
Aldrich LP, USA): 
250 µl 
Primer1-F (50 pmole/µl), Primer1-R (50 pmole/µl), Primer2-F (50 
pmole/µl), Primer2-R (50 pmole/µl), Primer3-F (50 pmole/µl), and 
Primer3-R (50 pmole/µl) (Eurogentec S.A., Belgium): 
4 µl each 
ddH2O: 176 µl 
 
2. Mastermixes for the simplex-PCRs: 
Reagent Amount 
JumpStart™ REDTaq® Ready Mix™ PCR Reaction Mix 
(Sigma-Aldrich LP, USA): 
500 µl 
Primer-F 50 pmole/µl (Eurogentec S.A., Belgium): 4 µl 
Primer-R 50 pmole/µl (Eurogentec S.A., Belgium): 4 µl 
ddH2O: 192 µl 
 
3. For each reaction, 2.5 µl template was added to 22.5 µl PCR Mastermix. 
4. The PCR thermocycler was programmed (appendix A. table 9). 
5. Gel electrophoresis was done in a 1.5 % agarose gel containing 0.5 µg/ml EtBr 
at 120V for 1 hour in 0.75X TBE. 
 
 
Determination of the genetic environment of qnrS1 
 
qnrS1 has been reported to be located upstream to truncated orfB of IS2, blaLAP, and 
pbp-3 and downstream to an open reading frame coding for a 213 amino acid 
polypeptide (Poirel et al. 2007). Therefore, the genetic environment of qnrS1 was 
analyzed by targeted PCR and sequencing. Targeted PCR amplifications were carried 
out using DNA extracted from the qnrS-positive isolates as template and six different 
sets of primers (qnrS-3`-ext and orfB-B), (qnrS-3`-ext and LAP-1A), (qnrS-3`-ext and 
pbp3-B), (qnrS-5`-ext and 213B), (qnrS-R.multiplex and LAP-1.Kres), and (qnrS-
F.multiplex and Sea15.Kres) (appendix A, table 8). qnrS1 has also been reported to be 
 71
located upstream to Tn3 (Kehrenberg et al. 2006). Thus, for the strains in which 
blaLAP-1 and pbp-3 were absent, further two PCR amplification were carried out with 
two sets of primers (qnrS-3`-ext with tnpRF/tnpRF2) and (qnrS-3`-ext with TEM-R 
mod TW) (appendix A, table 8). PCR amplification was followed by extracting and 
purifying the gel bands and sequencing the two strands of the DNA fragment using 
the same primers. 
 
Procedure: 
1. PCR Mastermixes: 
Reagent Amount 
JumpStart™ REDTaq® ReadyMix™ PCR Reaction Mix 
(Sigma-Aldrich LP, USA): 
250 µl 
Primer-F 50 pmole/µl (Eurogentec S.A., Belgium): 4 µl 
Primer-R 50 pmole/µl (Eurogentec S.A., Belgium): 4 µl 
ddH2O: 192 µl 
 
2. For each reaction, 2.5 µl template was added to 22.5 µl PCR Mastermix 
3. The PCR thermocycler was programmed (appendix A. table 9). 
4. Gel electrophoresis was done in a 0.8 % agarose gel containing 0.5 µg/ml EtBr 
at 120V for 1 hour and 15 minutes in 0.75X TBE. 
5. Amplified DNA was extracted and purified from the agarose gel according to 
the QIAquick SpinHandbook for QIAquick Gel Extraction Kit (QIAGEN, 
Germany) (appendix D, kit 3) and used as template for sequencing. 
6. Sequencing Mastermixes:  
Reagent Amount 
BigDye v3.1 (Applied Biosystems, USA): 2 µl 
Sequencing buffer (Applied Biosystems, USA):    3 µl 
Primer 3.2 pmol/µl:   1 µl 
ddH2O: 8 µl 
 
7. For each reaction, 6 µl template was added to 14 µl Sequencing Mastermix 
8. The PCR thermocycler was programmed (appendix A. table 9). 
9. Searching for nucleotide sequence homology was performed using BLAST 
available at the National Center for Biotechnology Information website 
(http://www.ncbi.nlm.nih.gov/BLAST). 























Prevalence of the qnr genes  
 
Screening for the qnrA, qnrB, and qnrS genes among the clinical isolates of E. coli 
and Klebsiella spp. included in this study was done by a multiplex PCR (Robicsek et 
al 2006). The amplification products were provisionally identified as qnr-positive 
from their sizes in EtBr-stained agarose gels and the positive results were confirmed 
by direct sequencing of PCR products on both strands. The nucleotide and amino acid 
sequences were aligned and compared with published sequences of the qnrS and qnrB 
variants. 
 
Overall, qnr-genes were identified in 8/487 (1.6%) of the clinical isolates (figure 18). 
The prevalence of qnr genes was 0.7% (3/422) and 7.7% (5/65) among E. coli and 
Klebsiella spp. isolates, respectively. Six isolates contained the qnrS1 gene, one 
isolate contained the qnrB1 gene, and one isolate contained qnrB7. The qnrA gene 
was not detected in any of the clinical isolates. Four qnrS1 genes were detected in the 
NORM and Kronoberg collections representing the common population of clinical 
isolates in Norway and Sweden, whereas the other four qnr genes (two qnrS1, one 
qnrB1, and one qnrB7) were detected in clinical isolates from the Norwegian ESBL 
study, one of the three K-res collection representing a resistant population of clinical 










Prevalence of the aac(6`)-Ib-cr gene  
 
Screening for the aac(6')-Ib gene among the E. coli and Klebsiella spp. clinical 
isolates was done by a simplex PCR (Park et al. 2006). The amplification products 
were provisionally identified as aac(6')-Ib-positive from their sizes in EtBr-stained 
agarose gels. The aac(6')-Ib-positive PCR products were subjected to BstCI digestion 
to identify the aac(6’)-Ib-cr variant. Digestion products that yielded only one band in 
EtBr-stained agarose gels were assigned to the aac(6’)-Ib-cr variant while those 
yielding two bands were identified as aac(6’)-Ib wild-type genes. The results were 
confirmed by sequencing PCR products on one strand to verify the two amino acid 
changes (Arg102Trp and Tyr179Asp) that characterize the aac(6’)-Ib-cr variant. 
 
The aac(6')-Ib gene was detected in 15.4 % (75/487) of the clinical isolates while the 
aac(6')-Ib-cr variant was detected in 14.1 % (69/487) of the isolates, representing 92 
% (69/75) of the detected aac(6')-Ib. The prevalence of aac(6')-Ib-cr was 15.6% 
(66/422) and 4.6% (3/65) among E. coli and Klebsiella spp. clinical isolates, 
respectively (table 6) (features of the aac(6`)-Ib-positive isolates are presented in 
appendix A, table 10). Interestingly, two isolates showed partial digest with BstCI 
suggesting that they could harbor both the wild type aac(6’)-Ib and the -cr variant. 
The sequence data showed the presence of both cytosine (C) and thymidine (T) 
nucleotide peaks corresponding to Trp and Arg amino acids (at position 102) and 
hence confirming this.  
 
While the prevalence of aac(6‘)-Ib-cr was only 0.5 % (1/152) and 5% (11/218) in the 
Kronoberg and NORM collections, respectively, it was 48.7 % (57/117) among the 
clinical isolates from K-res collections (the AmpC and ESBL studies). The aac(6‘)-
Ib-cr gene was detected in 50 % (4/8) of the qnr-positive isolates (figure 18) while it 











qnr qnr variant aac(6`)-Ib aac(6`)-Ib-cr 
Kronoberg collection  152 1 qnrS1 2 1 
NORM collection  218 3 qnrS1 11 11 
E. coli AmpC study  13 0 - 1 1 
Ullevål ESBL study  60 0 - 41 39 
Norwegian ESBL study  44 4 2 qnrS1,1 qnrB1, and 1 qnrB7 20 17 
E. coli  422 3 qnrS1 68 66 
Klebsiella spp.  65 5 3 qnrS1,1 qnrB1, and 1 qnrB7 7 3 
Total  487 8 (1.6%) 6 qnrS1,1 qnrB1, and 1 qnrB7 75 69 (14.1%) 
    
 
                                                                                                                
Table 7. Features of the qnr-positive clinical isolates. 
Ref. nr Species* qnr variant aac(6`)-Ib-cr MIC(µg/ml) 
NAL          CIP 
ESBL type 
K38-15 E. coli qnrS1 - 16 0.5 - 
K4-13 K. pneumoniae qnrS1 aac(6`)-Ib-cr 8 2 CTX-M gr.1 SHV-14 
K4-43 E. coli qnrS1 aac(6`)-Ib-cr ≥256 ≥32 CTX-M gr. 9 
K39-31 K. pneumoniae qnrS1 - 16 0.5 - 
K40-47 K. pneumoniae qnrS1 - 64 4 - 
K40-79 E. coli qnrS1 aac(6`)-Ib-cr ≥256 ≥32 - 
K2-78 K. pneumoniae qnrB7 - 16 1 SHV-5/5a/or12 
K8-5 K. pneumoniae qnrB1 aac(6`)-Ib-cr ≥256 ≥32 CTX-M gr.1 






Figure 18. (Top). Agarose gel electrophoresis of qnr-multiplex PCR products of the qnr-
positive clinical isolates. Lanes: 1, negative control; 2, E. coli A2-67 (qnrA positive control); 
3, E. coli A3-22 (qnrB positive control); 4, E. coli A3-20 (qnrS positive control); 5, K38-15; 
6, K4-13; 7, K4-43; 8, K39-31; 9, K40-47; 10, K40-79; 11, K2-78; and 12, K8-5. (Bottom). 
Agarose gel electrophoresis of aac(6')-Ib-simplex PCR products of the qnr-positive clinical 
isolates. Lanes: 1, negative control; 2, E. coli A3-21 (aac(6’)-Ib positive control); 3, K4-13; 4, 
K4-43; 5, K40-79; 6, K8-5; 7, K38-15; 8, K39-31; 9, K40-47; and 10, K2-78. M, molecular 
size marker (1 KB plus ladder, Invitrogen, USA). 
 
 
Resistance profiles of the qnr-positive isolates  
 
Antimicrobial susceptibility testing on the qnr-positive isolates was performed using 
Etest, VITEK® 2, and agar disc diffusion. The clinical MIC breakpoints defined by 
NWGA (Norwegian Working Group on Antibiotics), EUCAST (European Committee 
on Antimicrobial Susceptibility Testing), or BSAC (the British Society for 
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Antimicrobial Chemotherapy) and the zone breakpoints defined by SRGA (the 
Swedish Reference Group for Antibiotics) were used (appendix A, table 2). 
 
Four of the qnr-positive isolates (three qnrS1- and one qnrB1-) showed resistance to 
nalidixic acid and flouroquinolones with MICs ranging from 64 to ≥256 µg/ml and 
from 4 to ≥ 32 µg/ml, respectively. On the other hand, the other four qnr-positive 
isolates (three qnrS1- and one qnrB7-) were susceptible to nalidixic acid (MIC ≤ 16 
µg/ml), one of these isolates (K4-13) was ciprofloxacin-resistant (MIC, 2 µg/ml) 
while the other three showed reduced susceptibility to ciprofloxacin (MIC, 0.25-0.5 
µg/ml) (table 8).  
 
All the qnr-positive isolates were resistant to ampicillin with MICs ranging from 32 to 
≥ 256 µg/ml. Three of the four qnr- and ESBL-positive isolates (K4-13, K2-78, and 
K8-5) were, as expected, resistant to the oxyimino-cephalosporins (cefuroxime, 
cefotaxime, ceftazidime, and cefepime) while susceptible to the cephamycins 
(cefoxitin) and to the combination β-lactams/clavulanic acid (amoxicillin/clavulanic 
acid, and piperacillin/tazobactam). The fourth qnr- and ESBL-positive isolate, K4-43, 
was resistant to the oxyimino-cephalosporins (cefuroxime, cefotaxime, ceftazidime, 
and cefepime) but was furthermore resistant to cefoxitin, amoxicillin/clavulanic acid, 
and piperacillin/tazobactam (table 8). 
 
All the qnr- and aac(6`)-Ib-cr-positive clinical isolates (K4-13, K4-43, K8-5, and 
K40-79) showed reduced susceptibility or resistance to amikacin and tobramycin. 
Three of these aac(6`)-Ib-cr-positive isolates were also resistant to gentamycin while 
only one was gentamycin-susceptible. On the other hand, the qnr-positive but aac(6`)-
Ib-cr-negative clinical isolates (K38-15, K2-78, K39-31, and K40-47) were 
susceptible to amikacin, tobramycin, and gentamycin. 4/4 of the aac(6`)-Ib-cr-
positive and 1/4 of the aac(6`)-Ib-cr-negative clinical isolates were furthermore 
resistant to trimethoprim and trimethoprim-sulfmethoxazole (table 8) (results of 
VITEK® 2 and Agar disk diffusion susceptibility testing are presented in appendix A, 





Table 8. MICs by Etest for the qnr-positive clinical isolates.  
Antibiotic* 
MIC (µg/ml) 
K38-15     K4-13      K4-43       K39-31      K40-47     K40-79        K2-78        K8-5 
NAL 16 8 ≥256 16 64 ≥256 16 ≥256 
CIP 0,5 2 ≥32 0.25 4 ≥32 0.5 ≥32 
NOR 2 8 ≥256 2 16 ≥256 2 ≥256 
OFX 2 2 ≥32 2 32 ≥32 2 ≥32 
LVX 1 1 ≥32 1 4 ≥32 1 32 
MXF 1 2 ≥32 1 8 ≥32 2 ≥32 
GAT 0,5 1 ≥32 0,5 4 ≥32 0,5 32 
AMK 2 8 8 2 1 8 2 8 
TOB 0,5 32 ≥256 0,5 0,25 64 0,5 32 
GEN 0,5 64 128 0,5 0,25 1 0,5 64 
AMP ≥256 ≥256 ≥256 32 32 ≥256 ≥256 ≥256 
AMC 8 16 32 2 2 16 4 16 
PIP 128 ≥256 ≥256 8 4 256 ≥256 ≥256 
TZP 1 16 ≥256 2 4 4 4 12 
FOX 4 4 256 4 16 8 8 8 
CXM 4 ≥256 ≥256 4 8 8 32 ≥256 
CTX 0,125 256 64 0,064 0,125 0,25 8 256 
CAZ ≤0.5 ≥32 ≥32 ≤0.5 ≤0.5 ≤0.5 ≥32 ≥32 
CCV 0,064 0,25 ≥4 0,25 0,5 0,5 0,25 0,25 
FEP ≤0.25 ≥16 ≥16 ≤0.25 ≤0.25 0,5 2 ≥16 
FCV ≤0.064 0,064 2 ≤0.064 ≤0.064 0,064 0,064 0,094 
IPM 0,125 0,25 0,25 0,5 0,25 0,25 0,25 0,25 
MEM 0,016 0,064 0,25 0,032 0,032 0,032 0,064 0,064 
TMP 0,25 ≥32 ≥32 ≥32 2 ≥32 1 ≥32 
SXT 0,064 ≥32 ≥32 ≥32 4 ≥32 0,125 ≥32 
* NAL, nalidixic acid; CIP, ciprofloxacin; NOR, norfloxacin; OFX, ofloxacin; LVX, levofloxacin; 
MXF, moxifloxacin; GAT, gatifloxacin; AMK, amikacin; TOB, tobramycin; GEN, gentamicin; AMP, 
ampicillin; AMC, amoxicillin-clavulanic acid; PIP, piperacillin; TZP, piperacillin-tazobactam; FOX, 
cefoxitin; CXM, cefuroxime; CTX, cefotaxime; CAZ, ceftazidime; CCV, ceftazidime/clavulanic acid; 
FEP, cefepime; FCV, cefepime/clavulanic acid; IPM, imipenem; MEM, meropenem; TMP, 







Analysis of the quinolone resistance determining regions (QRDRs)  
 
To detect the presence of chromosomal mutations in the QRDRs of gyrA and parC 
genes in the qnr-positive isolates, PCR amplifications and sequencing were performed 
(Lavilla et al. 2008). The nucleotide and deduced amino acid sequences were aligned 
and compared with wild-type sequences. 
 
Mutations L83S in gyrA and I80S in parC were detected in the three qnr-positive 
clinical isolates with high nalidixic acid- and ciprofloxacin-resistance (MIC ≥ 256 
µg/ml and ≥ 32 µg/ml, respectively). Mutation N87D in gyrA was furthermore 
detected in two of these three isolates. No mutations were detected neither in the K. 
pneumoniae isolate K40-47 that was nalidixic acid- and ciprofloxacin-resistant but 
with lower MICs (64 µg/ml and 4 µg/ml, respectively) nor in the four clinical isolates 
with only reduced susceptibility to nalidixic acid and ciprofloxacin (table 9) (the 
amino acid alignments are presented in appendix B, figure 1). 
 
Table 9. Mutations in QRDR of gyrA and parC and the corresponding MICs of 
nalidixic acid and ciprofloxacin in the qnr-positive clinical isolates. 
Isolate Species 
MIC (µg/ml) 
          NAL                      CIP 
QRDR 
          gyrA             parC 
K38-15 E. coli 16 0.5 - - 
K4-13 K. pneumoniae 8 2 - - 
K4-43 E. coli ≥256 ≥32 L83S, N87D I80S 
K39-31 K. pneumoniae 16 0.5 - - 
K40-47 K. pneumoniae. 64 4 - - 
K40-79 E. coli ≥256 ≥32 L83S, N87D I80S 
K2-78 K. pneumoniae 16 0.5 - - 









Transfer of quinolone resistance 
 
The ability to horizontally transfer quinolone resistance conferred by qnrS or qnrB 
genes was examined by transconjugation and transformation experiments. 
Transconjugation was performed by the liquid mating assay (Sambrook et al. 1989) 
using rifampicin-resistant E. coli J53-2 as the recipient strain. For transformation, 
plasmid DNA was extracted from the donor strains and introduced into chemically 
competent E. coli TOP’10 recipients. 
 
The qnrS1 gene was successfully transferred by transconjugation from 3/8 of the qnr-
positive isolates using ampicillin 100 µg/ml for selection. The transconjugation 
frequencies varied between 1 x 10-4 and 5.8 x 10-4 Transconjugant per donor 
(appendix A, table 13). In addition, transformation experiments were successful with 
plasmid extracted from 2/5 of the non-transconjugable qnr-positive isolates, one of 
the donors was qnrS1-positive and the other one was qnrB7-positive. Co-transfer of 
the aac(6`)-Ib-cr gene was achieved from 2/3 of the qnr- and aac(6`)-Ib-cr-positive 
donor isolates (table 10). 
 








K38-15  qnrS1-positive transconjugation + Not applicable 
K4-13  qnrS1- and aac(6`)-Ib-cr-positive transconjugation + + 
K4-43 qnrS1- and aac(6`)-Ib-cr-positive transformation + - 
K39-31 qnrS1-positive - - - 
K40-47 qnrS1-positive - - - 
K40-79  qnrS1- and aac(6`)-Ib-cr-positive transconjugation + + 
K2-78  qnrB7-positive transformation + Not applicable 







By comparing the MICs for the transconjugants/transformants with those for the 
recipients (table 11) (results of VITEK® 2 susceptibility testing are presented in 
appendix A, table 14), it can be noticed that resistance to ampicillin and piperacillin 
(ampicillin was used for selection) and reduced susceptibility to fluoroquinolones 
were horizontally transferred from all the 5 donors. Interestingly, resistance to the β-
lactams, cefuroxime, cefotaxime, and ceftazidime were horizontally transferred from 
the qnrB7-positive isolate (K2-78) but not from the qnrS1-positive isolates.  For K4-
13 as a donor, resistance or reduced susceptibility to ampicillin, piperacillin, 
fluoroquinolones, amikacin, tobramycin, trimethoprim, and trimethoprim-
sulfamethoxazole were transferred as a bloc.  
 
The horizontal transfer of qnrS1 from K38-15, qnrS1 from K4-43, and qnrB7 from 
K2-78 as donors increased the MIC of nalidixic acid by 2, 4, and 2 folds, respectively, 
and of ciprofloxacin by 62, 83, and 10 folds, respectively (table 11). The horizontal 
transfer of both the qnrS and acc(6`)-Ib-cr genes from K4-13 as a donor increased the 
MIC of nalidixic acid, ciprofloxacin, amikacin, and tobramycin by 4, 125, 2, and 64 
folds, respectively. While for K40-79, the transfer of qnrS and acc(6`)-Ib-cr increased 
the MIC of nalidixic acid and ciprofloxacin by 4 and ~62 folds, respectively, whereas 
there were no increase in the MIC of amikacyin and tobramycin (table 11). 
 
Repeated transconjugation and transformation experiments using K8-5 (qnrB1-
positive), K4-43, K40-47 and K39-31 (qnrS1-positive) as donors yielded negative 













Table 11. MICs by Etest for the recipients E. coli J53-2 and E. coli TOP'10 and the 
qnr-positive transconjugants/transformants  
Antibiotic* 
MIC ((µg/ml) 
  TOP’10           J53-2            TC38-15       TC4-13      TF4-43      TC40-79        TF2-78   
NAL 2 2 4 8 8 8 4 
CIP 0.003 0.016 1 2 0.25 1 0.032 
NOR 0.032 ND 4 8 1 4 0.125 
OFX 0.032 0.064 1 1 1 2 0.064 
LVX 0.006 0.016 0.5 0.5 0.5 1 0.032 
MXF 0.006 0.032 0.5 0.5 0.25 1 0.064 
GAT 0.003 0.032 0.5 0.5 0.25 0.5 0.032 
AMK 2 2 2 4 2 2 2 
TOB 0.5 0.25 0.5 16 0.5 0.25 0.5 
GEN 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
AMP 4 16 ≥256 ≥256 ≥256 ≥256 ≥256 
AMC 4 8 16 24 8 16 8 
PIP 2 2 128 64 64 64 128 
TZP 0.5 2 4 16 2 4 2 
FOX 8 8 16 16 64 16 16 
CXM 8 16 16 16 8 16 32 
CTX 0.125 0.25 0.5 0.5 0.125 0.25 4 
CAZ 0.5 0,5 0.5 0.5 0.5 1 ≥32 
CCV 0.5 0,5 0.5 0.5 0.5 1 0.5 
FEP ≤0.25 ≤0.25 ≤0.25 0.032 <0.25 ≤0.25 ≤0.25 
FCV ≤0.064 0,094 0.125 0.125 0.064 ≤0.064 ≤0.064 
IPM 0.25 0,25 0.25 0,25 0.25 0.25 0.25 
MEM 0.032 0,064 0,032 0.032 0.064 0.064 0.032 
TMP ND 0.064 0.064 ≥32 0.032 0.064 0.25 
SXT 0.064 0,016 0.016 0.25 0.064 0.016 0.064 
* NAL, nalidixic acid; CIP, ciprofloxacin; NOR, norfloxacin; OFX, ofloxacin; LVX, levofloxacin; 
MXF, moxifloxacin; GAT, gatifloxacin; AMK, amikacin; TOB, tobramycin; GEN, gentamicin; AMP, 
ampicillin; AMC, amoxicillin-clavulanic acid; PIP, piperacillin; TZP, piperacillin-tazobactam; FOX, 
cefoxitin; CXM, cefuroxime; CTX, cefotaxime; CAZ, ceftazidime; CCV, ceftazidime/clavulanic acid; 
CEF, cephalothin; FEP, cefepime; FCV, cefepime/clavulanic acid; IPM, imipenem; MEM, 








For the qnr-positive isolates and their transconjugants/transformants, plasmid DNA 
was analyzed by plasmid isolation followed by gel electrophoresis (Woodford et al. 
1994). Plasmid DNA from E. coli strains NCTC 50192 (four plasmids of 148, 63.5, 
36, and 7 kb in size) and NCTC 50193 (eight plasmids of 48.3, 7.8, 5.2, 4.5, 3.3, 2.6, 
2.3, and 1.8 kb in size) was used as standard size marker. 
 
Clinical isolate K4-43 contained two plasmids of ≥ 150 kb in size. Also, isolate K40-
47 contained two plasmids of about 45 kb and 65 kb in size. Each of isolates K38-15 
and K40-79 contained only one plasmid of less than 10 kb whereas no plasmid DNA 





Figure 19. Agarose gel electrophoresis of isolated plasmid DNA from the qnr-positive 
clinical isolates, transconjugants, and transformants. Lanes: 1, E. coli NCTC 50192; 2, E. coli 
NCTC 50193; 3, K38-15; 4, TC38-15; 5, K4-13; 6, TCK4-13; 7, K4-43; 8, TF4-43; 9, K39-
31; 10, K40-47; 11, K40-79; 12, TC40-79; 13, K2-78; 14, TF2-78; and 15, K8-5. Chr, 
chromosomal DNA. Plasmid DNA is indicated by >. 
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Plasmid analysis was also performed using S1-nuclease, to convert the plasmids into 
unit-length linear molecules, followed by pulsed-field gel electrophoresis (PFGE) 
with appropriate linear DNA markers (Barton et al. 1995). After that, plasmid DNA 
was transferred from the agarose gel onto positively charged nylon membranes and 
hybridized with PCR-generated probe specific for qnrS1. 
 
Overall, each clinical isolate contained one to four plasmids ranging from 30 kb to ≥ 
195 kb in size while each transconjugant/transformant contained only one or two 
plasmids between 100 kb and 190 kb in molecular size. qnrS1 was located on a ~140 
kb plasmid in three clinical isolates and their transconjugants/transformants (K38-15, 
TC38-15, K4-43, TF4-43, K40-79, and TC40-79) while it was located on a plasmid of 
approximately 175 kb in K4-13 and TC4-13. For K40-47, qnrS1 was carried on 
plasmid of about 195 kb while for K39-31 it was not clear whether qnrS1 was carried 
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Figure 20. (A) Pulsed field gel electrophoresis of S1 nuclease–digested genomic DNA from 
the qnr-positive clinical isolates, transconjugants, and transformants. (B) Southern 
hybridization with qnrS1 probe. Lanes: 1, K38-15; 2, TC38-15; 3, K4-13; 4, TC4-13; 5, K4-
43; 6, TF4-43; 7, K40-79; 8, TC40-79; 9, K39-31; 10, K40-47; 11, K2-78; 12, K8-5; and 13, 
E. coli
 NCTC 50193. M, molecular size marker (Low Range PFG Marker, New England 
BioLabs, USA). Chr, chromosomal DNA.             
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PCR-based plasmid typing 
 
The inc/rep type of plasmid DNA isolated from the qnr-positive clinical isolates and 
their transconjugants/transformants was determined by performing 5 multiplex- and 3 
simplex-PCRs (Carattoli et al. 2005). This PCR-based replicon typing method is able 
to recognize 18 replicon types (FIA, FIB, FIC, HI1, HI2, I1-Iγ, L/M, N, P, W, T, A/C, 
K, B/O, X, Y, F, and FIIA), representing the major plasmid groups circulating among 
the Enterobacteriaceae. 
 
Overall, 5 replicon types (N, F, FIIs, FIB, and I1-Iy) were detected with IncN being 
the most identified replicon type. IncN type was found in plasmid DNA isolated from 
K38-15, TC38-15, K4-13, TC4-13, K40-79, TC40-79, K4-43, and K40-47. 
Interestingly, the replicon type F was detected for all the transconjugants and 
transformants while it was detected in only 2/5 donors (K38-15 and K40-79). Plasmid 
DNA from K2-78 and K39-31 had solely the replicon type FIIs while plasmid DNA 
from K8-5 could not be assigned to any of the 18 replicon types (table 12). 
 
Table 12. Rep/Inc types of the plasmid DNA 
Isolate Plasmid rep/inc type 
K38-15 I1-Iy, N, FIB, F 
TC38-15 N, F 
K4-13 N 
TC4-13  N, F 
K4-43 I1-Iy, N 
TF4-43  F 
K40-79 N, F 
TC40-79 N, F 
K39-31 FIIs 








Determination of the genetic environment of qnrS1 
 
Analyzing the genetic surrounding of qnrS1 was performed by PCR amplifications 
followed by sequencing with primers targeting the qnrS1 gene and the DNA elements 
that have been previously reported to be in its vicinity (orf-B of IS2, blaLAP-1, pbp-3, 
and orf encoding a 213-aminoacid polypeptide) (Poirel et al. 2007) (figure 21).  
 
The truncated insertion sequence ISEcl2 was detected downstream to qnrS1 in all the 
six qnrS1-positive strains. The blaLAP-1 and pbp-3 genes were detected further 
downstream in three isolates (K4-13, K39-31, and K40-47) while they were absent in 
the other three isolates (K38-15, K40-79, and K4-43). In addition, ∆res, orf259, and 
orf213 were detected upstream to qnrS1 in 5/6 of the qnrS1-positive strains. In K4-43, 
the presence of ∆res and orf259 was detected by PCR and confirmed by sequencing 
while the presence of orf213 could only be expected according to gel electrophoresis 
of the PCR product yet it was not confirmed by sequencing since sequencing yielded 
bad results. In K38-15, a deletion of about 350 bp was detected in the ∆res gene.  
 
For the three strains, K40-79, K38-15, and K4-43, in which blaLAP-1 and pbp-3 were 
absent, effort was done to link the qnrS1 with the blaTEM-containing transposon Tn3 
(Kehrenberg et al. 2006) (figure 21). Primers targeting the qnrS1 gene and the tnpR, 
and blaTEM genes were used for both PCR and sequencing. Using the (qnrS-3`-ext 
with tnpRF/tnpRF2) set of primers, a band of only 1300 bp was detected by gel 
electrophoresis of the PCR amplicons of the three isolates while the expected size of 
this PCR amplicon was > 3000 bp. The nucleotide sequence of these amplicons 
matched the qnrS1-orfB region (figure 21). No bands were detected with the (qnrS-3`-
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Figure 21. Schematic diagram comparing the qnrS-containing region found in the 6 qnrS1-
positive strains; K38-15, K4-13, K4-43, K39-31, K40-47, and K40-79 with that in pS3-1 from 
E. cloacae (Poirel et al. 2007), and pINF5 from S. enterica serovar Infantis (Kehrenberg et al. 
2006). Open reading frames are represented by arrows with the arrow head indicating the 


















Resistance to antimicrobial agents can take place in four major ways; by altering drug 
targets, reducing drug accumulation, protecting drug targets, and enzymatic drug 
modification (McDermott et al. 2003). Enterobacteriaceae resist quinolones by all of 
these ways. While chromosomal mutations in genes coding for DNA gyrase and 
topoisomerase IV and genes coding for outer membrane and efflux proteins are 
mostly responsible for this resistance, plasmid-mediated quinolone resistance 
(PMQR) involving the Qnr proteins protecting DNA gyrase and topoisomerase IV 
from quinolones and the AAC(6´)-Ib-cr enzyme able to modify some 
fluoroquinolones has lately been described (Robicsek et al. 2006). 
 
In this study, the aim was to evaluate the prevalence of qnr and aac(6')-Ib-cr genes 
among E. coli and Klebsiella spp. clinical isolates obtained from Norway and Sweden 
between 2003 and 2005 and showed resistance to nalidixic acid and/or reduced-
susceptibility to ciprofloxacine. The clinical isolates were taken from five collections 
which can be sorted into two main groups; the first group (the Kronoberg and NORM 
collections) included consecutive clinical isolates representing the common bacterial 
population, while the second group contained clinical isolates picked from three 
collections at K-res (the E. coli AmpC, Ullevål ESBL, and Norwegian ESBL studies) 
representing a bacterial population with other resistance mechanisms. 
 
 
Prevalence of the qnr genes  
 
Overall, prevalence of the qnr genes 1.6 % (8/487) in the E. coli and Klebsiella spp. 
clinical isolates collected from Norway and Sweden and included in this study was 
low. This was well consistent with a study conducted in Denmark showing that only 
1.63 % (2/122) of nalidixic acid-resistant E. coli isolates was qnr-positive (Cavaco et 
al. 2007). Low prevalence of qnr genes has also been reported from France and 
Canada. In France, the prevalence of qnr genes was 1.6 % (2/125) among ESBL-
 90
producing E. coli and Klebsiella spp. isolates (Poirel et al. 2006 and Cattoir et al. 
2007) while in Canada only about 1 % (5/550) of ciprofloxacin and/or tobramycin 
resistant E. coli and Klebsiella spp. isolates were qnr-positive (Pitout et al. 2008). 
Nevertheless, high prevalence has also been detected in other parts of the world such 
as Spain (5 %) (Lavilla et al. 2007), China (8 %) (Jiang et al. 2008) and the United 
States (15 %) (Robicsek et al. 2006). However, the comparison should be taken with 
caution since different criteria for selecting the bacterial isolates were used in these 
studies (appendix A, table 15). For instance, resistance to tobramycin was used as a 
selection criterion in the Spanish study which probably under-estimated the real 
prevalence (Lavilla et al. 2007). 
 
In this study, the criteria used for selecting these strains included: (1) resistance to 
nalidixic acid (MIC > 16 µg/ml) and (2) resistance or reduced susceptibility to 
ciprofloxacin (MIC ≥ 0.125 µg/ml). These criteria were chosen since QnrA1, the first 
PMQR determinant to be discovered, increased the MIC of nalidixic acid to clinically 
resistant levels (Tran & Jacoby. 2002) and because a ciprofloxacin MIC of ≥ 0.125 
µg/ml is the minimum expected for Enterobacteriaceae containing a qnr gene 
(Robicsek et al. 2006). However, it is noteworthy that several qnr-positive isolates 
have increasingly been detected in nalidixic acid-susceptible isolates (Cano et al. 
2006, Cavaco et al. 2007, and Hopkins et al. 2007) and so the true prevalence of Qnr 
determinants could be underestimated in this study.  
 
The qnr genes were detected in only 0.7 % (3/422) of the E. coli while in 7.7% (5/65) 
of the Klebsiella spp. clinical isolates. The higher prevalence of qnr genes in 
Klebsiella spp. isolates than in E. coli isolates was also noticed in other studies 
conducted in France (Poirel et al. 2006), USA (Robiscek et al. 2006), Spain (Lavilla 
et al. 2007), and recently China (Jiang et al. 2008). In France, for example, qnr was 
detected in 0.63 % (3/472) and 7 % (5/70) among the E. coli and Klebsiella spp. 
isolates, respectively. 
 
qnrS and qnrB were detected in six and two isolates, respectively, while qnrA was not 
found in any of the isolates. The dominance of qnrS and qnrB in our strain collections 
is similar to other studies from Europe (Chen et al. 2006 and Poirel et al. 2006). On 
the contrary, qnrA gene was highly detected in a selected collection of blood culture 
 91
isolates of Enterobacteriaceae resistant to both ciprofloxacin and cefotaxime in UK 
(Corkill et al. 2006). Furthermore, qnrA1 was the most prevalent qnr gene in a most 
recent Spanish study (Lavilla et al. 2008) where qnrA1 was detected in 14 of 305 
ESBL-producing enterobacterial isolates whereas only one qnrS and no qnrB were 
detected.  
 
The amino acid and nucleotide sequences of all the qnrS genes, qnrB from K8-5, and 
qnrB from K2-78 were 100% identical to those of qnrS1 (GenBank reference number 
DQ485529.1), qnrB1 (GenBank reference number DQ777878.1), and qnrB7 
(GenBank reference number ABW03156.3), respectively. However, the qnrB-positive 
PCR products that were sequenced did not cover the whole gene therefore amino acid 
changes could be present outside this region (the amino acid alignments are presented 
in appendix B, figures 2, 3, 4, and 5).  
 
Only two qnrS1 genes were detected in ESBL-producers, according to their 
phenotypic profile and to the Norwegian ESBL study data (Tofteland et al. 2007), 
while the other four qnrS1 genes were detected in non-ESBL-producing clinical 
isolates, according to their phenotypic profile. This was not unanticipated since 
similar finding was reported in studies from France and Korea where the qnrS1 gene 
was mostly identified in non-ESBL strains (Poirel et al. 2006 and Park et al. 2007, 
respectively). Furthermore, although the qnrS1 gene and genes encoding for 
extended-spectrum β-lactamases (ESBLs) have frequently been associated in same 
clinical isolates, they have been identified on different plasmids (Chen et al. 2006 and 
Hopkins et al. 2007). On the other hand, the detection of QnrB determinants in two 
ESBL-positive strains was also highly expected given that co-presence of qnrB and 
ESBL genes on same plasmids has been regularly reported (Jacoby et al. 2006, 
Robicsek et al. 2006, Cattoir et al. 2007, and Pai et al. 2007).  
 
Interestingly, three qnrS1- and one qnrB7-positive isolates were found in nalidixic 
acid-susceptible isolates. This has been found in other studies as mentioned above. 
The only reduced-susceptibility to quinolones conferred by qnr genes raises the 
concern that these genes could spread insidiously. Subsequently, a substantial 
population of clinical Enterobacteriaceae on the threshold of high-level resistance 
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would continue to be treated and exposed to quinolones (Gay et al. 2006). Thus, 
although the qnr genes might not allow a population of bacteria to survive in the 
presence of a quinolone, they enhance the selection of resistant mutants from the 
population (Robicsek et al. 2006). 
 
  
Prevalence of the aac(6`)-Ib-cr gene  
 
The prevalence of aac(6`)-Ib-cr among the selected E. coli and Klebsiella spp. clinical 
isolates was 14.1 % (69/487). This finding was comparable to or lower than what was 
been found in other studies; the prevalence of aac(6`)-Ib-cr was 11.3 % (62/549) 
among ciprofloxacin- and/or tobramycin-resistant E. coli and Klebsiella spp. clinical 
isolates from Canada (Pitout et al. 2008) and 9.9 % (36/365) among ESBL-producing 
E. coli and K. pnumoniae isolates from six provinces in China (Jiang et al. 2008) 
while it was 51% among ciprofloxacin-resistant clinical isolates of E. coli isolated 
from Shanghai, China (Robicsek et al. 2006).  
 
In this study 92 % of the aac(6`)-Ib were of the aac(6’)-Ib-cr variant. This is also 
observed in many other studies where 58 %, 84 %, and 100% of the aac(6`)-Ib were 
of the aac(6’)-Ib-cr variant (Jiang et al. 2008, Robicsek et al. 2006, and Samuelsen et 
al. 2007). The high percentage of this variant mostly reflect a long-time presence of 
under-screened aac(6’)-Ib-cr. Interestingly, two isolates harbored both the wild type 
aac(6’)-Ib and the -cr variant. This was similar to what been found in E. coli and 
Klebsiella spp. clinical isolates from Russia where four isolates were identified to 
hold both the aac(6')-Ib-cr variant and the aac(6')-Ib wild-type (Samuelsen et al. 
2007). 
 
While aac(6‘)-Ib-cr was found in only 3% (12/400) from the two collections 
representing the common bacterial population, it was detected in 48.7 % (57/117) of 
clinical isolates from the E. coli AmpC and ESBL studies. The high association 
between the PMQR genes (both the qnr and aac(6`)-Ib-cr genes) and genes encoding 
for ESBLs or AmpC β-lactams may somewhat explain the prevalence of 
enterobacterial clinical isolates resistant to both flouroquinolones and β-lactams, 
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mostly due to the co-selection of these bacteria by use of either agent alone (Gay et al. 
2006). Furthermore, this association could be clinically significant since the 
therapeutic options for treatment of the increasingly encountered ciprofloxacin- and β-
lactam-resistant E. coli are limited. 
 
It is worth mentioning that aac(6‘)-Ib-cr variant was detected more commonly among 
the qnr-positive than qnr-negative isolates; it was detected in 50 % (4/8) and 14.8 % 
(71/479) of the qnr-positive and the qnr-negative isolates, respectively. A comparable 
prevalence was reported from China where the aac(6‘)-Ib-cr variant was 55.2 % 
among qnr-positive and only 6 % among qnr-negative isolates (Jiang et al. 2008). 
This could be explained by the co-existence of the qnr and aac(6`)-Ib-cr genes on the 
same plasmid (Jiang et al. 2008). Nevertheless, this co-existence has been reported for 
qnrA and qnrB genes (Jiang et al. 2008 and Quiroga et al. 2007, respectively) while in 
this study qnrS1 was the most prevalent qnr gene.     
 
 
Resistance profiles of the qnr-positive isolates  
 
Four of the qnr-positive isolates were resistant to antimicrobials of four different 
classes; ß-lactams, aminoglycosides, quinolones and sulfonamides and were classified 
as multi-drug resistant isolates (Sahm et al. 2001). The prevalence of such multi-drug 
resistant clinical isolates could be due to either the spread of a successful single or 
few clonal groups (Manges et al. 2001) or the presence of transferable R-plasmids in 
these isolates (Shehabi et al. 2004). In this study, transferable R-plasmids were 
detected in 5/8 of the qnr-positive isolates suggesting that plasmids are responsible for 
the spread. Although the clonality of the isolates were not investigated, it is unlikely 
that the isolates are clonal since they are from different strain collections and from 
two countries. 
 
The ESBL-producing clinical isolate K4-43 was resistant to the oxyimino-
cephalosporins (cefuroxime, cefotaxime, ceftazidime, and cefepime) but was 
furthermore resistant to cephamycins (cefoxitin), amoxicillin/clavulanic acid, and 
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piperacillin/tazobactam as well. This finding was explained by the high 
impermeability of K4-43 according to the Norwegian ESBL study data. 
 
The four aac(6`)-Ib-cr-positive clinical isolates (K4-13, K4-43, K8-5, and K40-79) 
showed reduced susceptibility or resistance to amikacin and tobramycin. This can be 
clearly clarified by the fact the AAC(6`)-Ib-cr variant is able to modify these 
aminoglycosides though to a less degree compared with the AAC(6`)-Ib wild-type 
gene (Robiscek et al. 2006). The aac(6`)-Ib-cr-positive clinical isolates were in 
addition resistant to trimethoprim, and trimethoprim-sulfmethoxazole. The facts that 
aac(6`)-Ib-cr has mostly been found in complex integrons (Wang et al. 2003) and that 
the 3'-CS region of such integrons contains the sul1 gene encoding resistance to 
sulphonamides (Bennett. 1999) explain the associated resistant to trimethoprim, and 
trimethoprim-sulfmethoxazole. The considerable association between aac(6`)-Ib-cr 
and gentamycin resistance (3/4 of the isolates) was unexpected finding since aac(6`)-
Ib-cr does not confer resistance to gentamycin (Robicsek et al. 2006). The same 
unanticipated finding was reported from USA (Park et al. 2006). The explanation 




Analysis of the quinolone resistance determining regions (QRDRs)  
 
PMQR determinants have always been reported to confer only low level of resistance 
or just reduced susceptibility to nalidixic acid and fluoroquinolones (Robicesk et al. 
2006). Whereas, the most important mechanism for acquiring high levels of quinolone 
resistance has constantly developed by the acquisition of chromosomal point 
mutations in the QRDRs of target genes particularly gyrA and parC (Fendukly et al. 
2003).  
 
The presence of double mutations in the gyrA gene has been reported to be 
responsible for resistance to quinolones (Fendukly et al. 2003). In addition, the 
presence of single or double mutations in the parC gene seems to play a 
complementary role in increasing this quinolone resistance (Fendukly et al. 2003). In 
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this study, two qnr-positive E. coli clinical isolates (K4-43 and k40-79) were found to 
have high level of quinolone resistance. Double mutations L83S and N87D in the 
gyrA gene with the addition of a single mutation I80S in the parC gene were detected 
in both these strains.  
 
For K8-5, the qnr-positive K. pneumoniae clinical isolate with high level of quinolone 
resistance, a single mutation L83S in the gyrA gene and a single mutation I80S in the 
parC gene were detected. This finding is in accordance with previously published 
report where only one or two mutations in the gyrA gene are sufficient to explain the 
quinolone resistance (Fendukly et al. 2003). Once more, the presence of mutations in 
the parC gene seems to play a complementary role in increasing this quinolone 
resistance (Fendukly et al. 2003). 
 
No mutations were detected in the QRDRs of gyrA and parC genes neither in K40-47 
which was a qnr-positive quinolone-resistant K. pneumoniae clinical isolate but 
showed lower MICs of nalidixic acid (64 µg/ml) and ciprofloxacin (4 µg/ml) than the 
three isolates mentioned above nor in the four nalidixic acid-susceptible clinical 
isolates (K38-15, K2-78, K4-13, and K39-31). For isolate K40-47, the low-level 
resistance to nalidixic acid could be due to the presence of mutations in QRDRs of the 
gyrB or parE genes though these mutations are much less frequent and less significant 
than those in the QRDRs of gyrA and parC genes (Everett et al. 1996). In addition, 
decreased accumulation of quinolone could be the basis for this quinolone resistance 
(Ruiz. 2003). Decreased quinolone accumulation is generally associated with (1) 
alterations in membrane permeability usually due decreased expression of porins 
and/or (2) the over-expression of efflux systems capable of pumping out quinolones. 
This finding was encountered in previously published study conducted by Fendukly et 
al. where a K. pneumoniae clinical isolate with MIC of 128 µg/ml and 0.38 µg/ml for 
nalidixic acid and ciprofloxacin, respectively, was lacking any mutations in the gyrA 






Transfer of quinolone resistance 
 
Success in transferring the qnrS and qnrB genes by transconjugation has been 
frequently reported (Hata et al. 2005 and Hu et al. 2008). In addition, transfer of these 
qnr genes can also be performed by transformation (Lavilla et al. 2007). On the other 
hand, both of qnrS and qnrB genes have also been detected on non-transconjugative 
plasmids (Cavaco et al. 2007 and Cattoir et al. 2007). 
 
In this study, transfer of low-level quinolone resistance conferred by qnr genes was 
successful from 5/8 of the qnr-positive isolates. Three qnrS1 genes were transferred 
by transconjugation, while one qnrS1 and one qnrB7 genes were transferred by 
transformation. Additionally, the co-transfer of the aac(6`)-Ib-cr gene was also 
detected from 2/4 of the isolates. The success in transferring qnr genes using 100 
mg/L ampicillin as selection pressure indicates that both the qnr gene and a ß-
lactamase gene are carried on same plasmid. Furthermore, resistance to the β-lactams, 
cefuroxime, cefotaxime, and ceftazidime was horizontally transferred from the qnrB7-
positive isolate (K2-78) but not from the qnrS1-positive isolates. This finding was not 
unpredicted since the co-presence of qnrB and ESBL-encoding genes on same 
plasmids has been regularly reported (Jacoby et al. 2006, Robicsek et al. 2006, Cattoir 
et al. 2007, and Pai et al. 2007) while, in contrast, the qnrS1 gene and genes encoding 
for extended-spectrum β-lactamases (ESBLs) have frequently been identified on 
different plasmids (Chen et al. 2006 and Hopkins et al. 2007). 
 
The co-transfer of aac(6`)-Ib-cr again imply that this gene could be located at the 
same plasmid with the qnr and ß-lactamase genes. In the study conducted by Jiang et 
al, southern hybridization indicated that qnrA, aac(6`)-Ib-cr, and ESBL-encoding 
genes were always located on the same plasmids (Jiang et al. 2008). However, the 
association between these genes on same plasmids was not confirmed in this study.  
 
On the other hand, two qnrS1 genes and one qnrB1 gene were neither transconjugable 
nor transformable. The failure in transferring these qnr genes indicates that they are 
located on non-transferable plasmid. Nevertheless, a chromosomal location for qnr 
genes has been suggested by some studies (Rodriguez-Martinez et al. 2006 and 
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Cavaco et al. 2007). This could be the case for K39-31 where repeated 
transconjugation and transformation experiments yielded negative results though 
different antibiotics were used for selection and the qnrS1 probe could be hybridized 
with chromosomal DNA (figure 20). 
 
It has been reported that transfer of the qnrS or qnrB gene resulted in a 3 and 8 folds 
increase in the MIC of nalidixic acid and between 8 to 62.5 folds in the MIC of 
ciprofloxacin (Chen et al. 2006, Gay et al. 2006, Kehrenberg et al. 2006, Poirel et al. 
2006, Hu et al. 2008, Jacoby et al. 2006, Pai et al. 2007, Kehrenberg et al. 2007). 
Comparable results were detected in this study where the qnr genes increased the 
MIC for nalidixic acid by 2 to 4 folds and for ciprofloxacin by 10 to 125 folds. qnrS 
conferred higher fluoroquinolone MICs than qnrB (table 11). This has also been 
observed in other studies (Cattoir et al. 2007 and Hu et al. 2008).  
 
The differences in resistance levels to qiunolones among transconjugants have 
regularly been reported and could be caused by different gene expression, or different 
gene copy number (Robicsek et al. 2006). Different levels of expression of qnrA gene 
among transconjugants have been observed for the qnrA gene (Rodriguez-Martinez et 
al. 2006). The higher ciprofloxacin-resistance levels among transconjugants from K4-
13 (table 10) can be explained by the co-transfer of the aac(6`)-Ib-cr gene. The 
presence of aac(6`)-Ib-cr on certain qnrA plasmids from clinical E. coli collected in 
Shanghai provided about four-fold further higher levels of ciprofloxacin resistance 
(Robicsek et al. 2006). Furthermore, the co-transfer of aac(6`)-Ib-cr could be the 
explanation for the increase in MIC of amikacin (2 folds), and tobramycin (> 10 
folds) among the transconjugants from K4-13 (table 10). However, the aac(6`)-Ib-cr 
gene was also co-transferred from K40-79 as a donor but the increase in ciprofloxacin 
MIC was comparable and there was no increase in MIC of amikacin or tobramycin. 









Analyzing plasmid DNA by doing plasmid isolation followed by gel electrophoresis 
has been widely used (Corkill et al. 2005, Jiang et al. 2008). In this study this method 
did not give satisfying results. Only two plasmids were detected in K4-43 and K40-
47, one plasmid in K38-15 and K40-79, and no plasmid DNA was detected for the 
other four clinical isolates and all the transconjugants/transformants. For E. coli strain 
NCTC 50192, only three bands representing plasmids of 63.5, 36, and 7 kb in size 
were detected while the band representing a 148 kb plasmid was missed. For E. coli 
strain NCTC 50193, only two bands representing plasmids of 5.2, and 1.8 kb in size 
were detected while 6 bands representing plasmids of 48.3, 7.8, 4.5, 3.3, 2.6, and 2.3 
kb in size were all not detected. The absence of those bands in the gel photo in this 
study was in line with the finding of very week bands in gel photos from previously 
published studies (Woodford et al. 1994 and Cattoir et al. 2007). Furthermore, it was 
reported in another study from Spain that larger plasmids could not be visualized by 
using this method while they were detected by using the S1-PFGE method (Martinez 
et al. 2005). 
 
Plasmid analysis was also performed by the S1-PFGE method where the qnr-positive 
clinical isolates, transconjugants, and transformants contained one to four plasmids 
ranging in size from 30 kb to ≥ 195 kb. By southern blotting and hybridization with 
PCR-generated a probe specific for qnrS1, the qnrS1 genes were located on at least 
three different plasmid backbones according to the diversity in their sizes (140 kb, 
175 kb, and 195 kb) (figure 20) which implies a successful inter-plasmid 
dissemination of the qnrS1 gene itself. The variability in the molecular size of the 
qnr-carrying plasmids has frequently been reported (Veldman et al. 2008 and Hopkins 








PCR-based plasmid typing 
 
The IncN replicon type was detected in qnrS-positive plasmid DNA from K38-15, 
TC38-15, K4-13, TC4-13, K40-79, TC40-79, K4-43, and K40-47. In this respect, 
qnrS1-positive plasmids isolated from Salmonella isolates from the UK (Hopkins et 
al. 2007) and from the Netherlands (Veldman et al. 2008) also carried the IncN 
replicon type. Furthermore, the qnrS1- positive plasmid pINF5 from Salmonella 
enterica from Germany was hypothesized to have a pMUR050-like ancestor which is 
an IncN plasmid (Hata et al. 2005). However, the association between qnrS1 and 
IncN on same plasmids needs to be confirmed by hybridization experiments using an 
IncN probe. 
 
The replicon type FIIs was assigned to the qnrB7-positive plasmid DNA from K2-78 
given that it was the only type detected by PCR. The qnrB1-positive plasmid DNA 
from K8-5 was not positive for any of the 18 replicon types. Several plasmids isolated 
from Salmonella enterica from the UK as well as the pAH0376 plasmid from Shigella 
flexneri from China were also negative for all these 18 replicons (Hopkins et al.2007). 
However, those isolates were all qnrS1-positive. There is no explanation why replicon 
type F was present in plasmid DNA from four transconjugants/transformants while it 
was detected in only two donors. 
 
 
Determination of the genetic environment of qnrS1 
 
The nucleotide sequences of the region closely surrounding qnrS1 in all the six qnrS1-
positive clinical isolates detected in this study showed ≥ 99 % identity to the qnrS1-
containing region in plasmids pINF5 (AM234722.1) (Kehrenberg et al. 2006), pK245 
(DQ449578.1) (Chen et al. 2006), pS3-1 (Poirel et al. 2007), pHS8 (EF683584.1) (Hu 
et al. 2008) except that a 350 bp deletion was detected in K38-15. The area was of 
about 4200 bp in size and contained ∆ISEcl2 (orfB-∆orfA), qnrS1, ∆res, orf259, and 
orf213 (figure 21). An additional 99 % nucleotide identity was detected between the 
region further downstream to qnrS1 in K4-13, K39-31, and K40-47 and the parallel 
region in plasmids pK245 (DQ 449578.1) (Chen et al. 2006), pS3-1 (Poirel et al. 
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2007), pHS8 (EF 683584.1) (Hu et al. 2008). The area was of about 1150 bp in size 
and contained pbp-3, and blaLAP-1 (figure 21).  
 
The similarity of the qnrS1-containing area in plasmids from this study and from 
several other studies indicates a potential common origin of the region as a unit. This 
region could be contained in a composite transposon bounded by two flanking IS26 
elements, which explains its mobility (Chen et al. 2006). On the other hand, the 
universal association between qnrS1 and the ∆ISEcl2 could play a role in the 
dissemination of this gene itself probably by mediating an inter-plasmid insertional or 
recombinational genetic event. However, a recombination event appears more likely 
sine the insertion target site of the ∆ISEcl2 element was detected upstream to qnrS1 
suggesting that its insertion had occurred individually (Poirel et al. 2006)  
 
For the three strains, K40-79, K38-15, and K4-43, in which blaLAP-1 and pbp-3 were 
absent, attempts were done to link the qnrS1 with Tn3 (Kehrenberg et al. 2006). A 
band of 1300 bp was detected in the PCR amplicons of all the three isolates but the 
nucleotide sequence was again matching the qnrS1-orfB region. By looking in deep it 
was found that the orfB of the ∆ISEcl2 also encodes a resolvase enzyme so similarity 
between its DNA sequence and tnpR DNA sequence explains why the tnpRF/tnpRF2 
primers annealed with orfB instead of tnpR resulting in those 1300 bp bands. 
However, no band was detected with the (qnrS-3`-ext with TEM-R mod TW) set of 
primers and blaTEM-1. First of all, this could be because conventional PCR 
amplifications were performed and that the predicted distance between qnrS1 and 
blaTEM-1 is > 5000 bp (Kehrenberg et al. 2006) and so using long-range PCR kits 
would have been more appropriate. Secondly, this finding may simply suggest that 
Tn3 is absent in these 3 isolates. Although most studies on the genetic environment of 
qnrS1 have detected either (blaLAP-1 with pbp-3) or blaTEM-1-containing Tn3 
downstream qnrS1, their absence has recently been reported in plasmid TPqnrS-1a 
isolated from a multi-resistant Salmonella Typhimurium strain from the UK 







The prevalence of qnr (1.6%) and aac(6’)-Ib-cr (14.1%) determinants among 
Norwegian and Swedish clinical isolates of E. coli and Klebsiella spp. with resistance 
to nalidixic acid and/or resistance/reduced susceptibility to ciprofloxacin was low. 
The qnr-genes were more prevalent in Klebsiella spp. (7.7%) than in E. coli (0.7%).  
 
While qnrS1 was detected in six isolates and was the most common qnr gene, each of 
qnrB1 and qnrB7 was detected in only one isolate. The qnrS1 genes were located on 
at least three different plasmid backbones; two transconjugative plasmids of about 
140 kb and 175 kb and one non-transconjugative plasmid of about 195 kb. 
Nevertheless, the qnrS1-containing area containd matching structures in the six 
isolates.  
 
The global distribution of the qnr genes, their presence in several enterobacterial 
species, and the identification of several qnr variants suggest that they have had a 
substantial evolutionary history. The presence of qnrS1 gene in several enterobacterial 
species also indicates a successful dissemination of the qnrS1-carrying plasmids. 
Furthermore, the presence of qnrS1 gene on different plasmid backbones implies a 
successful dissemination of the qnrS1 gene itself which could result from association 
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Table 1. All qnrA, qnrB, and qnrS variants have been detected so far. 





The first identified qnr 
gene 
K. pneumoniae USA AY070235 
Martinez-Martinez et al. 1998 
Tran & Jacoby. 2002 
qnrA2  
Few amino acid 
substitutions from qnrA1 




Few amino acid 




Few amino acid 
substitutions from qnrA1 




Few amino acid 
substitutions from qnrA1 
S. algae France DQ058663 Poirel et al. 2005 
qnrA6 
Few amino acid 
substitutions from qnrA1 
P. mirabilis France DQ151889 Cambau et al. 2006 
qnrS1 
59% amino acid identity 
to qnrA1 
S. flexneri Japan AB187515 Hata et al. 2005 
92% amino acid identity 
to qnrS1 
Plasmid pGNB2 Germany DQ460733 Bonemann et al. 2006 
qnrS2 








83.9 % and 87.6 % amino 
acid identity to qnrS1 and 
qnrS2, respectively. 
V. splendidus USA 
EAP95542 
 (EMBL-Bank) 




83.1 % and 87.1 % amino 
acid identity to qnrS1 and 
qnrS2, respectively. 
4 amino acid substitutions 
from qnrVS1 
Vibro spp. France 
EAQ55748  
(EMBL-Bank) 
Cattoir et al. 2007 
qnrB1 
40% amino acid identity 
to qnrA1 
K. pneumoniae India/USA DQ351241 Jacoby et al. 2006 
qnrB2  
5 amino acid substitutions 
from qnrB1 C. koseri USA DQ351242 Jacoby et al. 2006 
qnrB3 
99% amino acid identity 
to qnrB1 
E. coli USA DQ303920 Robicsek et al. 2006 
qnrB4 
94% amino acid identity 
to qnrB1 
E. coli USA DQ303921 Robicsek et al. 2006 
qnrB5 




USA DQ303919 Gay et al. 2006 
qnrB6 Similar to qnrB3 E. aerogenes China EF517946 Ma et al. unpublished 
qnrB7 
97% amino acid identity 
to qnrB1 
E. cloacae France EU043311 Cattoir et al. 2007 
qnrB8 
96% amino acid identity 
to qnrB6 
C. freundii France EU043312 Cattoir et al. 2007 
qnrB9 Not-determined C. freundii France EF653270 Rodriguez-Zulueta et al. unpublished 
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Table 1. All qnrA, qnrB, and qnrS variants have been detected so far, cont. 




98% amino acid identity 
to qnrB5 
C. freundii Argentina DQ631414 Quiroga et al. 2007 
qnrB10 
Not-determined C. freundii Spain EU136182 
Sanchez-Cespedes et al. 
unpublished 
qnrB11 Not-determined C. freundii Spain EU136183 
Sanchez-Cespedes et al. 
unpublished 
qnrB12 
98.9% amino acid identity 
to qnrB9 
C. werkmanii Germany AM774474 Kehrenberg et al. 2008 
qnrB13 Not-determined C. freundii Korea EU273756 Tamang et al. unpublished 
qnrB14 Not-determined C. freundii China EU325573 Wang et al. unpublished 
qnrB15 Not-determined C. freundii Korea EU302865 Tamang et al. unpublished 
qnrB16 Not-determined C. freundii Spain AM919398 
Gonzalez-Lopez et al. 
unpublished 
qnrB17 Not-determined C. freundii Spain AM919399 





Table 2. Clinical MIC and zone breakpoints 
Antibiotic Reference 
Clinical MIC breakpoints (µg/ml) 
    Susceptible                 Resistant 
Nalidixic acid  NORM* ≤ 16 > 16 
Ciprofloxacin EUCAST** ≤ 0.5 > 1 
Ofloxacin EUCAST ≤ 0.5 > 1 
Norfloxacin EUCAST ≤ 0.5 > 1 
Levofloxacin EUCAST ≤ 1 > 2 
Moxifloxacin EUCAST ≤ 0.5 > 1 
Amikacin EUCAST ≤ 8 > 16 
Tobramycin EUCAST ≤ 2 > 4 
Gentamicin EUCAST ≤ 2 > 4 
Ampicillin BSAC*** ≤ 16 > 16 
Amoxicillin/clavulanic acid BSAC ≤ 16 > 16 
Piperacillin EUCAST ≤ 8 > 16 
Piperacillin/tazobactam EUCAST ≤ 8 > 16 
Cefuroxime EUCAST ≤ 8 > 8 
Cetriaxone EUCAST ≤ 1 > 2 
Ceftazidime EUCAST ≤ 1 > 8 
Cefotaxime EUCAST ≤ 1 > 2 
Cefoxitin BSAC ≤ 8 > 8 
Meropenem EUCAST ≤ 2 > 8 
Imipenem EUCAST ≤ 2 > 8 
Trimethoprim  EUCAST ≤ 2 > 4 
Trimethoprim sulfamethoxazole EUCAST ≤ 2 > 4 
Antibiotic Reference 
Clinical zone breakpoints (mm) 
    Susceptible                 Resistant 
Nalidixic acid 30 µg  SRAG**** > 20  ≤16  
Ciprofloxacin 10 µg  SRAG > 20  ≤16  
* NWGA (Norwegian Working Group on Antibiotics), according to the NORM/NORM-VET 2006 
report, ** EUCAST (the European Committee on Antimicrobial Susceptibility Testing) 
http://www.escmid.org/sites/index_f.aspx?par=2.4, *** BSAC (the British Society for Antimicrobial 
Chemotherapy) http://www.bsac.org.uk/_db/_documents/version_6.1.pdf, **** SRAG (the Swedish 
Reference Group for Antibiotics) http://www.srga.org/ZONTAB/zontab2b.htm 
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Table 3. Bacterial isolates of the Kronoberg collection.  
CIP profile* NAL profile* Material Species Lab. nr Ref. nr Nr. 
>32 R >256 R urine E. coli 04-64719 K37-01 1 
0.064 S 64 R urine E. coli 04-35036 K37-02 2 
0.25 S >256 R urine E. coli 04-67291 K37-03 3 
0.5 S >256 R urine E. coli 04-74539 K37-04 4 
>32 R >256 R urine E. coli 04-74492 K37-05 5 
>32 R >256 R urine E. coli 04-77210 K37-06 6 
>32 R >256 R urine E. coli 05-5648 K37-07 7 
0.125 S >256 R urine E. coli 05-4791 K37-08 8 
0.25 S 128 R urine E. coli 04-73969 K37-09 9 
16 R >256 R urine E. coli 04-69398 K37-10 10 
>32 R >256 R urine E. coli 04-75431 K37-11 11 
32 R >256 R urine E. coli 04-74872 K37-12 12 
0.25 S >256 R urine E. coli 04-73296 K37-13 13 
>32 R >256 R urine E. coli 04-52450 K37-14 14 
0.25 S >256 R urine E. coli 04-56221 K37-15 15 
0.25 S 128 R urine E. coli 04-58589 K37-16 16 
0.25 S >256 R urine E. coli 04-35296 K37-17 17 
0.25 S >256 R urine E. coli 04-37984 K37-18 18 
>32 R >256 R urine E. coli 04-41416 K37-19 19 
8 R >256 R urine E. coli 04-45097 K37-20 20 
>32 R >256 R urine E. coli 04-48663 K37-21 21 
32 R >256 R urine E. coli 04-61100 K37-22 22 
0.25 S >256 R urine E. coli 04-64385 K37-23 23 
0.25 S >256 R urine E. coli 04-34725 K37-24 24 
Not determined Not determined urine E. coli 04-37622 K37-25 25 
>32 R >256 R urine E. coli 04-41151 K37-26 26 
0.064 S 32 R urine E. coli 04-43618 K37-27 27 
0.25 S 128 R urine E. coli 04-48586 K37-28 28 
0.25 S >256 R urine E. coli 04-53744 K37-29 29 
>32 R >256 R urine E. coli 04-56355 K37-30 30 
>32 R >256 R urine E. coli 04-58593 K37-31 31 
0.125 S 64 R urine E. coli 04-61103 K37-32 32 
>32 R >256 R urine E. coli 04-78102 K37-33 33 
1 I >256 R urine E. coli 04-77833 K37-34 34 
>32 R >256 R urine E. coli 04-77588 K37-35 35 
>32 R >256 R urine E. coli 04-77275 K37-36 36 
>32 R >256 R urine E. coli 04-69026 K37-37 37 
Not determined Not determined urine E. coli 04-68894 K37-38 38 
0.25 S >256 R urine E. coli 04-67984 K37-39 39 
>32 R >256 R urine E. coli 04-37909 K37-40 40 
>32 R >256 R urine E. coli 04-41351 K37-41 41 
0.25 S 128 R urine E. coli 04-43810 K37-42 42 
0.5 S >256 R urine E. coli 04-48644 K37-43 43 
0.125 S 256 R urine E. coli 04-54371 K37-44 44 
>32 R >256 R urine E. coli 04-57421 K37-45 45 
16 R >256 R urine E. coli 04-59168 K37-46 46 
0.125 S 32 R urine E. coli 04-61558 K37-47 47 
0.125 S 128   R urine E. coli 04-65082 K37-48 48 
Not determined Not determined urine E. coli 04-39413 K37-49 49 
2 R >256 R urine E. coli 04-42314 K37-50 50 
0.125 S 64 R urine E. coli 04-45827 K37-51 51 
>32 R >256 R urine E. coli 04-50457 K37-52 52 
>32 R >256 R urine E. coli 04-55415 K37-53 53 
>32 R >256 R urine E. coli 04-57880 K37-54 54 
0.125 S 128 R urine E. coli 04-59861 K37-55 55 
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Table 3. Bacterial isolates of the Kronoberg collection, cont.  
CIP profile* NAL profile* Material Species Lab. nr Ref. nr Nr. 
16 S >256 R urine E. coli 04-63391 K37-56 56 
0.125 S 128 R urine E. coli 04-33244 K37-57 57 
0.5 S >256 R urine E. coli 04-36171 K37-58 58 
0.25 S >256 R urine E. coli 04-39850 K37-59 59 
0.25 S 256 R urine E. coli 04-42645 K37-60 60 
0.25 S >256 R urine E. coli 04-46789 K37-61 61 
0.125 S 64 R urine E. coli 04-51866 K37-62 62 
0.25 S >256 R urine E. coli 04-55463 K37-63 63 
>32 R >256 R urine E. coli 04-48328 K37-64 64 
0.25 S >256 R urine E. coli 04-78174 K37-65 65 
4 R >256 R urine E. coli 04-78145 K37-66 66 
0.25 S 128 R urine E. coli 04-43417 K37-67 67 
0.064 S 128 R urine E. coli 04-40350 K37-68 68 
0.25 S >256 R urine E. coli 04-37147 K37-69 69 
>32 R >256 R urine E. coli 04-34147 K37-70 70 
>32 R >256 R urine E. coli 04-32611 K37-71 71 
16 R >256 R urine E. coli 04-35964 K37-72 72 
0.125 S 64 R urine E. coli 04-59170 K37-73 73 
>32 R >256 R urine E. coli 04-61779 K37-74 74 
0.125 S 32 R urine E. coli 04-65529 K37-75 75 
0.125 S 128 R urine E. coli 04-35340 K37-76 76 
1 I >256 R urine E. coli 04-39100 K37-77 77 
1 I >256 R urine E. coli 04-41681 K37-78 78 
0.25 S >256 R urine E. coli 04-45139 K37-79 79 
>32 R >256 R urine E. coli 04-49504 K37-80 80 
0.5 S 256 R urine E. coli 04-54549 K37-81 81 
>32 R >256 R urine E. coli 04-57577 K38-01 82 
16 R >256 R urine E. coli 04-59400 K38-02 83 
0.25 S >256 R urine E. coli 04-61781 K38-03 84 
0.25 S 64 R urine E. coli 04-65561 K38-04 85 
0.125 S 32 R urine E. coli 04-52017 K38-05 86 
0.25 S >256 R urine E. coli 04-47745 K38-06 87 
0.25 S >256 R urine E. coli 04-42672 K38-07 88 
0.25 S >256 R urine E. coli 04-39856 K38-08 89 
0.5 S >256 R urine E. coli 04-36547 K38-09 90 
0.25 S 64 R urine E. coli 04-54383 K38-10 91 
>32 R >256 R urine E. coli 04-57573 K38-11 92 
0.125 S 64 R urine E. coli 04-58249 K38-12 93 
>32 R >256 R urine E. coli 04-41791 K38-13 94 
0.25 S >256 R urine E. coli 04-45560 K38-14 95 
0.5 S 16 S urine E. coli 04-35623 K38-15 96 
0.5 S 256 R urine E. coli 04-39396 K38-16 97 
0.064 S 32 R urine E. coli 04-59461 K38-17 98 
>32 R >256 R urine E. coli 04-57824 K38-18 99 
32 R >256 R urine E. coli 04-54826 K38-19 100 
0.5 S >256 R urine E. coli 04-49747 K38-20 101 
0.25 S >256 R urine E. coli 04-58203 K38-21 102 
0.25 S >256 R urine E. coli 04-55469 K38-22 103 
>32 R >256 R urine E. coli 04-64075 K38-23 104 
0.064 S 64 R urine E. coli 04-60150 K38-24 105 
0.25 S >256 R urine E. coli 04-55841 K38-25 106 
>32 R >256 R urine E. coli 04-52374 K38-26 107 
0.125 S 128 R urine E. coli 04-48326 K38-27 108 
8 R >256 R urine E. coli 04-43365 K38-28 109 
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Table 3. Bacterial isolates of the Kronoberg collection, cont.  
CIP profile* NAL profile* Material Species Lab. nr Ref. nr Nr. 
16 R >256 R urine E. coli 04-64316 K38-29 110 
0.25 S >256 R urine E. coli 04-60831 K38-30 111 
16 R >256 R urine E. coli 04-63670 K38-31 112 
4 R >256 R urine E. coli 04-60057 K38-32 113 
0.25 S >256 R urine E. coli 04-57923 K38-33 114 
32 R >256 R urine E. coli 04-33757 K38-34 115 
0.125 S 64 R urine E. coli 04-40345 K38-35 116 
>32 R >256 R urine E. coli 04-37016 K38-36 117 
0.25 S >256 R urine E. coli 04-33847 K38-37 118 
>32 R >256 R urine E. coli 04-61795 K38-38 119 
>32 R >256 R urine E. coli 04-70413 K38-39 120 
32 R 256 R urine E. coli 04-78983 K38-40 121 
0.25 S >256 R urine E. coli 05-36 K38-41 122 
0.5 S >256 R urine E. coli 05-6086 K38-42 123 
0.125 S 64 R urine E. coli 04-69673 K38-43 124 
32 R >256 R urine E. coli 05-5696 K38-44 125 
0.25 S >256 R urine E. coli 04-73270 K38-45 126 
>32 R >256 R urine E. coli 04-73216 K38-46 127 
0.25 S >256 R urine E. coli 04-72705 K38-47 128 
0.064 S 64 R urine E. coli 04-72655 K38-48 129 
>32 R >256 R urine E. coli 04-78775 K38-49 130 
32 R >256 R urine E. coli 05-4059 K38-50 131 
>32 R >256 R urine E. coli 05-3524 K38-51 132 
0.25 S >256 R urine E. coli 05-2833 K38-52 133 
0.25 S 256 R urine E. coli 05-2523 K38-53 134 
4 R >256 R urine E. coli 05-1794 K38-54 135 
>32 R >256 R urine E. coli 05-1349 K38-55 136 
8 R >256 R urine E. coli 04-66886 K38-56 137 
0.25 S >256 R urine E. coli 04-66705 K38-57 138 
>32 R >256 R urine E. coli 04-72651 K38-58 139 
>32 R >256 R urine E. coli 04-66700 K38-59 140 
>32 R >256 R urine E. coli 04-66594 K38-60 141 
0.25 S 64 R urine E. coli 04-77012 K38-61 142 
>32 R >256 R urine E. coli 04-76966 K38-62 143 
>32 R >256 R urine E. coli 04-65934 K38-63 144 
>32 R >256 R urine E. coli 04-72378 K38-64 145 
0.064 S 128 R urine E. coli 04-72375 K38-65 146 
0.25  S 256 R urine E. coli 04-71288 K38-66 147 
32 R >256 R urine E. coli 04-71062 K38-67 148 
0.25 S >256 R urine E. coli 04-71060 K38-68 149 
4 R >256 R urine E. coli 04-70948 K38-69 150 
16 R >256 R urine E. coli 05-4670 K38-70 151 
0.125 S >256 R urine E. coli 05-4490 K38-71 152 











Table 4. Bacterial isolates of the NORM collection.  
Nr. Ref  nr. Species Sample Location NAL profile* CIP profile** 
1 K40-06 E. coli Blood Bodø 6 R 32 R 
2 K40-07 K. pneumoniae Blood Bodø 6 R 0,5 S 
3 K40-08 K. pneumoniae Blood Bodø 11 R 0,25 S 
4 K40-09 K. pneumoniae Blood Bodø 16 R 0,125 S 
5 K40-45 E. coli Blood Levanger 6 R 32 R 
6 K40-46 E. coli Blood Levanger 9 R 0,064 S 
7 K40-47 Klebsiella spp. Blood Levanger 10 R 0,125 S 
8 K40-48 K. pneumoniae Blood Levanger 19 R 0,125 S 
9 K40-49 K. pneumoniae Blood Levanger 6 R 0,25 S 
10 K40-50 K. pneumoniae Blood Levanger 6 R 0,5 S 
11 K39-21 E. coli Blood Molde 6 R 32 R 
12 K39-22 E. coli Blood Molde 6 R 0,008 S 
13 K39-23 E. coli Blood Molde 6 R 2 R 
14 K39-24 E. coli Blood Molde 6 R 0,25 S 
15 K39-25 E. coli Blood Molde 6 R 0,064 S 
16 K39-26 K. pneumoniae Blood Molde 6 R 2 R 
17 K39-27 Klebsiella spp. Blood Molde 6 R 0,125 S 
18 K39-28 K. pneumoniae Blood Molde 6 R 0,5 S 
19 K39-29 K. pneumoniae Blood Molde 16 R 0,064 S 
20 K40-10 E. coli Blood Ålesund 6 R 4 R 
21 K40-11 E. coli Blood Ålesund 6 R 4 R 
22 K40-12 E. coli Blood Ålesund 6 R 0,125 S 
23 K40-13 E. coli Blood Ålesund 6 R 32 R 
24 K40-14 E. coli Blood Ålesund 6 R 32 R 
25 K40-15 E. coli Blood Ålesund 6 R 0,25 S 
26 K40-16 E. coli Blood Ålesund 19 R 0,016 S 
27 K40-17 E. coli Blood Ålesund 6 R 32 R 
28 K40-18 K. pneumoniae Blood Ålesund 19 R 0,032 S 
29 K40-70 E. coli Blood Førde 6 R 32 R 
30 K40-71 E. coli Blood Førde 6 R 0,25 S 
31 K40-72 E. coli Blood Førde 6 R 32 R 
32 K40-73 Klebsiella spp. Blood Førde 6 R 1 R 
33 K40-74 K. pneumoniae Blood Førde 16 R 0,125 S 
34 K40-19 E. coli Blood Haugesund 6 R 0,25 S 
35 K40-20 E. coli Blood Haugesund 6 R 0,25 S 
36 K40-21 E. coli Blood Haugesund 7 R 0,125 S 
37 K40-22 E. coli Blood Haugesund 7 R 0,25 S 
38 K40-23 E. coli Blood Haugesund 6 R 32 R 
39 K40-24 E. coli Blood Haugesund 6 R 0,5 S 
40 K40-25 K. pneumoniae Blood Haugesund 26 S 0,125 S 
41 K40-26 K. pneumoniae Blood Haugesund 20 S 0,25 S 
42 K40-27 E. coli Blood Stavanger 6 R 0,25 S 
43 K40-28 E. coli Blood Stavanger 6 R 32 R 
44 K40-29 E. coli Blood Stavanger 8 R 0,125 S 
45 K40-30 E. coli Blood Stavanger 6 R 32 R 
46 K40-31 E. coli Blood Stavanger 6 R 0,125 S 
47 K39-53 E. coli Blood Kristiansand 6 R 32 R 
48 K39-54 E. coli Blood Kristiansand 6 R 1 R 
49 K39-55 E. coli Blood Kristiansand 8 R 0,125 S 
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Table 4. Bacterial isolates of the NORM collection, cont.  
Nr. Ref  nr. Species Sample Location NAL profile* CIP profile** 
50 K39-56 E. coli Blood Kristiansand 12 R 0,25 S 
51 K39-57 E. coli Blood Kristiansand 6 R 32 R 
52 K39-58 E. coli Blood Kristiansand 6 R 0,25 S 
53 K39-59 Klebsiella spp. Blood Kristiansand 9 R 0,25 S 
54 K39-60 K. pneumoniae Blood Kristiansand 21 S 0,125 S 
55 K39-61 K. pneumoniae Blood Kristiansand 11 R 0,25 S 
56 K39-12 E. coli Blood Telelab 6 R 0,25 S 
57 K39-15 E. coli Blood Telelab 6 R 1 R 
58 K39-16 E. coli Blood Telelab 6 R 0,25 S 
59 K39-17 E. coli Blood Telelab 6 R 0,25 S 
60 K39-18 E. coli Blood Telelab 6 R 32 R 
61 K39-19 E. coli Blood Telelab 6 R 0,5 S 
62 K40-32 E. coli Blood Tønsberg 6 R 32 R 
63 K40-33 E. coli Blood Tønsberg 6 R 32 R 
64 K40-34 E. coli Blood Tønsberg 6 R 32 R 
65 K40-35 E. coli Blood Tønsberg 10 R 0,25 S 
66 K40-36 K. pneumoniae Blood Tønsberg 15 R 0,125 S 
67 K40-37 E. coli Blood Drammen 6 R 32 R 
68 K40-38 E. coli Blood Drammen 6 R 32 R 
69 K40-39 E. coli Blood Drammen 6 R 0,25 S 
70 K40-40 E. coli Blood Drammen 6 R 16 R 
71 K40-41 K. pneumoniae Blood Drammen 15 R 0,25 S 
72 K40-42 K. oxytoca Blood Drammen 19 R 0,064 S 
73 K40-43 K. pneumoniae Blood Drammen 14 R 0,125 S 
74 K40-44 K. pneumoniae Blood Drammen 7 R 0,5 S 
75 K39-03 E. coli Blood AHUS 7 R 0,125 S 
76 K39-04 E. coli Blood AHUS 6 R 0,5 S 
77 K39-05 E. coli Blood AHUS 6 R 32 R 
78 K39-06 E. coli Blood AHUS 6 R 0,5 S 
79 K39-08 K. pneumoniae Blood AHUS 14 R 0,25 S 
80 K39-09 K. pneumoniae Blood AHUS 18 R 0,125 S 
81 K39-10 K. pneumoniae Blood AHUS 14 R 0,25 S 
82 K39-11 K. pneumoniae Blood AHUS 20 S 0,125 S 
83 K39-73 E. coli Blood Haukeland 6 R 32 R 
84 K39-74 E. coli Blood Haukeland 6 R 1 R 
85 K39-75 E. coli Blood Haukeland 6 R 32 R 
86 K39-76 E. coli Blood Haukeland 15 R 0,064 S 
87 K39-77 E. coli Blood Haukeland 6 R 32 R 
88 K39-78 E. coli Blood Haukeland 6 R 32 R 
89 K39-79 E. coli Blood Haukeland 6 R 4 R 
90 K39-80 E. coli Blood Haukeland 6 R 32 R 
91 K39-81 K. pneumoniae Blood Haukeland 6 R 4 R 
92 K40-02 K. pneumoniae Blood Haukeland 18 R 0,25 S 
93 K40-03 K. pneumoniae Blood Haukeland 6 R 0,5 S 
94 K40-04 K. pneumoniae Blood Haukeland 22 S 0,125 S 
95 K40-05 E. coli Blood Haukeland 6 R 8 R 
96 K40-52 E. coli Blood Trondheim 6 R 0,25 S 
97 K40-53 E. coli Blood Trondheim 6 R 0,25 S 
98 K40-54 E. coli Blood Trondheim 6 R 32 R 
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Table 4. Bacterial isolates of the NORM collection, cont.  
Nr. Ref  nr. Species Sample Location NAL profile* CIP profile** 
99 K40-56 K. pneumoniae Blood Trondheim 10 R 1 R 
100 K40-58 K. oxytoca Blood Trondheim 13 R 0,125 S 
101 K40-59 K. pneumoniae Blood Trondheim 13 R 0,125 S 
102 K40-60 K. pneumoniae Blood Trondheim 11 R 0,25 S 
103 K40-61 K. oxytoca Blood Trondheim 6 R 0,25 S 
104 K40-62 K. pneumoniae Blood Tromsø 20 S 0,25 S 
105 K40-63 K. pneumoniae Blood Tromsø 9 R 0,25 S 
106 K40-64 E. coli Blood Tromsø 6 R 4 R 
107 K40-68 E. coli Blood Tromsø 6 R 0,25 S 
108 K40-69 E. coli Blood Tromsø 6 R 0,25 S 
109 K39-31 K. pneumoniae Blood Rikshospitalet 22 S 0,5 S 
110 K39-32 E. coli Blood Rikshospitalet 6 R 8 R 
111 K39-33 E. coli Blood Rikshospitalet 21 S 0,125 S 
112 K39-34 E. coli Blood Rikshospitalet 19 R 0,016 S 
113 K39-35 E. coli Blood Rikshospitalet 18 R 0,016 S 
114 K39-36 E. coli Blood Rikshospitalet 19 R 0,008 S 
115 K39-37 E. coli Blood Rikshospitalet 6 R 32 R 
116 K39-50 E. coli Blood Lillehammer 6 R 0,25 S 
117 K39-51 E. coli Blood Lillehammer 15 R 1 R 
118 K39-52 E. coli Blood Lillehammer 6 R 0,25 S 
119 K39-30 K. pneumoniae Blood Bærum 16 R 0,125 S 
120 K39-62 E. coli Blood Fredrikstad 6 R 32 R 
121 K39-63 E. coli Blood Fredrikstad 6 R 0,125 S 
122 K39-64 E. coli Blood Fredrikstad 6 R 32 R 
123 K39-65 E. coli Blood Fredrikstad 6 R 32 R 
124 K39-66 E. coli Blood Fredrikstad 6 R 32 R 
125 K39-67 E. coli Blood Fredrikstad 19 R 0,125 S 
126 K39-68 E. coli Blood Fredrikstad 6 R 0,125 S 
127 K39-69 K. pneumoniae Blood Fredrikstad 15 R 0,25 S 
128 K39-70 K. pneumoniae Blood Fredrikstad 19 R 0,25 S 
129 K40-75 E. coli Blood Aker 6 R 32 R 
130 K40-76 E. coli Blood Aker 6 R 32 R 
131 K40-77 E. coli Blood Aker 6 R 0,125 S 
132 K40-78 E. coli Blood Aker 6 R 4 R 
133 K40-79 E. coli Blood Aker 6 R 32 R 
134 K40-80 Klebsiella spp. Blood Aker 6 R 0,5 S 
135 K40-81 Klebsiella spp. Blood Aker 9 R 0,5 S 
136 K43-05 Klebsiella spp. Blood Aker 6 R 1 R 
137 K43-06 Klebsiella spp. Blood Aker 6 R 0,25 S 
138 K39-38 K. pneumoniae Blood Ullevål 6 R 32 R 
139 K39-39 Klebsiella spp. Blood Ullevål 8 R 0,5 S 
140 K39-40 K. pneumoniae Blood Ullevål 9 R 0,5 S 
141 K39-41 K. pneumoniae Blood Ullevål 16 R 0,125 S 
142 K39-42 K. pneumoniae Blood Ullevål 15 R 0,25 S 
143 K39-43 E. coli Blood Ullevål 6 R 16 R 
144 K39-44 E. coli Blood Ullevål 8 R 0,064 S 
145 K39-45 E. coli Blood Ullevål 11 R 0,25 S 
146 K39-46 E. coli Blood Ullevål 9 R 0,125 S 
147 K39-47 E. coli Blood Ullevål 6 R 32 R 
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Table 4. Bacterial isolates of the NORM collection, cont.  
Nr. Ref  nr. Species Sample Location NAL profile* CIP profile** 
148 K39-48 E. coli Blood Ullevål 6 R 32 R 
149 K39-49 E. coli Blood Ullevål 12 R 0,064 S 
Nr. Ref  nr. Species Sample Location NAL profile* CIP profile* 
150 K42-48 E. coli Urine 2005 Bodø 6 R 8 R 
151 K42-49 E. coli Urine 2005 Bodø 6 R 13 R 
152 K42-17 E. coli Urine 2005 Molde 6 R 29 S 
153 K42-16 E. coli Urine 2005 Molde 6 R 6 R 
154 K42-15 E. coli Urine 2005 Molde 19 R 29 S 
155 K42-14 E. coli Urine 2005 Molde 6 R 6 R 
156 K42-50 E. coli Urine 2005 Ålesund 6 R 18 R 
157 K42-51 E. coli Urine 2005 Ålesund 6 R 29 S 
158 K42-52 E. coli Urine 2005 Ålesund 6 R 31 S 
159 K42-80 E. coli Urine 2005 Førde 6 R 6 R 
160 K42-81 E. coli Urine 2005 Førde 6 R 12 R 
161 K42-53 E. coli Urine 2005 Haugesund 6 R 10 R 
162 K42-54 E. coli Urine 2005 Haugesund 6 R 29 S 
163 K42-55 E. coli Urine 2005 Stavanger 6 R 6 R 
164 K42-56 E. coli Urine 2005 Stavanger 6 R 6 R 
165 K42-57 E. coli Urine 2005 Stavanger 6 R 28 S 
166 K42-38 E. coli Urine 2005 Kristiansand 6 R 29 S 
167 K42-39 E. coli Urine 2005 Kristiansand 6 R 27 S 
168 K42-11 E. coli Urine 2005 Telelab 32 S 10 R 
169 K42-58 E. coli Urine 2005 Tønsberg 6 R 29 S 
170 K42-59 E. coli Urine 2005 Drammen 28 S 17 R 
171 K42-60 E. coli Urine 2005 Drammen 7 R 8 R 
172 K42-61 E. coli Urine 2005 Drammen 7 R 10 R 
173 K42-62 E. coli Urine 2005 Drammen 19 R 30 S 
174 K42-63 E. coli Urine 2005 Drammen 8 R 29 S 
175 K42-64 E. coli Urine 2005 Drammen 7 R 7 R 
176 K42-65 E. coli Urine 2005 Drammen 7 R 7 R 
177 K42-36 E. coli Urine 2005 Radiumhospitalet 6 R 6 R 
178 K42-37 E. coli Urine 2005 Radiumhospitalet 6 R 6 R 
179 K42-01 E. coli Urine 2005 AHUS 6 R 28 S 
180 K42-02 E. coli Urine 2005 AHUS 6 R 6 R 
181 K42-03 E. coli Urine 2005 AHUS 6 R 11 R 
182 K42-06 E. coli Urine 2005 AHUS 10 R 30 S 
183 K42-07 E. coli Urine 2005 AHUS 6 R 6 R 
184 K42-09 E. coli Urine 2005 AHUS 6 R 6 R 
185 K42-41 E. coli Urine 2005 Haukeland 6 R 36 S 
186 K42-42 E. coli Urine 2005 Haukeland 6 R 10 R 
187 K42-45 E. coli Urine 2005 Haukeland 6 R 25 S 
188 K42-46 E. coli Urine 2005 Haukeland 6 R 6 R 
189 K42-66 E. coli Urine 2005 Trondheim 6 R 8 R 
190 K42-67 E. coli Urine 2005 Trondheim 6 R 8 R 
191 K42-70 E. coli Urine 2005 Trondheim 6 R 32 S 
192 K42-72 E. coli Urine 2005 Trondheim 6 R 29 S 
193 K42-73 E. coli Urine 2005 Tromsø 6 R 8 R 
194 K42-74 E. coli Urine 2005 Tromsø 12 R 30 S 
195 K42-75 E. coli Urine 2005 Tromsø 10 R 30 S 
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Table 4. Bacterial isolates of the NORM collection, cont.  
Nr. Ref  nr. Species Sample Location NAL profile* CIP profile* 
196 K42-79 E. coli Urine 2005 Tromsø 6 R 26 S 
197 K42-22 E. coli Urine 2005 Rikshospitalet 6 R 25 S 
198 K42-23 E. coli Urine 2005 Rikshospitalet 6 R 6 R 
199 K42-24 K. oxytoca Urine 2005 Rikshospitalet 6 R 22 S 
200 K42-25 E. coli Urine 2005 Rikshospitalet 6 R 21 S 
201 K42-26 E. coli Urine 2005 Rikshospitalet 17 R 28 S 
202 K42-27 E. coli Urine 2005 Rikshospitalet 6 R 24 S 
203 K42-28 E. coli Urine 2005 Rikshospitalet 6 R 25 S 
204 K42-29 E. coli Urine 2005 Rikshospitalet 6 R 6 R 
205 K42-30 E. coli Urine 2005 Rikshospitalet 6 R 9 R 
206 K42-31 E. coli Urine 2005 Rikshospitalet 6 R 23 S 
207 K42-18 E. coli Urine 2005 Bærum 6 R 27 S 
208 K42-19 E. coli Urine 2005 Bærum 6 R 6 R 
209 K42-20 E. coli Urine 2005 Bærum 6 R 7 R 
210 K42-21 E. coli Urine 2005 Bærum 6 R 30 S 
211 K42-40 E. coli Urine 2005 Fredrikstad 6 R 28 S 
212 K43-01 E. coli Urine 2005 Aker 27 S 21 S 
213 K43-02 E. coli Urine 2005 Aker 6 R 14 R 
214 K43-03 E. coli Urine 2005 Aker 6 R 22 S 
215 K43-04 E. coli Urine 2005 Aker 6 R 6 R 
216 K42-33 E. coli Urine 2005 Ullevål 6 R 6 R 
217 K42-34 E. coli Urine 2005 Ullevål 6 R 12 R 
218 K42-35 E. coli Urine 2005 Ullevål 6 R 6 R 
* Zones of inhibition (mm) determined by agar diffusion; R, resistant; I, intermediate; and S, 




Table 5. Bacterial isolates of the E. coli AmpC collection. 






1 K2-67 E. coli Urine > 32 R ≥ 4 R Plasmid-mediated 
2 K2-68 E. coli Nose ≥ 32 R ≥ 4 R Chromosomal upregulation mutation 
3 K4-37 E. coli Blood ≥ 32 R ≥ 4 R Chromosomal upregulation mutation 
4 K5-20 E. coli Urine ≥ 32 R ≥ 4 R 
Both plasmid-mediated and 
chromosomal upregulation mutation 
5 K5-41 E. coli Urine ≥ 32 R ≤ 0.25 S Plasmid-mediated 
6 K5-63 E. coli Urine ≥ 32 R ≥ 4 R Plasmid-mediated 
7 K15-8 E. coli Blood ≥ 32 R 1 I ND 
8 K22-31 E. coli Urine ≥ 32 R 0.5 S Chromosomal upregulation mutation 
9 K22-51 E. coli Urine ≥ 32 R 2 R ND 
10 K25-65 E. coli Blood ≥ 32 R ≥ 4 R Chromosomal upregulation mutation 
11 K26-7  E. coli Urine ≥ 32 R 1 I Plasmid-mediated 
12 K26-21  E. coli Urine ≥ 32 R ≥ 4 R Plasmid-mediated 
13 K26-35 E. coli Urine ≥ 32 R 0.5 S Plasmid-mediated 







Table 6. Bacterial isolates of Ullevål ESBL study. 
Nr. Ref.nr Ref.nr UUS Species NAL profile* CIP profile* ESBL profile 
1 K2-70 B 1364 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
2 K4-69 B 1418 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
3 K4-79 B 1436 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
4 K5-9 B 1468 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
5 K5-11 B 1472 st 1 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
6 K5-12 B 1473 st 2 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
7 K5-43 B 1502 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
8 K5-65 B 1509 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
9 K15-28 B 790 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
10 K15-29 12774 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
11 K15-30 13094 E. coli ≥ 32 R ≥ 4 R SHV ESBL 
12 K15-31 B 1046 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
13 K15-33 B 1079 E. coli ≥ 32 R ≥ 4 R SHV ESBL 
14 K15-35 12120 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
15 K15-36 B 547 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
16 K15-37 B 548 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
17 K15-38 B 549 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
18 K15-39 12515 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
19 K15-41 B 1130 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
20 K15-42 B 1131 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
21 K15-43 B 1141 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
22 K15-44 B 988 E. coli ≥ 32 R 1 I CTX-M ESBL 
23 K15-45 13231 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
24 K15-46 13441 E. coli ≥ 32 R 1 I CTX-M ESBL 
25 K15-47 B 1004 E. coli ≥ 32 R 1 I CTX-M ESBL 
26 K15-48 13527 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
27 K15-49 B 265 E. coli ≥ 32 R 1 I CTX-M ESBL 
28 K15-50 B 306 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
29 K15-52 B 459 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
30 K15-76 B 1781 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
31 K15-77 B 1782 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
32 K18-2 B 1871 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
33 K18-3 B 1641 E. coli ≥ 32 R 0.5 S CTX-M ESBL 
34 K18-4 B 1721 E. coli ≥ 32 R 0.5 S CTX-M ESBL 
35 K18-5 B 1722 E. coli ≥ 32 R 1 I CTX-M ESBL 
36 K18-7 B 1761 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
37 K18-8 14901 E. coli ≥ 32 R 1 I CTX-M ESBL 
38 K18-9 B 1724 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
39 K18-10 B 1723 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
40 K18-11 B 1845 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
41 K18-12 B 1844 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
42 K18-13 B 1830 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
43 K18-14 B 1935 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
44 K18-15 B 2162 E. coli ≥ 32 R ≥ 4 R TEM ESBL 
45 K18-16 B 1194 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
46 K18-17 B 1225 K. pneumoniae ≥ 32 R 1 I SHV ESBL 
47 K18-19 B 1253 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
48 K18-22 B 2132 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
49 K18-24 B 1911 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
50 K18-26 B 1868 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
51 K18-27 B 1866 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
52 K18-28 B 1590 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
53 K18-29 B 1589 E. coli ≥ 32 R 1 I CTX-M ESBL 
54 K18-30 B 1591 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
55 K18-31 B 1604 E. coli ≥ 32 R 1 I SHV ESBL 
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Table 6. Bacterial isolates of Ullevål ESBL study, cont. 
Nr. Ref.nr Ref.nr UUS Species NAL profile* CIP profile* ESBL profile 
56 K18-32 B 1962 E. coli ≥ 32 R 0.5 S SHV ESBL 
57 K18-33 B 1952 E. coli ≥ 32 R 2 R CTX-M ESBL 
58 K18-34 B 1981 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 
59 K18-35 B 1988 E. coli ≥ 32 R 1 I CTX-M ESBL 
60 K4-60 B 1413 st 3 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL 




Table 7. Bacterial isolates of the Norwegian ESBL study.  
 Nr. Ref. nr Species NAL profile* CIP profile* ESBL  profile 
1 K2-57 K. oxytoca 4 S ≥ 64 R Not ESBL 
2 K4-13 K. pneumoniae 8 S 2 R ESBL+ 
3 K2-78 K. pneumoniae 16 S 1 I ESBL+ 
4 K4-51 E. coli ≥32 R ≤ 0.25 S ESBL+ 
5 K4-46 E. coli ≥32 R 1 I ESBL+ 
6 K5-16 E. coli ≥32 R 1 I ESBL+ 
7 K5-64 E. coli ≥32 R 1 I ESBL+ 
8 K4-39 E. coli ≥32 R 2 R ESBL+ 
9 K2-35 E. coli ≥32 R ≥4 R Not ESBL 
10 K2-63 E. coli ≥32 R ≥4 R ESBL+ 
11 K2-64 E. coli ≥32 R ≥4 R ESBL+ 
12 K4-40 E. coli ≥32 R ≥4 R ESBL+ 
13 K4-43 E. coli ≥32 R ≥4 R ESBL+ 
14 K4-45 E. coli ≥32 R ≥4 R ESBL+ 
15 K4-76 E. coli ≥32 R ≥4 R ESBL+ 
16 K4-81 E. coli ≥32 R ≥4 R ESBL+ 
17 K5-8 E. coli ≥32 R ≥4 R ESBL+ 
18 K5-13 E. coli ≥32 R ≥4 R Not ESBL 
19 K5-15 E. coli ≥ 32 R ≥4 R Not ESBL 
20 K5-21 E. coli ≥ 32 R ≥4 R Not ESBL 
21 K5-23 E. coli ≥ 32 R ≥4 R ESBL+ 
22 K5-34 E. coli ≥ 32 R ≥4 R ESBL+ 
23 K5-51 E. coli ≥ 32 R ≥4 R ESBL+ 
24 K5-56 E. coli ≥ 32 R ≥4 R ESBL+ 
25 K5-58 E. coli ≥ 32 R ≥4 R ESBL+ 
26 K5-59 E. coli ≥ 32 R ≥4 R ESBL+ 
27 K5-62 E. coli ≥ 32 R ≥4 R ESBL+ 
28 K5-72 E. coli ≥ 32 R ≥4 R Not ESBL 
29 K5-76 E. coli ≥ 32 R ≥4 R ESBL+ 
30 K5-78 E. coli ≥ 32 R ≥4 R Not ESBL 
31 K8-1 E. coli ≥ 32 R ≥4 R ESBL+ 
32 K8-4 E. coli ≥ 32 R ≥4 R ESBL+ 
33 K8-8 E. coli ≥ 32 R ≥4 R ESBL+ 
34 K4-19 K. pneumoniae ≥ 32 R ≤0.25 S Not ESBL 
35 K5-45 K. pneumoniae ≥ 32 R ≤0.25 S Not ESBL 
36 K5-32 K. pneumoniae ≥ 32 R 0.5 S Not ESBL 
37 K5-6 K. pneumoniae ≥ 32 R 1 I ESBL+ 
38 K4-49 K. pneumoniae ≥ 32 R 2 R ESBL+ 
39 K4-61 K. pneumoniae ≥ 32 R ≥4 R ESBL+ 
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Table 7. Bacterial isolates of the Norwegian ESBL study, cont.  
 Nr. Ref. nr Species NAL profile* CIP profile* ESBL  profile 
40 K4-77 K. pneumoniae ≥ 32 R ≥4 R ESBL+ 
41 K2-55 E. coli ≥ 32 R ≥4 R ESBL+ 
42 K4-31 E. coli ≥ 32 R ≥4 R ESBL+ 
43 K5-60 E. coli ≥ 32 R ≥4 R ESBL+ 
44 K8-5 K. pneumoniae ≥ 32 R ≥4 R ESBL+ 
* MICs (µg/ml) were determined by E-test; R, resistant; I, intermediate; and S, susceptible 
 
 
Table 8. Primers used in this study. 







Park et al. 2006 
 
aac(6’)-Ib-SEQ cgtcactccatacattgcaa aac(6’)-Ib 482 Park et al. 2006 
qnrA-F.multiplex  atttctcacgccaggatttg  
qnrA-R.multiplex  gatcggcaaaggttaggtca 
qnrA 516 Robicsek et al. 2006 
qnrB-F.multiplex  gatcgtgaaagccagaaagg  
qnrB-R.multiplex  acgatgcctggtagttgtcc 
qnrB 469 Robicsek et al. 2006 
qnrS-F.multiplex  acgacattcgtcaactgcaa  
qnrS-R.multiplex  taaattggcaccctgtaggc 
qnrS 417 Robicsek et al. 2006 
gyrA6 cgaccttgcgagagaaat 
gyrA631R gttccatcagcccttcaa 
QRDR of gyrA 620 Weigel et al. 1998 
parCF tgaatttagggaaaacgccta 
parCR gccacttcacgcaggttatg 
QRDR of parC 559 Qiang et al, 2002 
HI1 FW ggagcgatggattacttcagtac 
HI1 RV tgccgtttcacctcgtgagta 
parA-parB 471 Carattoli et al. 2005 
HI2 FW tttctcctgagtcacctgttaacac 
HI2 RV ggctcactaccgttgtcatcct 
iterons 644 Carattoli et al. 2005 
I1 FW cgaaagccggacggcagaa 
I1 RV tcgtcgttccgccaagttcgt 
RNAI 139 Carattoli et al. 2005 
X FW aaccttagaggctatttaagttgctgat 
X RV tgagagtcaatttttatctcatgttttagc 
orig 376 Carattoli et al. 2005 
L/M FW ggatgaaaactatcagcatctgaag 
L/M RV ctgcaggggcgattctttagg 
repA,B,C 785 Carattoli et al. 2005 
N FW gtctaacgagcttaccgaag 
N RV gtttcaactctgccaagttc 
repA 559 Carattoli et al. 2005 
FIA FW ccatgctggttctagagaaggtg 
FIA RV gtatatccttactggcttccgcag 
iterons 462 Carattoli et al. 2005 
FIB FW ggagttctgacacacgattttctg 
FIB RV ctcccgtcgcttcagggcatt 
repA 702 Carattoli et al. 2005 
W FW cctaagaacaacaaagcccccg 
W RV ggtgcgcggcatagaaccgt 
repA 242 Carattoli et al. 2005 
Y FW aattcaaacaacactgtgcagcctg 
Y RV gcgagaatggacgattacaaaacttt 
repA 765 Carattoli et al. 2005 
P FW ctatggccctgcaaacgcgccagaaa 
P RV tcacgcgccagggcgcagcc 
iterons 534 Carattoli et al. 2005 
FIC FW gtgaactggcagatgaggaagg 
FIC RV ttctcctcgtcgccaaactagat 
repA2 262 Carattoli et al. 2005 
A/C FW gagaaccaaagacaaagacctgga 
A/C RV acgacaaacctgaattgcctcctt 
repA 465 Carattoli et al. 2005 
T FW ttggcctgtttgtgcctaaaccat 
T RV cgttgattacacttagctttggac 
repA 750 Carattoli et al. 2005 
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Table 8. Primers used in this study, cont. 




FIIS FW ctgtcgtaagctgatggc 
FIIS RV ctctgccacaaacttcagc 
repA 270 Carattoli et al. 2005 
FrepB FW tgatcgtttaaggaattttg 
FrepB RV gaagatcagtcacaccatcc 
RNAI/repA 270 Carattoli et al. 2005 
K/B FW gcggtccggaaagccagaaaac 
K RV tctttcacgagcccgccaaa 
RNAI 160 Carattoli et al. 2005 
K/B FW gcggtccggaaagccagaaaac 
B/O RV tctgcgttccgccaagttcga 
RNAI 159 Carattoli et al. 2005 
qnrS-3`ext gaactcgacggtttagatcc 
213B cgatgaatcaggctccagtc 
Upstream qnrS1 2000 Poirel et al. 2007 
qnrS-F.multiplex  acgacattcgtcaactgcaa  
Sea15.Kres atgaggctgaaggtgctcat 
Upstream qnrS1 1800 This study 
qnrS-5`ext gcgaatgaatgtgcaagcgg 
orfB-B cagcagtcctgcgcgaagg 
Downstream qnrS1 1300 Poirel et al. 2007 
qnrS-5`ext gcgaatgaatgtgcaagcgg 
pbp3b cgtcctgaagtggcactgg 
Downstream qnrS1 3000 Poirel et al. 2007 
qnrS-5`ext gcgaatgaatgtgcaagcgg 
LAP-1A caatacaaagcacagaagacc 
Downstream qnrS1 3000 Poirel et al. 2007 
qnrS-R.multiplex  taaattggcaccctgtaggc 
LAP-1.Kres gcggatgatgttcgttgtaa 
Downstream qnrS1 2000 This study 
TEM-R mod TW ccaatgcttaatcagtgagg Downstream qnrS1 This study 
tnpRF2 gcgcatgtcaatcaattcgg Downstream qnrS1 This study 











Elongation Final elongation 
16S rDNA 95ºC / 1 min 30 95ºC / 30 sec 55ºC / 30 sec 72°C / 1 min 
72°C / 7 min 
 (then 4°C → ∞) 
qnr multiplex 95ºC / 5 min 30 95ºC / 15 sec 55ºC / 15 sec 72ºC / 40 sec 
72°C / 4 min 
 (then 4°C → ∞) 
aac(6’)-Ib 95ºC / 5 min 30 95ºC / 15 sec 58ºC / 15 sec 72ºC / 40 sec 
72°C / 4 min  
(then 4°C → ∞) 
QRDR gyrA/parC 94ºC / 5 min 30 94ºC / 15 sec 55ºC / 15 sec 72ºC / 40 sec 
72°C / 4 min  
(then 4°C → ∞) 
All multiplex and simplex 
PCRs for amplicon typing 
except F-simplex PCR 
94ºC / 5 min 30 94ºC / 40 sec 60ºC / 20 sec 72ºC / 30 sec 
72°C / 5 min  
(then 4°C → ∞) 
F-simplex PCR 94ºC / 5 min 30 94ºC / 40 sec 52ºC / 20 sec 72ºC / 30 sec 
72°C / 5 min  
(then 4°C → ∞) 
Targeted PCRs (qnrS1 
genetic  environment)  
94ºC / 5 min 20 94ºC / 20 sec 58ºC / 20 sec 
72ºC / 2 min 
and 30 sec 
72°C / 15 min  
(then 4°C → ∞) 










Table 10. Features of the aac(6`)-Ib-positive isolates.  





ESBL status Aac(6`)-Ib 
1 K37-80 E.coli >256 R >32 R Not determined aac(6`)-Ib-cr 
2 K38-23 E.coli >256 R >32 R Not determined Wild-type 
3 K5-63 E.coli ≥ 32 R ≥ 4 R Not determined aac(6`)-Ib-cr 
4 K2-70 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
5 K5-9 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
6 K5-11 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
7 K5-12 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
8 K5-43 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
9 K5-65 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
10 K15-28 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
11 K15-31 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
12 K15-36 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
13 K15-37 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
14 K15-38 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
15 K15-41 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
16 K15-42 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
17 K15-43 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
18 K15-45 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
19 K15-46 E. coli ≥ 32 R 1 I CTX-M ESBL aac(6`)-Ib-cr 
20 K15-47 E. coli ≥ 32 R 1 I CTX-M ESBL aac(6`)-Ib-cr 
21 K15-48 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
22 K15-50 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
23 K15-52 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
24 K15-76 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
25 K15-77 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
26 K18-2 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
27 K18-7 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
28 K18-9 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
29 K18-11 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
30 K18-12 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
31 K18-13 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
32 K18-14 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
33 K18-16 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
34 K18-17 K. pneumoniae ≥ 32 R 1 I SHV ESBL Wild-type 
35 K18-19 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL both 
36 K18-22 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
37 K18-24 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
38 K18-26 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
39 K18-27 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
40 K18-28 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
41 K18-30 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
42 K18-31 E. coli ≥ 32 R 1 I SHV ESBL Wild-type 
43 K18-34 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
44 K4-60 E. coli ≥ 32 R ≥ 4 R CTX-M ESBL aac(6`)-Ib-cr 
45 K15-32 E. coli ≤ 2 S ≤ 0.25 S TEM ESBL Wild-type 
46 K15-78 E. coli ≤ 2 S ≤ 0.25 S CTX-M ESBL aac(6`)-Ib-cr 
47 K4-13 K. pneumoniae 8 S 2 R CTX-M/SHV ESBL aac(6`)-Ib-cr 
48 K4-39 E. coli ≥32 R 2 R ESBL+ aac(6`)-Ib-cr 
49 K2-35 E. coli ≥32 R ≥4 R Not ESBL aac(6`)-Ib-cr 
50 k2-63 E. coli ≥32 R ≥4 R ESBL+ aac(6`)-Ib-cr 
51 k4-40 E. coli ≥32 R ≥4 R ESBL+ aac(6`)-Ib-cr 
52 k4-43 E. coli ≥32 R ≥4 R ESBL+ both 
53 k4-45 E. coli ≥32 R ≥4 R ESBL+ aac(6`)-Ib-cr 
54 k4-76 E. coli ≥32 R ≥4 R ESBL+ aac(6`)-Ib-cr 
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55 k5-34 E. coli ≥ 32 R ≥4 R ESBL+ aac(6`)-Ib-cr 
56 k5-51 E. coli ≥ 32 R ≥4 R ESBL+ aac(6`)-Ib-cr 
57 k5-56 E. coli ≥ 32 R ≥4 R ESBL+ aac(6`)-Ib-cr 
58 k5-59 E. coli ≥ 32 R ≥4 R ESBL+ aac(6`)-Ib-cr 
59 k5-62 E. coli ≥ 32 R ≥4 R ESBL+ aac(6`)-Ib-cr 
60 k8-1 E. coli ≥ 32 R ≥4 R ESBL+ aac(6`)-Ib-cr 
61 k8-4 E. coli ≥ 32 R ≥4 R ESBL+ aac(6`)-Ib-cr 
62 k5-6 K. pneumoniae ≥ 32 R 1 I ESBL+ Wild-type 
63 k4-49 K. pneumoniae ≥ 32 R 2 R ESBL+ Wild-type 
64 k4-77 K. pneumoniae ≥ 32 R ≥4 R ESBL+ Wild-type 
65 K2-55 E. coli ≥ 32 R ≥4 R ESBL+ aac(6`)-Ib-cr 
66 k8-5 K. pneumoniae ≥ 32 R ≥4 R CTX-M ESBL aac(6`)-Ib-cr 
67 K40-30 E. coli 6 R** 32 R Not determined aac(6`)-Ib-cr 
68 K39-60 K. pneumoniae 21 S** 0,125 S Not determined aac(6`)-Ib-cr 
69 K40-38 E. coli 6 R** 32 R** Not determined aac(6`)-Ib-cr 
70 K39-05 E. coli 6 R** 32 R** Not determined aac(6`)-Ib-cr 
71 K40-79 E. coli 6 R** 32 R** Not determined aac(6`)-Ib-cr 
72 K42-55 E. coli 6 R** 6 R** Not determined aac(6`)-Ib-cr 
73 K42-56 E. coli 6 R** 6 R** Not determined aac(6`)-Ib-cr 
74 K42-65 E. coli 7 R** 7 R** Not determined aac(6`)-Ib-cr 
75 K42-36 E. coli 6 R** 6 R** Not determined aac(6`)-Ib-cr 
76 K42-07 E. coli 6 R** 6 R** Not determined aac(6`)-Ib-cr 
77 K43-04 E. coli 6 R** 6 R** Not determined aac(6`)-Ib-cr 
* MICs (µg/ml) were determined by E-test; R, resistant; I, intermediate; and S, susceptible 
** Zones of inhibition determined by agar diffusion; R, resistant; I, intermediate; and S, susceptible 
 
 




K38-15       K4-13        K4-43       K39-31      K40-47      K40-79       K2-78          K8-5 
NAL 16 S 4 S ≥32 R 4 S ≥32 R ≥32 R 16 S ≥32 R 
CIP 1 S 2 I ≥4 R 1 S ≥4 R ≥4 R 0.5 S ≥4 R 
TOB ≤1 S ≥16 R ≥16 R ≤1 S ≤1 S ≥16 R ≤1 S ≥16 R 
GEN ≤1 S ≥16 R ≥16 R ≤1 S ≤1 S 2 S ≤1 S ≥16 R 
CXM 4 I ≥64 R ≥64 R 2 I 4 I 16 I 16 I ≥64 R 
FOX ≤4 S ≤4 S ≥64 R ≤4 S ≤4 S 8 S ≤4 S ≤4 S 
CTX ≤1 S ≥64 R ≥64 R ≤1 S ≤1 S ≤1 S 4 S ≥64 R 
AMP ≥32 R ≥32 R ≥32 R ≥32 R ≥32 R ≥32 R ≥32 R ≥32 R 
AMC 4 S 16 I ≥32 R ≤2 S ≤2 S 16 I 8 S 16 I 
TZP ≤4 S 8 S ≥128 R ≤4 S ≤4 S 8 S ≤4 S 8 S 
CAZ ≤1 S 16 I ≥64 R ≤1 S ≤1 S ≤1 S ≥64 R 32 R 
CPO ≤1 S 16 I ≥64 R ≤1 S ≤1 S ≤1 S ≤1 S 16 I 
CPD ≤0.25 S ≥8 R ≥8 R ≤0.25 S ≤0.25 S 1 S ≥8 R ≥8 R 
NIT ≤16 S 64 I 64  I 64  I ≥512 R ≤16 S 64 I 256 R 
ATM ≤1 S ≥64 R ≥64 R ≤1 S ≤1 S ≤1 S ≥64 R ≥64 R 
CEP 16 I ≥64 R ≥64 R ≤2 S 4 S 16 I ≥64 R ≥64 R 
CXA 4 S ≥64 R ≥64 R 2 S 4 S 16 I 16 I ≥64 R 
MEM ≤0.25 S ≤0.25 S ≤0.25 S ≤0.25 S ≤0.25 S ≤0.25 S ≤0.25 S ≤0.25 S 
TMP ≤0.5 S ≥16 R ≥16 R ≥16 R 1 S ≥16 R ≤0.5 S ≥16 R 
SXT ≤20 S ≥320 R ≥320 R ≥320 R ≤20 S ≥320 R ≤20 S ≥320 R 
* NAL, nalidixic acid; CIP, ciprofloxacin; AMP, ampicillin; AMC, amoxicillin-clavulanic acid; TZP, 
piperacillin-tazobactam; CAZ, ceftazidime; FOX, cefoxitin; CTX, cefotaxime; CPO, cefpirome; CPD, 
cefpodoxime; CEP, cephalothin; CXM, cefuroxime; CXA, cefuroxime axetil; ATM, aztreonam; MEM, 
meropenem; nitrofurantoin; GEN, gentamicin; TOB, tobramycin; and SXT, trimethoprim-
sulfamethoxazole.    ** S, susceptible; I, intermediate; and R, resistant.  
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Table 12. Inhibition zone diameters obtained with nalidixic acid 30 µg and 
ciprofloxacin 10 µg discs for the qnr-positive clinical isolates  
 
Clinical isolate 
Zone diameter (mm)** 
                         NAL30*                                                  CIP10* 
K38-15 18 I 28 S 
K4-13 24 S 23 S 
K2-78 18 I 29 S 
K4-43 6R 6R 
K8-5 6R 6R 
K39-31 24 S 28 S 
K40-47 8 R 16 R 
K40-79 6R 6R 
* NAL30, 30µg nalidixic acid disk; CIP10, 10µg ciprofloxacin disk.  
** S, susceptible; I, intermediate; and R, resistant.  
 
 
Table 13. Transconjugation frequencies 
Donor clinical isolate 
Transconjugation frequency* 
        Transconjugant per donor                     Transconjugant per recipient 
K38-15 (E. coli) 1.1 x 10-4 0.8 x 10-4 
K4-13 (K. pneumoniae) 5.8 x 10-4 2.9 x 10-4 
K40-79 (E. coli) 1 x 10-4 1 x 10-4 
* transconjugation frequencies were calculated by dividing the number of transconjugants by the 
number of donors or by the number of reciepients.  
 
 
Table 14. Results of the susceptibility testing by VITEK 2 for the recipient E. coli 




  TC38-15       TC4-13         TF4-43       TC40-79      TF2-78 
NAL nalidixic acid 16 S 8 S 8 S 16 S 4 S 
CIP ciprofloxacin 1 S 2 I ≤0.25 S 1 S ≤0.25 S 
TOB tobramycin ≤1 S 8 I ≤1 S ≤1 S ≤1 S 
GEN gentamicin ≤1 S ≤1 S ≤1 S ≤1 S ≤1 S 
CXM cefuroxime 32 R 32 R 8 I 16 I 32 R 
FOX cefoxitin ≥64 R 16 I 8 S 32 R 8 S 
CTX cefotaxime ≤1 S ≤1 S ≤1 S ≤1 S 2 S 
AMP ampicillin ≥32 R ≥32 R ≥32 R ≥32 R ≥32 R 
AMC amoxicillin/clavulanic acid 16 I ≥32 R 8 S 16 I 4 S 
TZP piperacillin/tazobactam ≤4 S 8 S ≤4 S ≤4 S ≤4 S 
CAZ ceftazidime ≤1 S ≤1 S ≤1 S ≤1 S ≥64 R 
CPO cefpirome  ≤1 S ≤1 S ≤1 S ≤1 S ≤1 S 
CPD cefpodoxime 2 S 2 S 1 S 1 S ≥8 R 
NIT nitrofurantoin 32 S ≤16 S ≤16 S 32 S ≤16 S 
ATM aztreonam ≤1 S ≤1 S ≤1 S ≤1 S ≥64 R 
CEP cefalotin ≥64 R 16 I 16 I ≥64 R ≥64 R 
CXA cefuroxime axetil 32 R 32 R 8 I 16 I 32 R 
MEM meropenem ≤0.25 S ≤0.25 S ≤0.25 S ≤0.25 S ≤0.25 S 
TMP trimethoprim ≤0.5 S ≥16 R ≤0.5 S ≤0.5 S ≤0.5 S 
SXT trimethoprim/sulfamethoxazole ≤20 S ≥320 R ≤20 S ≤20 S ≤20 S 
* NAL, nalidixic acid; CIP, ciprofloxacin; AMP, ampicillin; AMC, amoxicillin-clavulanic acid; TZP, 
piperacillin-tazobactam; CAZ, ceftazidime; FOX, cefoxitin; CTX, cefotaxime; CPO, cefpirome; CPD, 
cefpodoxime; CEP, cephalothin; CXM, cefuroxime; CXA, cefuroxime axetil; ATM, aztreonam; MEM, 
meropenem; nitrofurantoin; GEN, gentamicin; TOB, tobramycin; SXT, trimethoprim-
sulfamethoxazole. ** S, susceptible; I, intermediate; and R, resistant.  
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Criteria for selecting the clinical isolates Reference 
Norway & 
Sweden 
1.6 % (8/487) 
nalidixic acid resistant and/or ciprofloxacin-reduced- 
susceptible E. coli and klebsiella spp. isolates from wild-
type consecutive, ESBL-, or AmpC- collections 
 
This study  
 
Denmark  1.63 % (2/122)   nalidixic acid-resistant E. coli isolates Cavaco et al. 2007  
France  1.6 % (2/125) ESBL-producing E. coli and klebsiella spp. isolates 
Poirel et al. 2006 
Cattoir et al. 2007 
Canada 1 % (5/550) 
ciprofloxacin and/or tobramycin resistant E. coli and 
Klebsiella spp. isolates 
Pitout et al. 2008 
Spain  5 % (15/305) ESBL-producing enterobacterial isolates  Lavilla et al. 2007 
USA 15 % (23/153) 
ceftazidime-resistant and ciprofloxacin-reduced-
susceptible E. coli and klebsiella spp. isolates 
Robicsek et al. 2006 













































QRDR/GyrA NP_416734 GLKPVHRRVLYAMNVLGNDWNKAYKKSARVVGDVIGKYHPHGDSAVYDTIVRMAQPFSLR 60 
QRDR/GyrA K40-47    GLKPVHRRVLYAMNVLGNDWNKAYKKSARVVGDVIGKYHPHGDSAVYDTIVRMAQPFSLR 60 
QRDR/GyrA K2-78     GLKPVHRRVLYAMNVLGNDWNKAYKKSARVVGDVIGKYHPHGDSAVYDTIVRMAQPFSLR 60 
QRDR/GyrA K4-13     GLKPVHRRVLYAMNVLGNDWNKAYKKSARVVGDVIGKYHPHGDSAVYDTIVRMAQPFSLR 60 
QRDR/GyrA K39-31    GLKPVHRRVLYAMNVLGNDWNKAYKKSARVVGDVIGKYHPHGDSAVYDTIVRMAQPFSLR 60 
QRDR/GyrA K38-15    GLKPVHRRVLYAMNVLGNDWNKAYKKSARVVGDVIGKYHPHGDSAVYDTIVRMAQPFSLR 60 
QRDR/GyrA K8-5      GLKPVHRRVLYAMNVLGNDWNKAYKKSARVVGDVIGKYHPHGDIAVYDTIVRMAQPFSLR 60 
QRDR/GyrA K4-43     GLKPVHRRVLYAMNVLGNDWNKAYKKSARVVGDVIGKYHPHGDLAVYNTIVRMAQPFSLR 60 
QRDR/GyrA K40-79    GLKPVHRRVLYAMNVLGNDWNKAYKKSARVVGDVIGKYHPHGDLAVYNTIVRMAQPFSLR 60 
                    *******************************************↑***↑************ 
 
 
QRDR/GyrA NP_416734 YMLVDGQGNFGSIDGDSAA-- 79 
QRDR/GyrA K40-47    YMLVDGQGNFGSIDGDSAA-- 79 
QRDR/GyrA K2-78     YMLVDGQGNFGSIDGDSAA-- 79 
QRDR/GyrA K4-13     YMLVDGQGNFGSIDGDSAA-- 79 
QRDR/GyrA K39-31    YMLVDGQGNFGSIDGDSAA-- 79 
QRDR/GyrA K38-15    YMLVDGQGNFGSIDGDSAAQH 81 
QRDR/GyrA K8-5      YMLVDGQGNFGSIDGDSAA-- 79 
QRDR/GyrA K4-43     YMLVDGQGNFGSIDGDSAA-- 79 
QRDR/GyrA K40-79    YMLVDGQGNFGSIDGDSAA-- 79 
                    *******************   
 
 
QRDR/ParC NP_417491 NASAKFKKSARTVGDVLGKYHPHGDSACYEAMVLMAQPFSYRYPLVDGQG 50 
QRDR/ParC K2-78     NASAKFKKSARTVGDVLGKYHPHGDSACYEAMVLMAQPFSYRYPLVDGQG 50 
QRDR/ParC K4-13     NASAKFKKSARTVGDVLGKYHPHGDSACYEAMVLMAQPFSYRYPLVDGQG 50 
QRDR/ParC K40-47    NASAKFKKSARTVGDVLGKYHPHGDSACYEAMVLMAQPFSYRYPLVDGQG 50 
QRDR/ParC K39-31    NASAKFKKSARTVGDVLGKYHPHGDSACYEAMVLMAQPFSYRYPLVDGQG 50 
QRDR/ParC K38-15         ------------GKYHPXGDSXCXEAMVLMAQPFSYRYPLVDGQG 33 
QRDR/ParC K8-5      NASAKFKKSARTVGDVLGKYHPHGDIACYEAMVLMAQPFSYRYPLVDGQG 50 
QRDR/ParC K40-79    NASAKFKKSARTVGDVLGKYHPHGDIACYEAMVLMAQPFSYRYPLVDGQG 50 
QRDR/ParC K4-43     NXSAKFKKSXRXVGDVLGKXHPHGDIACYEAMVXMAQPFSYRYPLVDGQG 50 
                                     ********↑************************ 
 
 
QRDR/ParC NP_417491 NWGAPDDPKSFAAM 64   
QRDR/ParC K2-78     NWGAPDDPKSFAAM 64 
QRDR/ParC K4-13     NWGAPDDPKSFAAM 64 
QRDR/ParC K40-47    NWGAPDDPKSFAAM 64 
QRDR/ParC K39-31    NWGAPDDPKSFAAM 64 
QRDR/ParC K38-15    NWGAPDDPKSFAAM 47 
QRDR/ParC K8-5      NWGAPDDPKSFAAM 64 
QRDR/ParC K40-79    NWGAPDDPKSFAAM 64 
QRDR/ParC K4-43     NWGAPDDPKSFAAM 64 
                                    ************** 
 
  
Figure 1. Amino acid sequence alignment of the QRDR of GyrA and ParC of the qnr-
positive isolates detected in this study in comparison with the published wild types. GenBank 









QnrB   K8-5       ------------------------------------------------------------ 
QnrB1  DQ777878.1 MTPLLYKKTGTNMALALVGEKIDRNRFTGEKIENSTFFNCDFSGADLSGTEFIGCQFYDR 60 
QnrB16 CAP45902.1 MTPLLYKKTGTNMALALVGEKIDRNRFTGEKIENSTFFNCDFSGADLSGTEFIGCQFYDR 60 
QnrB3  DQ30392    MTPLLYKKTGTNMALALVGEKIDRNRFTGEKIENSTFFNCDFSGADLSGTEFIGCQFYDR 60 
QnrB6  EF523819.1 MTPLLYKKTGTNMALALVGEKIDRNRFTGEKIENSTFFNCDFSGADLSGTEFIGCQFYDR 60 
QnrB17 CAP45903.1 MTPLLYKKTGTNMALALVGEKIDRNRFTGEKIDNSTFFNCDFSGADLSGTEFIGCQFYDR 60 
QnrB14 ABX72044.1 MTPLLYKKTGTNMALALVGEKIDRNRFTGEKIDNSTFFNCDFSGADLSGTEFIGCQFYDR 60 
QnrB15 ABX72227.1 MTPLLYKKTGTNMALALVGEKIDRNRFTGEKIESSTFFNCDFSGADLSGTEFIGCQFYDR 60 
QnrB2  AB281054.1 ------------MALALVGEKINRNRFTGEKIENSTFFNCDFSGADLSGTEFIGCQFYDR 48 
QnrB13 ABX72043.1 MTPLLYKKTSTNMALALVGEKIDRNRFTGEKIENSTFFNCDFSGADLSGTEFIGCQFYDR 60 
QnrB8  EF526508.1 ------------MALALVGEKIDRNRFTGEKIENSTFFNCDFSGADLSGTEFIGCQFYDR 48 
QnrB11 EU136183.1 MTPLLYKKTSTNMALALVGEKIDRNRFTGEKIENSTFFNCDFSGADLSGTEFIGCQFYDR 60 
QnrB7  ABW03156.3 ------------MALALVGEKIDRNRFTGEKIENSTFFNCDFSGADLSGTEFIGCQFYDR 48 
QnrB   K2-78      ------------------------------------------------------------ 
QnrB5  DQ303919.1 MTPLLYKNTGIDMTLALVGEKIDRNRFTGEKVENSTFFNCDFSGADLSGTEFIGCQFYDR 60 
QnrB10 DQ631414.1 MLSLLYKNTGIDMTLALVGEKIDRNRFTGEKVENSTFFNCDFSGADLSGTEFIGCQFYDR 60 
QnrB19 ACB12691.1 ------------MTLALVGEKIDRNRFTGEKVENSTFFNCDFSGADLSGTEFIGCQFYDR 48 
QnrB9  EF653270.1 -----------MMTLALVGEKIDRNRFTGAKVENSTFFNCDFSGADLSGTEFIGCQFYDR 49 
QnrB12 ABX72042.1 -----------MMTLALVGEKIDRNRFTGAKVENSTFFNCDFSGADLSGTEFIGCQFYDR 49 
QnrB4  DQ303921.2 -----------MMTLALVGEKIDRNRFTGEKVENSTFFNCDFSGADLSGTEFIGCQFYDR 49 
 
                                                                          
QnrB   K8-5       ---KGCNFSRAMLKDAIFKSCDLSMADFRNSSALGIEIRHCRAQGADFRGASFMNMITTR 57 
QnrB1  DQ777878.1 ESQKGCNFSRAMLKDAIFKSCDLSMADFRNSSALGIEIRHCRAQGADFRGASFMNMITTR 120 
QnrB16 CAP45902.1 ESQKGCNFSRAMLKDAIFKSCDLSMADFRNSSALGIEIRHCRAQGADFRGASFMNMITTR 120 
QnrB3  DQ30392    ESQKGCKFSRAMLKDAIFKSCDLSMADFRNSSALGIEIRHCRAQGADFRGASFMNMITTR 120 
QnrB6  EF523819.1 ESQKGCNFSRAMLKDAIFKSCDLSMADFRNASALGIEIRHCRAQGADFRGASFMNMITTR 120 
QnrB17 CAP45903.1 ESQKGCNFSRAMLKDAIFKSCDLSMADFRNASALGIEIRHCRAQGADFRGASFMNMITTR 120 
QnrB14 ABX72044.1 ESQKGCNFSRAMLKDAIFKSCDLSMADFRNASALGIEIRHCRAQGADFRGASFMNMITTR 120 
QnrB15 ABX72227.1 ESQKGCNFSRAMLKDAIFKSCDLSMADFRNANALGIEIRHCRAQGADFRGASFMNMITTR 120 
QnrB2  AB281054.1 ESQKGCNFSRAMLKDAIFKSCDLSMADFRNASALGIEIRHCRAQGADFRGASFMNMITTR 108 
QnrB13 ABX72043.1 ESQKGCNFSRAMLKDAIFKSCDLSMADFRNASALGIEIRHCRAQGADFRGASFMNMITTR 120 
QnrB8  EF526508.1 ESQKGCNFSRAMLKDAIFKSCDLSMADFRNASALGIEIRHCRAQGADFRGASFMNMITTR 108 
QnrB11 EU136183.1 ESQKGCNFSRAMLKDAIFKSCDLSMADFRNASALGIEIRHCRAQGADFRGASFMNMITTR 120 
QnrB7  ABW03156.3 ESQKGCNFSRAMLKDAIFKSCDLSMADFRNASALGIEIRHCRAQGADFRGASFMNMITTR 108 
QnrB   K2-78      ---KGCNFSRAMLKDAIFKSCDLSMADFRNASALGIEIRHCRAQGADFRGASFMNMITTR 57 
QnrB5  DQ303919.1 ESQKGCNFSRAMLKDAIFKSCDLSMADFRNVSALGIEIRHCRAQGADFRGASFMNMITTR 120 
QnrB10 DQ631414.1 ESQKGCNFSRAMLKDAIFKSCDLSMADFRNVSALGIEIRHCRAQGADFRGASFMNMITTR 120 
QnrB19 ACB12691.1 ESQKGCNFSRAMLKDAIFKSCDLSMADFRNVSALGIEIRHCRAQGADFRGASFMNMITTR 108 
QnrB9  EF653270.1 ESQKGCNFSRAILKDAIFKSCDLSMADFRNVSALGIEIRHCRAQGSDFRGASFMNMITTR 109 
QnrB12 ABX72042.1 ESQKGCNFSRAILKDAIFKSCDLSMADFRNVSALGIEIRHCRAQGSDFRGASFMNMITTR 109 
QnrB4  DQ303921.2 ESQKGCNFSRANLKDAIFKSCDLSMADFRNINALGIEIRHCRAQGSDFRGASFMNMITTR 109 




Figure 2. Amino acid sequence alignment of the qnrB genes from K8-5 and K2-78 detected 
in this study in comparison with all the qnrB variants that have been published so far. 
GenBank accession numbers for the published qnrB variants are shown. The ClustalW 



















QnrB   K8-5       TWFCSAYITNTNLSYANFSKVVLEKCELWENRWIGAQVLGATFSGSDLSGGEFSTFDWRA 117 
QnrB1  DQ777878.1 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWIGAQVLGATFSGSDLSGGEFSTFDWRA 180 
QnrB16 CAP45902.1 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGAQVLGATFSGSDLSGGEFSTFDWRA 180 
QnrB3  DQ30392    TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGAQVLGATFSGSDLSGGEFSTFDWRA 180 
QnrB6  EF523819.1 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGAQVLGATFSGSDLSGGEFSTFDWRA 180 
QnrB17 CAP45903.1 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGAQVLGATFSGSDLSGGEFSTFDWRA 180 
QnrB14 ABX72044.1 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGAQVLGATFSGSDLSGGEFSTFDWRA 180 
QnrB15 ABX72227.1 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGAQVLGATFSGSDLSGGEFSTFDWRA 180 
QnrB2  AB281054.1 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGAQVLGATFSGSDLSGGEFSTFDWRA 168 
QnrB13 ABX72043.1 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGAQVLGATFSGSDLSGGEFSTFDWRA 180 
QnrB8  EF526508.1 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGAQVLGATFSGSDLSGGEFSTFDWRA 168 
QnrB11 EU136183.1 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGTQVLGATFSGSDLSGGEFSTFDWRA 180 
QnrB7  ABW03156.3 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGAQVLGATFSGSDLSGGEFTTFDWRA 168 
QnrB   K2-78      TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGAQVLGATFSGSDLSGGEFTTFDWRA 117 
QnrB5  DQ303919.1 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGTQVLGATFSGSDLSGGEFSTFDWRA 180 
QnrB10 DQ631414.1 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGTQVLGATFSGSDLSGGEFSTFDWRA 180 
QnrB19 ACB12691.1 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGTQVLGATFSGSDLSGGEFSTFDWRA 168 
QnrB9  EF653270.1 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGTQVLGATFSGSDLSGGEFSSFDWRA 169 
QnrB12 ABX72042.1 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGTQVLGATFSGSDLSGGEFSSFDWRA 169 
QnrB4  DQ303921.2 TWFCSAYITNTNLSYANFSKVVLEKCELWENRWMGTQVLGATFSGSDLSGGEFSSFDWRA 169 




QnrB   K8-5       ANFTHCDLTNSELGDLDIRGVDLQGVKLDNY--------------- 148 
QnrB1  DQ777878.1 ANFTHCDLTNSELGDLDIRGVDLQGVKLDNYQASLLMERL------ 220 
QnrB16 CAP45902.1 ANFTHCDLTNSELGDLDIRGVDLQGVKLDNYQASLLMERLGIAVIG 226 
QnrB3  DQ30392    ANFTHCDLTNSELGDLDIRGVDLQGVKLDNYQASLLMERLGIAVIG 226 
QnrB6  EF523819.1 ANFTHCDLTNSELGDLDIRGVDLQGVKLDNYQASLLMERLGIAVIG 226 
QnrB17 CAP45903.1 ANFTHCDLTNSELGDLDIRGVDLQGVKLDNYQASLLMERLGIAVIG 226 
QnrB14 ABX72044.1 ANFTHCDLTNSELGDLDIRGVDLQGVKLDNYQASLLTERLGIAIIG 226 
QnrB15 ABX72227.1 ANFTHCDLTNSELGDLDIRGVDLQGVKLDNYQASLLMERLGIAIIG 226 
QnrB2  AB281054.1 ANFTHCDLTNSELGDLDIRRVDLQGVKLDNYQASLLMERLGIAIIG 214 
QnrB13 ABX72043.1 ANFTHCDLTNSELGDLDIRRVDLQGVKLDNYQASLLMERLGIAIIG 226 
QnrB8  EF526508.1 ANFTHCDLTNSELGDLDIRGVDLQGVKLDNYQASLLMERLGIAIIG 214 
QnrB11 EU136183.1 ANFTHCDLTNSELGDLDIRGVDLQGVKLDNYQASLLMERLGIAIIG 226 
QnrB7  ABW03156.3 ANFTHCDLTNSELGDLDIRGVDLQGVKLDNYQASLLMERLGIAIIG 214 
QnrB   K2-78      ANFTHCDLTNSELGDLDIRGVDLQGVKLD----------------- 146 
QnrB5  DQ303919.1 ANFTHCDLTNSELGDLDIRGVDLQGVKLDSYQASLLMERLGIAIIG 226 
QnrB10 DQ631414.1 ANFTHCDLTNSELGDLDIRGVDLQGVKLDNYQASLLMERLGIAVIG 226 
QnrB19 ACB12691.1 ANFTHCDLTNSELGDLDIRGVDLQGVKLDSYQASLLMERLGIAVIG 214 
QnrB9  EF653270.1 ANFTHCDLTNSELGDLDVRGVDLQGVKLDSYQASLILERLGIAVMG 215 
QnrB12 ABX72042.1 ANFTHCDLTNSELGDLDVRGVDLQGVKLDSYQASLILERLGIAVIG 215 
QnrB4  DQ303921.2 ANVTHCDLTNSELGDLDIRGVDLQGVKLDSYQASLLLERLGIAVMG 215 
                                           **.**************:* *********                  
 
 
Figure 2 (cont). Amino acid sequence alignment of the qnrB genes from K8-5 and K2-78 
detected in this study in comparison with all the qnrB variants that have been published so far. 
GenBank accession numbers for the published qnr variants are shown. The ClustalW program 




















K8-5            ------------------------------------------------------------ 
QnrB1           MTPLLYKKTGTNMALALVGEKIDRNRFTGEKIENSTFFNCDFSGADLSGTEFIGCQFYDR 60 
                                                                             
K8-5            ---KGCNFSRAMLKDAIFKSCDLSMADFRNSSALGIEIRHCRAQGADFRGASFMNMITTR 57 
QnrB1           ESQKGCNFSRAMLKDAIFKSCDLSMADFRNSSALGIEIRHCRAQGADFRGASFMNMITTR 120 
                   ********************************************************* 
 
K8-5            TWFCSAYITNTNLSYANFSKVVLEKCELWENRWIGAQVLGATFSGSDLSGGEFSTFDWRA 117 
QnrB1           TWFCSAYITNTNLSYANFSKVVLEKCELWENRWIGAQVLGATFSGSDLSGGEFSTFDWRA 180 
                ************************************************************ 
 
K8-5            ANFTHCDLTNSELGDLDIRGVDLQGVKLDNY--------- 148 
QnrB1           ANFTHCDLTNSELGDLDIRGVDLQGVKLDNYQASLLMERL 220 
                *******************************     
 
 
Figure 3. Amino acid sequence of the qnrB gene from K8-5 was 100% identical to that of the 
published qnrB1. GenBank accession number for qnrB1 is shown. The ClustalW program 







K2-78           ---------------------------------------------------KGCNFSRAM 9 
QnrB7           MALALVGEKIDRNRFTGEKIENSTFFNCDFSGADLSGTEFIGCQFYDRESQKGCNFSRAM 60 
                                                                   ********* 
 
K2-78           LKDAIFKSCDLSMADFRNASALGIEIRHCRAQGADFRGASFMNMITTRTWFCSAYITNTN 69 
QnrB7           LKDAIFKSCDLSMADFRNASALGIEIRHCRAQGADFRGASFMNMITTRTWFCSAYITNTN 120 
                ************************************************************ 
 
K2-78           LSYANFSKVVLEKCELWENRWMGAQVLGATFSGSDLSGGEFTTFDWRAANFTHCDLTNSE 129 
QnrB7           LSYANFSKVVLEKCELWENRWMGAQVLGATFSGSDLSGGEFTTFDWRAANFTHCDLTNSE 180 
                ************************************************************ 
 
K2-78           LGDLDIRGVDLQGVKLD----------------- 146 
QnrB7           LGDLDIRGVDLQGVKLDNYQASLLMERLGIAIIG 214 
                *****************                      
 
 
Figure 4. Amino acid sequence of the qnrB gene from K2-78 was 100% identical to that of 
the published qnrB7. GenBank accession number for qnrB7 is shown. The ClustalW program 


















QnrS   K40-79      --------------------------------------------NCKFIEQGDIEGCHFD 16 
QnrS   K39-31      --------------------------------------------NCKFIEQGDIEGCHFD 16 
QnrS   K4-13       --------------------------------------------NCKFIEQGDIEGCHFD 16 
QnrS   K40-47      ---------------------------------------------CKFIEQGDIEGCHFD 15 
QnrS   K38-15      --------------------------------------------NCKFIEQGDIEGCHFD 16 
QnrS   K4-43       ---------------------------------------------CKFIEQGDIEGCHFD 15 
QnrS1  DQ485529.1  METYNHTYRHHNFSHKDLSDLTFTACTFIRSDFRRANLRDTTFVNCKFIEQGDIEGCHFD 60 
QnrS2  DQ485530.1  METYRHTYRHHSFSHQDLSDITFTACTFIRCDFRRANLRDATFINCKFIEQGDIEGCHFD 60 
                                                                *************** 
 
 
QnrS   K40-79      VADLRDASFQQCQLAMANFSNANCYGIEFRACDLKGANFSRTNFAHQVSNRMYFCSAFIS 76 
QnrS   K39-31      VADLRDASFQQCQLAMANFSNANCYGIEFRACDLKGANFSRTNFAHQVSNRMYFCSAFIS 76 
QnrS   K4-13       VADLRDASFQQCQLAMANFSNANCYGIEFRACDLKGANFSRTNFAHQVSNRMYFCSAFIS 76 
QnrS   K40-47      VADLRDASFQQCQLAMANFSNANCYGIEFRACDLKGANFSRTNFAHQVSNRMYFCSAFIS 75 
QnrS   K38-15      VADLRDASFQQCQLAMANFSNANCYGIEFRACDLKGANFSRTNFAHQVSNRMYFCSAFIS 76 
QnrS   K4-43       VADLRDASFQQCQLAMANFSNANCYGIEFRACDLKGANFSRTNFAHQVSNRMYFCSAFIS 75 
QnrS1  DQ485529.1  VADLRDASFQQCQLAMANFSNANCYGIEFRACDLKGANFSRTNFAHQVSNRMYFCSAFIS 120 
QnrS2  DQ485530.1  VADLRDASFQQCQLAMANFSNANCYGIELRECDLKGANFSRANFANQVSNRMYFCSAFIT 120 
                   ****************************:* **********:***:*************: 
 
 
QnrS   K40-79      GCNLSYANMERVCLEKCELFENRWIGTNLAGASLKESDLSRGVFSEDVWGQFSLQ----- 131 
QnrS   K39-31      GCNLSYANMERVCLEKCELFENRWIGTNLAGASLKESDLSRGVFSEDVWGQFSLQ----- 131 
QnrS   K4-13       GCNLSYANMERVCLEKCELFENRWIGTNLAGASLKESDLSRGVFSEDVWGQFSLQ----- 131 
QnrS   K40-47      GCNLSYANMERVCLEKCELFENRWIGTNLAGASLKESDLSRGVFSEDVWGQFSLQ----- 130 
QnrS   K38-15      GCNLSYANMERVCLEKCELFENRWIGTNLAGASLKESDLSRGVFSEDVWGQFSLQG---- 132 
QnrS   K4-43       GCNLSYANMERVCLEKCELFENRWIGTNLAGASLKESDLSRGVFSEDVWGQFSLQG---- 131 
QnrS1  DQ485529.1  GCNLSYANMERVCLEKCELFENRWIGTNLAGASLKESDLSRGVFSEDVWGQFSLQGANLC 180 
QnrS2  DQ485530.1  GCNLSYANMERVCLEKCELFENRWIGTHLAGASLKESDLSRGVFSEDVWGQFSLQGANLC 180 
                   ***************************:***************************      
 
 
QnrS   K40-79      -------------------------------------- 
QnrS   K39-31      -------------------------------------- 
QnrS   K4-13       -------------------------------------- 
QnrS   K40-47      -------------------------------------- 
QnrS   K38-15      -------------------------------------- 
QnrS   K4-43       -------------------------------------- 
QnrS1  DQ485529.1  HAELDGLDPRKVDTSGIKIAAWQQELILEALGIVVYPD 218 




Figure 5. Amino acid sequence alignment of the qnrS genes from K38-15, K4-13, K4-43, 
K39-31, K40-47, and K40-79 detected in this study in comparison with the published qnrS1 
and qnrS2 variants. Amino acid sequence of all the qnrS genes was 100% identical to that of 
the published qnrS1. GenBank accession numbers for qnrS1 and qnrS2 are shown. The 






















Reagents and Solutions 
 
Antibody solution  
30.0 ml Buffer #1 Solution  
3.00 µl AP-conjugate antibody (Vial 8, 
DIG DNA labeling and detection kit, 
Roche Applied Science, Germany) 
Basic buffer 
100 mM EDTA pH 7.5 
6 mM Tris-HCl pH 7.6 
1 M NaCl 
0.5 % Brij 58 
 
10X Blocking solution 
50 g Blocking Reagent powder  
500 ml Maleic acid buffer 
 
Blocking solution  
1 volume 10X Blocking solution 




40 µl NBT/BCIP (vial 9, DIG DNA 
labeling and detection kit, Roche Applied 
Science, Germany) 
2 ml Detection buffer 
 
Denaturing buffer                         
58.4 g of NaCl      
20 g of NaOH                                
1 L ddH2O 
 
Depurination buffer 
20.8 mls concentrated HCl  






Lysis buffer (for 5 plugs) 
10 ml basic buffer 
0.02 g deoxycholate 
0.05 g N-laurosylsarcosine, Na-salt 
0.01 g lysozyme  
1 µl RNase ONE (10U/µl) 
 
Hybridization solution  
25.0 ml 20X SSC  
10.0 ml 1% Lauroyl Sarcosine  
100.0 ml 20% SDS  
10.0 ml 10% Blocking Reagent 
55.0 ml ddH2O  
 
2 % LMP-agarose 
50 ml PIV buffer 
1 g LMP-agarose (Bio-Rad, USA) 
 
ESP buffer:  
0.5 M EDTA (pH 9.0 to 9.5) 
1 % Sarkosyl  
50 µg/ml proteinase K 
 
Maleic acid buffer 
0.1M Maleic Acid 
0.15 M NaCl 
 
 
Neutralizing buffer 5x 
79.25 g Na2HPO4 
60.25 g NaH2PO4·H2O 
Brought to 1 liter with dd H2O 
 
x 1Neutralizing buffer  
1 volume 5x neutralizing buffer  
4 volume dd H2O 
 
PIV buffer: 
1 M NaCl  
10 mM Tris-HCl (pH 7.6) 
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Reagents and Solutions 
 
Phosphate-buffered saline (PBS) 
solution 
0.14 M NaCl 
0.003 M KCl 
0.008 M Na2H2PO4x2H2O 
0.0015 M KH2PO4 
Prehybridization solution 
250 ml 20X SSC 
10 ml 1 % N-lauroylsarcosine 
2 ml 10 % SDS 
100 ml 10X Blocking solution 
638 ml ddH2O 
 
Proteinase K-stock solution 
100 mg Proteinase K 
10 ml 50 mM Tris-CL pH 8.0 
10 mM CaC 
 
 X SSC20 
88.2 g Trisodium citrate (citric acid) 
175.3 g NaCl 
Brought to 1 liter with ddH2O 
 
nuclease buffer-1S 
1 volume S1-nuclease buffer (10X) 
(Sigma-Aldrich, USA) 
9 volume ddH2O 
 
X TBE buffer10 
108 g Tris base 
55 g boric acid 
9.3 g EDTA 




0.79 g Tris HCl 
0.19 g EDTA 
ddH2O to 0.5 liter 
 
Washing buffer 
0.1 M Maleic acid buffer  
0.15 M NaCl  
0.3 % Tween 20 (v/v) 
 
Bacterial Growth media  
 
broth ) BHI(usion Heart InfBrain  
BHI broth base (Oxoid Ltd, UK) 
ddH2O 
agar) MH(Muller Hinton  




)ISA(seneitest agar -Iso 









Luria-Bertani (LB) agar   




Luria-Bertani (LB) broth   





Tryptose blood agar base (Oxoid Ltd, UK) 
Lactose LP0070 




       
 
 














Kit 1. Purification of PCR products according to the E.Z.N.A™ Cycle-Pure Kit Spin 
Protocol (Omega Bio-tek, USA): 
 
1. 4-5 volumes of CP Buffer (90 µl) were added to 1 volume of PCR-mixture (20 
µl) and mixed.  
2. A HiBind® DNA spin column was placed in a 2 ml collection tube.  
3. The sample was transferred to the column and centrifuged at 13000 rpm for 1 
min.  
4. The flow-through was discarded and the spin column was placed back into the 
same tube.  
5. 0.75 ml Wash Buffer diluted with ethanol was added and the tube was 
centrifuged at 13000 rpm for 1 min.  
6. The flow-through was discarded, and the washing was repeated once.  
7. The flow-through was discarded and the column was placed in the same tube 
and the tube was centrifuged at 13000 rpm for 1min to dry the column matrix.  
8. The column was placed in a clean eppendorf tube.  
9. 30 µl Elution Buffer was added to the centre of the column-membrane and the 
tube was centrifuged at 13000 rpm for 1min.  
 
 
Kit 2. Plasmid DNA extraction according to the E.Z.N.A™ Plasmid Miniprep 
Protocol I (Omega Bio-tek, USA): 
 
1. Green agar plate was streaked and incubated over night at 37°C. 
2. LB-broth medium (5 ml each) was inoculated with a single isolated colony 
from the agar plate and incubated over night at 37°C with vigorous shaking 
(about 300 rpm). 
3. The bacterial cells were pelleted by centrifugation at 10,000 x g for 1 min at 
room temperature. 
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4. The supernatant was discarded and the bacterial ballet was resuspended by 
adding 250 µl of Solution I/RNase A solution, and vortexing. 
5. 250 µl of Solution II were added and gently mixed by inverting and rotating 
the tube several times to obtain a clear lysate. 
6. 350 µl of Solution III were added and mixed immediately by inverting several 
times until a flocculent white precipitate was formed. 
7. The tube was centrifuged at 13000 x g for 10 min.  
8. The cleared supernatant was added carefully into a HiBind® Miniprep spin 
column assembled in a provided 2 ml collection tube and centrifuged at 13000 
x g for 1 min.  
9. The flow-through was discarded and the spin column was placed back into the 
same tube.  
10. 500 µl of Buffer HB was added and the tube was centrifuged at 13000 x g for 
1 min.  
11. The flow-through was discarded and 700 µl of DNA Wash Buffer diluted with 
absolute ethanol was added and the tube was centrifuged at 13000 x g for 1 
min.  
12. The flow-through was discarded and the column was placed in the same tube 
and the empty tube was centrifuged at 13000 x g for 2 min to dry the column 
matrix.  
13. The column was placed in a clean eppendorf tube.  
14. 50 µl Elution Buffer was added to the centre of the column-membrane and the 
tube was centrifuged at 13000 x g for 1min.  
 
 
Kit 3. Extraction and purification DNA from agarose gel according to the QIAquick 
SpinHandbook for QIAquick Gel Extraction Kit (QIAGEN, Germany): 
 
1. The DNA fragment was excised from the agarose gel with a clean sharp 
scalpel. 
2. The gel slice was weighed and 3 volumes of Buffer QG were added to 1 
volume of gel (100 mg or approximately 100 µl) 
3. The tubes were incubated at 50º C for 10 min. 
4. A QIAquick spin column was placed in a provided 2 ml collection tube. 
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5. The sample was applied to the QIAquick spin column and centrifuged for 1 
min. 
6. The flow-through was discarded and QIAquick spin column was placed back 
in the same collection tube. 
7. 0.5 ml of Buffer QG was added to the QIAquick spin column and centrifuged 
for 1 min. 
8. The flow-through was discarded and QIAquick spin column was placed back 
in the same collection tube. 
9. 0.75 ml of Buffer PE was added to the QIAquick spin column and centrifuged 
for 1 min. 
10. The flow-through was discarded and the empty QIAquick spin column was 
placed back in the same collection tube and centrifuged for 1 min. 
11. The empty QIAquick spin column was placed in a clean 1.5 ml 
microcentrifuge tube. 
12. 30 µl Elution Buffer was added to the center of the QIAquick spin column 
membrane. Then the column was let stand for 1 min after that centrifuged for 
1 min. 
13. All centrifugation steps were carried out at 13000 rpm. 
14. Ethanol 96% was added to Buffer PE before use. 

























                                                                                                                                       
 
 
